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“Of course, the universe is gradually slowing down and will eventually collapse 
inwardly on itself, according to the laws of entropy when all its thermal and 
mechanical functions fail, thus rendering all human endeavors ultimately pointless. 
Just to put the gig in some sort of context.” 
 
Bill Bailey, Part Troll 
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Summary 
G protein-coupled receptors (GPCRs) are a superfamily of membrane proteins that 
bind to a diverse array of stimuli and are involved in a large number of physiological 
functions. The family A GPCRs are the largest and most comprehensively studied. 
The family B GPCRs are a small but important group of receptors (~15 members) 
that bind to peptide ligands and are involved in physiological processes that include 
vasodilation, stress, digestion and glucose homeostasis. The CGRP receptor is a 
unique member of this family as it is a heterodimer consisting of a GPCR subunit 
(calcitonin receptor-like receptor, CLR) and a single transmembrane accessory 
protein (receptor activity modifying protein, RAMP1). 
The extracellular loop two (ECL2) domain is involved in ligand binding and activation 
in a number of studied GPCRs. This makes it vital both with respect to receptor 
function and in the design of therapeutics. The main focus of this thesis is to study 
the structure and function of the ECL2 domain in the CGRP receptor. This was 
initially done through individual alanine substitutions of each ECL2 residue and 
measuring the effect of this on a number of receptor processes. Residues that were 
identified as important for receptor function through this investigation were 
selected for an extensive set of mutagenesis to identify the precise molecular 
interactions that were involved at each position. These experiments have shown 
that ECL2 is the most important domain of the CGRP receptor for ligand-based 
activation. The N-terminal half of ECL2 contains residues predicted to have 
structural function and the C-terminal half is predicted to be involved in direct 
ligand binding. These results have been used in collaboration to refine a computer 
model of receptor structure and ligand binding to predict specific ligand docking 
sites that can be used to design therapeutics for migraine, heart attack and 
hypertension. 
The final part of thesis produced preliminary data to support proof of concept for 
two techniques that can be used in the study of CGRP receptor function.   
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 Introduction 1
1.1 GPCRs 
1.1.1 Introduction 
G protein-coupled receptors (GPCRs) are a superfamily of membrane proteins that 
function to transmit an extracellular signal across the plasma membrane to the 
inside of a cell, resulting in a cellular response. There are over 800 different types of 
GPCRs in the human body (Fredriksson et al., 2003) that respond to a diverse array 
of stimuli. These include photons, odorants, hormones, proteins, lipids, 
pheromones, chemokines and neurotransmitters (Bockaert & Pin, 1999). GPCRs are 
involved in a huge array of physiological processes, including sight, smell, taste, 
movement, immunity, mood, autonomic functions, homeostasis, thought and 
feeling. This makes GPCRs a common site of action for both medicinal and 
recreational drugs. Approximately 25-50% of medical pharmaceutical products 
target GPCRs (Salon et al., 2011). The involvement of GPCRs in such a diverse array 
of physiological process has led to GPCR research being of considerable interest, 
both academically and pharmaceutically. 
All GPCRs share a common molecular architecture of an N-terminal extracellular 
domain (ECD), seven transmembrane (7TM) spanning helices connected by 3 
extracellular loops (ECLs) and three intracellular loops (ICLs) with an intracellular C-
terminus (Palczewski et al., 2000). However given this common three-dimensional 
structure, there is very little overall primary sequence homology. The standard 
model of ligand binding is that an extracellular ligand binds to the ECD, the ECLs or 
the TM bundle, stabilising a particular receptor conformation. GPCRs are coupled to 
an intracellular heterotrimeric G protein through their ICLs and the intracellular C-
terminus (Rasmussen et al., 2011b). It is through the G protein that the majority of 
the signalling occurs however GPCRs can also signal through G protein independent 
pathways (DeWire et al., 2007). This phenomena has led to these receptors to be 
alternatively named 7TM receptors, however the GPCR terminology is more 
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established (Fredriksson et al., 2003). All these aspects of GPCR structure and 
function will be discussed in more detail in this introduction. 
The introduction is split into three sections. The first section discusses the whole 
GPCR super family, the second section focuses on the family B GPCRs and the final 
section looks at CGRP and its receptor in more detail. As the entire GPCR family is 
involved in the first section, general details of the family B GPCRs will be included 
however as they are being discussed in more detail in the second section, the first 
section will only contain a general overview.    
1.1.2 Classification 
The diversity of GPCRs and the lack of sequence homology that accompanies this 
has led to a number of different classification systems being developed. One of the 
original classification systems was based on primary sequence homology and 
separated the GPCR superfamily into six groups. These were categorized as family A 
(1, Rhodopsin-like), family B (2, Secretin), family C (3, Metabotropic 
glutamate/pheromone), family D (4, Fungal mating pheromone), family E (5, cyclic 
AMP) and family F (6, Frizzled/Smoothened) according to sequence homology and 
functional similarity (Attwood & Findlay, 1994; Kolakowski, 1994). These groups 
comprised GPCRs for both vertebrates and invertebrates. Human GPCRs are 
contained within families A-C and F. A more recent phylogenetic analysis of the 
human genome has organized the functional GPCRs into 5 groups. These are 
glutamate (G), rhodopsin (R), adhesion (A), frizzled/taste 2 (F) and secretin (S) which 
is commonly abbreviated as GRAFS (Fredriksson et al., 2003). The phylogenetic tree 
of the human GPCRs is presented in Figure 1.1. 
Rhodopsin is the largest family and corresponds with the family A group of 
receptors. The rhodopsin family is subdivided into four main groups (α, β, γ and δ) 
and 13 subfamilies. The α group contains the prostaglandin, amine (including the 
serotonin, dopamine, muscarinic, histamine and adrenergic receptors), opsin, 
melatonin, and MECA receptor clusters. The β group contains receptors to peptide 
ligands. The γ group contains the SOG (including the opioid receptors), MCH, and 
the chemokine receptor clusters. The δ group contains the MAS-related,
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Figure 1.1. GPCR phylogenetic tree of the human GPCR superfamily classified using the 
GRAFS system. 
The non-olfactory human GPCRs are presented following phylogenetic analysis. 
Classification was based on sequence similarity of the transmembrane domains. GPCRs are 
named based on the gene names in the Uniprot database. Families with solved structures 
have been highlighted. Schematic diagram was adapted from Stevens et al., 2013. 
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glycoprotein, purine, and the olfactory receptor clusters (Fredriksson et al., 2003). 
The secretin and adhesion groups were combined as the family B receptors in the A-
F classification system. They share structural similarities within the TM domains and 
a high level of N-terminal cysteine residues, however there are major differences in 
the N-termini of these receptor groups. The secretin family all bind to moderately 
large peptide ligands and are named after the first receptor in the family to be 
cloned. The adhesion family have large N-terminal domains which contain motifs 
involved in cell adhesion (Nordström et al., 2011).  
The glutamate family corresponds with the family C receptors. These include the 
metabotropic glutamate and GABA receptors found in the central nervous system, a 
single calcium sensing receptor and the TAS1 taste receptors. These receptors have 
a large N-terminus containing two “lobes” with a cavity in between. Binding of 
glutamate causes the lobes to close around the ligand sometimes called the “venus 
fly trap” mechanism. These two lobes are connected to the TM regions through a 
cysteine rich domain (with the exception of the GABAB receptor). Another 
characteristic of the glutamate family of GPCRs is constitutive dimerisation at the 
cell surface, either as homodimers (mGlu and CaS) or heterodimers (GABAB and 
T1Rs) (Kniazeff et al., 2011). 
The final family contains the frizzled receptors and the TAS2 taste receptors. 
Surprisingly these showed no sequence similarities to the TAS1 receptors in the 
glutamate family. Since this classification however it was found that TAS2 has 
greater similarity with the MCH group of the Rhodopsin family (Nordström et al., 
2011). 
1.1.3 Nomenclature and numbering systems 
The sequencing of the human genome has allowed potential human GPCR genes to 
be catalogued. The International Union of Pharmacology Committee on Receptor 
Nomenclature and Drug Classification (NC-IUPHAR) provides information on the 
classification, pharmacology, structure and terminology of this list through their 
receptor database website (www.guidetopharmacology.org) and various reports 
(Foord et al., 2005). 
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The numbering of GPCR amino acids provides information into the location and 
order within the sequence. Often the position in the primary amino acid sequence 
is used. However to allow comparison between GPCRs and to provide details with 
respect to positioning within the structure, three different numbering systems have 
been proposed. The Schwartz and Baldwin numbering systems are essentially 
identical. The TM helix is described using I to VII and the most conserved residue 
within each helix is given a generic number describing the predictive relative 
position in a standard helix of 26 residues. However, with the exception of TM1, 
these two systems do not agree on the conserved residue. In the Ballesteros-
Weinstein numbering system, two numbers are used. The first describes the helix 
that the residue is in (1-8) and the second describes the position in relation to the 
most conserved residue, which is given the number 50 (Gether, 2000). This 
numbering system has also been used to described the family B GPCRs using the 
same principle but using conserved residues specific to this family (Wootten et al., 
2013). This is referred to as the Wootten numbering system. In this work the 
Ballesteros-Weinstein/Wootten numbering system will be written in superscript 
(eg. X1.50) and will be the Ballesteros-Weinstein system unless stated. 
1.1.4 Evolution 
It is thought that all the human families of GPCRs share a common ancestor. Using 
alignment and motif analysis of newly published sequence genomes it was found 
that the adhesion, frizzled and rhodopsin families descended from the cAMP family 
(family E) (Nordström et al., 2011). The origin of these families is thought to occur 
at a similar point in time. Later the secretin family evolved from the adhesion 
family, which happened after the split of N. vectensis (starlet sea anemone) and 
before the split of C. elegans (nematodes) from the vertebrate lineage (Nordström 
et al., 2009). The glutamate family was found to be one of the most ancient due to 
its presence in Th. Pseudonana (eukaryotic phytoplankton) and there are 
suggestions of a link in origin with the other families. cAMP receptors are the most 
ancient, found in alveolata, choanoflagellata, fungi and metazoan (Krishnan et al., 
2012). In this study, the origin of the rhodopsin family was found to have evolved 
from the cAMP family with the common ancestor of opisthokonts (fungi/metazoa), 
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~1100 million years ago. There are a number of similarities between these two 
families suggesting that rhodopsin expanded from the more ancient cAMP family, 
while this family became more redundant in more complex organisms. The 
melatonin subgroup had the highest identity to the cAMP and the adhesion family 
(Nordström et al., 2011). The adhesion and frizzled families evolved from the cAMP 
family before the split of the unikonts (eukaryotic cells with a single flagellum or 
amoeba with no flagellum) ~1275 million years ago. The glutamate and the cAMP 
family was traced back to the common ancestor of alveolates (superphylum of 
protists) and unikonts, ~1400 million years ago. The secretin family evolved from 
the adhesion family between the split of cnidaria (aquatic animal phylum including 
jellyfish) and nematoda (Nordström et al., 2009). 
Microbial rhodopsins are 7TM proteins found in both prokaryotes and eukaryotes. 
These include light-sensitive proteo-, bacterio- and halorhodopsins that use light 
induced retinal isomerisation to create proton or chloride gradients. These are used 
to drive membrane bound ATPases. Sensory rhodopsins in some halobacteria are 
used for phototaxis (Béjà et al., 2000; Fuhrman et al., 2008; Oesterhelt, 1998; 
Spudich & Luecke, 2002). The N-terminal ECD of the family C glutamate receptors 
show both sequential and structural homology with bacterial periplasmic binding 
proteins which are involved in amino acid and nutrient transport (O'Hara et al., 
1993). Despite structural similarities the sequence homology with GCPRs is low and 
therefore phylogenetic analysis has not linked the GPCR ancestry to these proteins. 
It is therefore still unknown how the 7TM bundle in eukaryotes evolved.  Some of 
the greatest sequence similarities occur between non-homologous helices. This 
effect has been explained due to exon shuffling (Pardo et al., 1992) or a duplication 
of a three helical module which results in TM1-3 and TM5-7 (Taylor & Agarwal, 
1993). The search for a common ancestor is further complicated by the length of 
time that prokaryote and eukaryote TM proteins have been independently evolving 
and with lateral gene transfer observed by type 1 microrhodopsins even between 
prokaryotes and eukarotes (Ruiz-González & Marín, 2004; Sharma et al., 2006). 
The genetic expansion of GPCRs is thought to occur through gene duplication 
followed by independent evolution (Semyonov et al., 2008). There is evidence for 
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two distinct genome duplication events early in the vertebrate evolution (Dehal & 
Boore, 2005). It was also found the GPCR genes have a greater retention rate 
following gene duplication compared with other gene duplicates (Semyonov et al., 
2008). 
The plant kingdom is considerably different. Whilst there have been several 
proposed 7TM receptors, the homology that has been used to link these to GPCRs is 
weak and there is little evidence that they act as receptor GEFs (Urano & Jones, 
2013). 
1.1.5 GPCR Structure 
All GPCRs share a common three-dimensional structure consisting of an N-terminal 
extracellular domain (ECD), seven transmembrane (TM) spanning helices which 
cluster in a barrel formation and an intracellular C-terminus. The TM helices are 
connected by three extracellular loops (ECLs) and three intracellular loops (ICLs) 
(Figure 1.2) (Palczewski et al., 2000).  
1.1.5.1 Techniques used to obtain GPCR structures 
The first structure of a 7TM protein was that of Halobacterium halobium 
bacteriorhodopsin, obtained using electron microscopy (Henderson & Unwin, 
1975). Using this and sequence analysis, probability maps of GPCRs were 
constructed (Baldwin, 1993; Baldwin et al., 1997; Schertler et al., 1993). 
The first GPCR crystal structure was of bovine rhodopsin, published in 2000 
(Palczewski et al., 2000). Following this no new GPCR structures were published 
until that of the 2-AR in 2007 (Cherezov et al., 2007; Rasmussen et al., 2007). Both 
of these structures are presented in Figure 1.2. This delay represents the difficulty 
in successfully expressing, purifying and crystallising a highly dynamic eukaryotic 
membrane protein. Rhodopsin has proved an exception in that is has been obtained 
through its natural source where it is highly expressed (Palczewski et al., 2000).  In 
contrast, most GPCRs are found in small amounts.  
To obtain the high yields necessary for crystallography, effective recombinant 
expression systems are required. Most of the crystal structures published since then  
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Figure 1.2. Crystal structures of bovine rhodopsin (PDB1F88) and β2-adrenergic receptor 
(β2-AR, PDB 2RH1).  
The N-terminal extracellular domain (ECD) and extracellular loops (ECLs) are highlighted 
magenta, the seven transmembrane domains (7TM) are highlighted cyan and the 
intracellular loops (ICLs) and intracellular C-terminal domain is highlighted yellow. Each 
structure is presented twice, in a parallel orientation to the membrane, rotated 180°. 
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have used an insect expression system. This expression system is slower and more 
expensive than yeast and E.coli but is effective at expressing mammalian GPCRs. 
There have been exceptions for example with the human adenosine A2A receptor 
(A2AR) (Hino et al., 2012) and the Histamine H1 receptor (Shimamura et al., 2011), 
which have been expressed in the yeast strain Pichia pastoris. The yeast expression 
system has the benefits of a fast growth rate but also eukaryotic expression 
machinery. However it does differ from mammalian cells with respect to some post 
translational modifications and membrane lipid composition (Opekarová & Tanner, 
2003). Recently the neurotensin receptor 1 has been expressed in E.coli  (Egloff et 
al., 2014). E.coli is the cheapest and most convenient system of protein expression 
however is not always sufficient to successfully express mammalian GPCRs. It has 
been a useful screening expression system.  Mammalian cells have been used to 
successfully express and crystallise rhodopsin structures (Standfuss et al., 2007).   
A number of different techniques have been adopted to obtain GPCR crystal 
structures. These include deletions of the flexible C-terminal domain (Singh et al., 
2010) and in some cases the extracellular N-terminus (Tucker & Grisshammer, 1996; 
Warne et al., 2003). The introduction of tags has also been used to enhance 
purification (André et al., 2006). The high resolution crystal structure of 2-AR fused 
the T4 lysozyme in the place of the flexible ICL3 domain (Cherezov et al., 2007). T4 
lysozyme can crystallise but also fits between the cytoplasmic ends of TM5 and 6 
with minimal disruption (Rosenbaum et al., 2007). T4 lysozyme insertion into the 
ICL3 domain has been successfully used for the crystallisation of a number of 
receptors, including human A2AR, the muscarinic M2 and M3 receptors, the CXCR4 
chemokine receptor, the human dopamine D3 receptor and the , , and human -
opioid receptors (Chien et al., 2010; Granier et al., 2012; Haga et al., 2012; Jaakola 
et al., 2008; Kruse et al., 2012; Manglik et al., 2012; Wu et al., 2010; Wu et al., 
2012). Crystal structures have also been obtained with the T4 lysozyme fused to the 
N-terminus (Rasmussen et al., 2011b; Thompson et al., 2012). A thermostabilised 
cytochrome b562 insertion in the place of ICL3 was used to successfully obtain a 
high resolution structure of the human A2A adenosine receptor allowing 
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observation of bound water and lipid molecules, providing insights into the 
allosteric effects of sodium ions (Liu et al., 2012). 
Antibody fragments and nanobodies have also been used to stabilise the receptor 
and facilitate crystallisation (Rasmussen et al., 2007; Rasmussen et al., 2011a) and 
thermostabilising mutagenesis has been successfully used to create receptors with 
increased stability. This was initially used for the turkey 1-AR (Serrano-Vega et al., 
2008) and has been successful in obtaining crystal structures for a number of other 
receptors, including that of CRHR1, the first family B GPCR crystal structure 
(Hollenstein et al., 2013). 
The use of detergents is another important factor when obtaining crystals of 
membrane proteins. There are two major groupings of the methods used for this. 
The first is the in surfo methods which utilizes detergent micelles. The other is the 
bilayer method which include the bicelle, vesicle and in meso methods (Caffrey & 
Cherezov, 2009). The in meso or lipid cubic phase (LCP) methods have proved 
considerably successful in obtaining crystals for GPCRs (Caffrey et al., 2012). 
The success in these techniques in obtaining GPCR crystals has led to receptors 
being crystallised in less stable conformations and in complexes with other proteins. 
These include the co-crystallisation of  the 2-AR with its heterotrimeric G protein 
(Rasmussen et al., 2011b), and with the G C-terminus which corresponds to the 
interaction sites between the GPCR and G protein (Scheerer et al., 2008; Standfuss 
et al., 2011). 
1.1.5.2 Extracellular region 
The extracellular region of GPCRs consists of the N-terminal extracellular domain 
(ECD) and the extracellular loops (ECL2) connecting TM2 and 3, TM4 and 5 and TM6 
and 7. The extracellular region of family A GPCRs either covers the TM bundle in the 
case of covalently attached or hydrophobic ligands (Hanson et al., 2012; Palczewski 
et al., 2000) or leaves it open in the cases of receptors with water soluble ligands 
(Cherezov et al., 2007; Haga et al., 2012; Jaakola et al., 2008).  
In the case of rhopdopsin, the ligand is a covalently bound retinal chromophore 
within the TM bundle. The N-terminus of rhodopsin contains 34 amino acids 
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forming strand and -sheet structures over the top of the TM bundle and 
interacting with ECL1 and 3. ECL1 and 3 run parallel with the membrane but the 
structure of ECL2 is a -strand extending across the molecule forming a -sheet 
structure with an anti-parallel -strand running deeper into the pocket (Palczewski 
et al., 2000). The N-terminus of the sphingosine-1-phosphate 1 receptor (S1P1R), 
which binds to a lipid ligand, is an α-helix that forms a cap over the top of the 
receptor. ECLs 1 and 2 of the S1P1R tightly pack over the N-terminus of the receptor 
forming a lid over the TM bundle (Hanson et al., 2012).  
GPCRs that bind water-soluble ligands have a more open extracellular region, 
however structures still vary. In the 2-AR, ECLs 1 and 3 are short loops. ECL2 is 
extended but instead of a -sheet structure it forms a short -helix running parallel 
to the top of the membrane which contains an intra-loop disulphide bond as well as 
the TM3-ECL2 disulphide and also a glycosylation site (Cherezov et al., 2007). 
The -sheet structure of rhodopsin ECL2 is a feature common to the peptide ligand 
receptors of the opioid and the chemokine receptor families (Granier et al., 2012; 
Manglik et al., 2012; Wu et al., 2010; Wu et al., 2012). In other receptors this 
secondary structure element of ECL2 is absent however this domain still folds over 
the TM bundle and facilitates ligand entry to the binding pocket (Haga et al., 2012; 
Kruse et al., 2012). 
Another feature of the extracellular regions are disulphide bonds. The TM3-ECL2 
disulphide is present in most family A GPCRs and additional disulphide bonds have 
been observed that link the N-terminus-ECL2 (gonadotropin releasing hormone 
receptor), the N-terminus-ECL3/TM7 junction (CXCR4), the N-terminus-ECL3 
(AT1AR), ECL1-ECL2 (A2AR) and an ECL3 intraloop disulphide bond (A2AR). N-
glycosylation of ECL2 is seen family A GPCRs. Sequence analysis found that 32% of 
the 613 family A GPCRs studied had at least one N-glycosylation consensus site and 
85% of these were between the top of TM4 and the conserved cysteine of ECL2 
(Wheatley et al., 2012). 
The family B GPCRs have a large N-terminal ECD. Currently, only two crystal 
structures have been solved for the family B TM domains however there are a large 
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number of structures of the ECD regions. These include receptors for AMY2, CGRP, 
CRH1, CRH2 GIP, GLP-1, Glucagon, PAC1, PTH1 and VPAC2 (Hollenstein et al., 2014). 
These structures reveal a common N-terminal -helix followed by two central 
antiparallel -sheets connected by several loops and stabilised by three disulphide 
bonds. 10 out of the 11 peptide-ligand bound complexes have a similar binding 
orientation with the ligand adopting a -helical conformation and binding between 
the two -sheets. For the CGRP and adrenomedullin receptors, there are 
interactions between the N-terminal -helix of the ECD and -helices of 
transmembrane accessory (RAMP) proteins (Kusano et al., 2012; ter Haar et al., 
2010). 
The crystal structures of the CRHR1 and GCGR in 2013 showed structural similarities 
with both the TM domains and the ECLs (Hollenstein et al., 2013; Siu et al., 2013). 
ECL2 is the longest of the loops extending into the middle of the TM bundle. It lacks 
the secondary structure observed in many of the family A GPCRs. ECL3 points away 
from the centre in both receptors. Before these structures, identifying the TM-ECL 
boundaries of the family B GPCRs was attempted through various alignment 
strategies (Chugunov et al., 2010; Donnelly, 1997; Frimurer & Bywater, 1999). 
Alignment of the ECLs found ECL1 to be the most variable in length, ECL2 shows the 
highest conservation across the family and ECL3 is relatively short. The ECLs have 
been implicated in ligand binding and activation (Gkountelias et al., 2009; Koole et 
al., 2012) however the specific mechanism by which this occurs is not yet 
understood. 
The family C GPCRs have a large N-terminal ECD consisting of two regions. The N-
terminal ligand-binding region is divided into an N and C-terminal domain (LB1 and 
2 respectively) (Kunishima et al., 2000). The ligand binds between these two 
domains. The cysteine rich domain is at the C-terminus of the ECD and consists of 
nine cysteine residues and three -sheets. Eight of these cysteine residues are 
involved in four intradomain disulphide bonds stabilising the structure. The 
remaining cysteine forms a disulphide bond with the cysteine in LB2. It is thought 
the cysteine rich domain transmits the signal from the ligand binding domain to the 
TM bundle (Muto et al., 2007). This nine cysteine domain is conserved across family 
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C GPCRs with the exception of the GABAB receptor (Liu et al., 2004b). Another 
property of family C GPCRs is the constitutive dimerisation between the ECDs. This 
dimerisation occurs between hydrophobic patches of LB1 for mGlu1 and is 
stabilised by a disulphide bond between Cys140 of each monomer, located in a 
disordered part of the structure (Kunishima et al., 2000). This interaction can still 
occur even when this cysteine has been mutated (Kunishima et al., 2000; Ray & 
Hauschild, 2000; Romano et al., 2001; Tsuji et al., 2000). This LB1 interaction is also 
observed with the GABA2 receptor (Liu et al., 2004a; Rondard et al., 2008). 
1.1.5.3 TM domains 
GPCRs share a similar TM architecture of seven α-helices arranged in a cylindrical 
bundle. This was definitively shown with the crystal structure of rhodopsin in 2000 
(Palczewski et al., 2000) describing the TM domain as a bundle of α-helices, 
stabilised by interhelical hydrogen bonding. This conformation was confirmed with 
the publication of the β2-AR structure (Rasmussen et al., 2007) and with the 
continuing structures that are being obtained. The TM domain of the β2-AR is 
presented in Figure 1.3, with each helix highlighted a separate colour for clear 
identification. 
Despite this structural similarity, the primary sequence homology of GPCRs is low. 
However there are a number of conserved residues, motifs and inter-helical 
contacts present between receptors. There is a conserved D/ERY motif at the 
cytoplasmic end of TM3, a conserved tryptophan (CWxP motif) in TM6, which is 
predicted to act as a toggle switch and a conserved NPxxY motif near the 
cytoplasmic end of TM7 (Figure 1.4).  
In the D/ERY motif the arginine (R3.50) is conserved in 96% of family A GPCRs and 
forms a salt bridge with the preceding D/E3.49 in every solved inactive family A 
structures (Katritch et al., 2013). R3.50 also forms hydrogen bonds with a glutamate 
(E6.30) at cytoplasmic end of TM6 in the rhodopsin receptor (Palczewski et al., 2000). 
These interactions were also observed in the D3 receptor and the A2AR (Chien et 
al., 2010; Doré et al., 2011). 
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Figure 1.3. TM domain of the β2-AR (PDB 2RH1).  
Each TM helix (including helix 8) has been highlighted a different colour. TM1 is red, TM2 is 
yellow, TM3 is green, TM4 is cyan, TM5 is blue, TM6 is magenta, TM7 is purple and H8 is 
light blue. The receptor is presented in four orientations. The top two are parallel to the 
membrane rotated 180°. The bottom two are perpendicular to the membrane from the 
extracellular and intracellular side. 
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Figure 1.4. Conserved GPCR motifs highlighted using the β2-AR structure (PDB 2RH1).  
These are the D/ERY motif at the cytoplasmic end of TM3, the CWxP motif in TM6 and 
NPxxY motif in TM7. 
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In the 2-AR the proximity of R3.50 to E6.30 is not close enough for hydrogen bonding 
however there are hydrophobic residues at the cytoplasmic ends of TM3, 5 and 6 
that are close enough to form interactions with each other and a hydrogen bond 
between Y3.60 (ICL2) and H6.31 is present (Cherezov et al., 2007; Rasmussen et al., 
2007). In the histamine H1 receptor the ionic lock is absent however R3.50 forms a 
hydrogen bond with Q6.36 in TM6 (Shimamura et al., 2011). The DRY motif also 
interacts with ICL2 stabilising it in a conformation that can interact with the G 
protein. The arginine of this motif also directly interacts with the G protein through 
a tyrosine residue and with the tyrosine in the NPxxY motif of TM7 (Rasmussen et 
al., 2011b).  
The CWxP motif in TM6 is highly conserved in non-olfactory family A GPCRs. P6.50 
creates a kink in the helix. W6.48 and F6.44 move towards P5.50 during activation in a 
process named the transmission switch (originally called the rotamer toggle switch) 
(Deupi & Standfuss, 2011). In inactive structures C6.47 interacts with 7.44/7.45 in 
TM7 which constrains TM6 and TM7 preventing the interaction that occurs 
between N7.49 and D2.50 in the active state (Olivella et al., 2013). 
The NPxxY motif is located near the cytoplasmic end of TM7 (Figure 1.4). The Y7.53 
residue is highly conserved (92%) and is orientated towards TM1, 2 or 8 in inactive 
structures. In active structures the Y7.53 side chain changes conformation and is 
orientated towards the middle of the TM bundle forming interactions with TM3 and 
6. In may also form a water mediated hydrogen bond with a conserved Y5.58 reside 
in TM5 (Katritch et al., 2013). 
A common set of interactions is maintained through highly conserved (N1.50, D2.50, 
W4.50 and P7.50) and non-conserved residues. These interactions are orientated in 
the middle and cytoplasmic sides of the TM bundle between TM1-2, TM3-4, TM3-5 
and TM3-6-7. Given the lack of movement of TM1 and 2 during activation it was 
proposed that these conserved interactions are important for correct folding, 
membrane insertion and receptor structure. TM3 is a structural hub. This domain is 
inserted into the membrane at a tilted angle, which may facilitate these multiple 
interactions. The consensus contacts with TM4 and 6 occur in the middle of the 
domain and with TM2 and 5 on the cytoplasmic side (Venkatakrishnan et al., 2013).  
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Prolines in several of the helices caused kinking, most predominantly in TM6. 
Prolines are a common feature in GPCR TM domains and are predicted to enable 
the structural re-arrangement that occur during activation (Cherezov et al., 2007). 
The two crystal structures of family B GPCRs have confirmed the consistent 7TM 
bundle structure seen with the family A GPCRs and predicted throughout this 
receptor family (Hollenstein et al., 2013; Siu et al., 2013).  Examination of these two 
structures in greater detail does reveal some notable differences. 
The N-terminus of TM1 in the glucagon receptor (GCGR) extends much further into 
the extracellular space than observed in family A structures (Siu et al., 2013). The 
reasons for this were speculated to be for glucagon binding and orientation of the 
ECD. The distance between the extracellular ends on TM2 and 6 and 3 and 7 is 
much larger than for most other GPCRs creating a wide deep cavity of the ligand-
binding pocket, much larger than for family A GPCRs. This V shaped TM binding 
pockets was also a feature of the CRHR1 (Hollenstein et al., 2013). In TM7 of both 
receptors, the conserved proline in the family A NP(7.50)xxY motif is absent 
however the glycine (7.50) that replaces it results in a helical bend. In the GCGR, 
this is stabilised by hydrophobic interactions with F184 in helix 2. 
The TM domains of the family C GPCRs share a number of the conserved residues of 
family A. These include the cysteine residues of TM3 and ECL2, that form a 
disulphide bond, W6.50 in TM6 and conserved basic residues at the bottom of TM3 
that were proposed to function similarly to the DRY lock (Binet et al., 2007). 
1.1.5.4 Intracellular region 
The intracellular region of GPCRs consists of three ICLs connecting TM1 and 2, TM3 
and 4 and TM5 and 6. Following TM7 in some GPCRs is another α-helix (helix 8), 
which associates with the plasma membrane through palmitoylation sites. 
Following helix 8 (H8) is an intracellular C-terminal domain. ICL1 is often a short 
loop consisting of a helical turn. The length of ICL2 is most conserved but the 
secondary structure is more varied, usually consisting of a one or two turn α-helix 
or an unstructured stretch of amino acids. ICL3 varies considerably in length across 
the family A GPCRs which was proposed to relate to selectivity to different G 
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proteins. Crystal structures usually find ICL3 to be disordered (Moreira, 2014; 
Venkatakrishnan et al., 2013). In the opioid receptors, ICL2 is tethered to TM3 
through a salt bridge between an ICL2 arginine and D3.49 of the DRY motif 
(Thompson et al., 2012). A similar effect occurs with some aminergic receptors, 
which have an ICL2 tyrosine that forms hydrogen bonds with the DRY aspartate 
(Valiquette et al., 1995; Warne et al., 2008). In the crystal structure of the β2-AR 
complex with the G protein, ICL2 formed interactions with the Gα N-terminus 
(Rasmussen et al., 2011b). ICL2 was also important for G protein coupling in the 
dopamine receptor, m5 muscarinic receptor and m3 muscarinic receptor (Blin et al., 
1995; Burstein et al., 1998; Han et al., 2009). The ICL2 domain of the TSHR had 
residues important for both Gαs and Gαq coupling (Kosugi et al., 1994). ICL3 is also an 
important domain for G protein-coupling. Basic, polar and hydrophobic residues are 
involved in coupling to different G proteins (Burstein et al., 1996; Dalman & Neubig, 
1991; Wade et al., 1996). The C-terminus is usually implicated in receptor 
phosphorylation however ICL3 can be phosphorylated in multiple receptors and in 
some cases ICL1 and 2 (Gurevich & Gurevich, 2006).   
1.1.6 Post-translational modifications 
Following expression, GPCRs can undergo a number of post-translational 
modifications. These include glycosylation of the N-terminal ECD and the ECLs, 
phosphorylation and palmitoylation of the intracellular C-terminal domain and the 
ICLs and interactions with cholesterol and the TM domain (Chini & Parenti, 2009; 
Tobin, 2008; Wheatley & Hawtin, 1999; Wheatley et al., 2012).  
Glycosylation can either be N-linked through the nitrogen of the asparagine side 
chain amide group, or O-linked glycosylation through the hydroxyl group of serine 
or threonine residues (Wheatley & Hawtin, 1999). N-linked glycosylation occurs at 
the NXS/T consensus sequence in the endoplasmic reticulum (ER) and the Golgi. O-
linked glycosylation lacks a consensus motif making it harder to study (Duvernay et 
al., 2005). N-linked glycosylation has been found in both the N-terminal ECD and 
the ECLs. Glycosylation can be essential for successful expression to the cell surface 
(Deslauriers et al., 1999) and efficient folding of the receptor (Davis et al., 1995), 
but in other cases has no effect on cell surface expression, ligand binding or 
38 
 
receptor signalling (Fukushima et al., 1995; van Koppen & Nathanson, 1990). In the 
β2-AR, glycosylation of ECL2 was not required for successful cell surface expression 
and internalisation, however was required for the receptor to enter the degradation 
pathway following prolonged agonist exposure (Mialet-Perez et al., 2004). 
Palmitoylation is the addition of a 16 carbon saturated fatty acid (palmate), most 
often to cysteine residues through a thioester bond. It was first described in the 
transferrin receptor (Omary & Trowbridge, 1981) then in rhodopsin where it was 
located at the end of helix 8 and inserted into the membrane (Moench et al., 1994; 
O'Brien & Zatz, 1984; Palczewski et al., 2000). Palmitoylation was discovered in β2-
AR which confirmed that in was a general feature of GPCRs and not just specific to 
rhodopsin (O'Dowd et al., 1989). Palmitoylation appears to be important for cell 
surface expression of the receptor (Karnik et al., 1993) and to prevent degradation 
(Gao et al., 1999). Palmitoylation has been shown to be a transient process, with 
increased palmate turnover occurring in response to agonist binding. This has an 
influence on downstream signalling, including coupling with the G protein, 
phosphorylation, desensitization, internalisation and down-regulation (Qanbar & 
Bouvier, 2003). A bound cholesterol was discovered in the crystal structure of β2-AR 
between TM2 and 4 (Hanson et al., 2008). 
1.1.7 Ligand binding 
1.1.7.1 Ligand-receptor binding sites 
The binding of ligands to family A GPCRs occurs on the extracellular side of the TM 
bundle. Some ligands bind deeply into the pocket (doxepin at the human histamine 
H1 receptor) (Shimamura et al., 2011) and others bind closer to the ECLs (IT1t at the 
CXCR4) (Wu et al., 2010). In a consensus analysis of the receptor it was found that 
certain residues of TM3, 6 and 7 contact the ligand in nearly all receptors. 
Interactions with other residues occur on a more ligand-specific basis with the 
exception of TM1, which does not form any direct ligand binding contacts 
(Venkatakrishnan et al., 2013). 
Ligand binding of the 2-AR is similar to that of the retinal bound rhodopsin 
structure. The inverse agonist carazol does not bind as deeply as the retinal 
39 
 
chromophore however they both interact with a series of aromatic residues in TM5 
and 6, which are positioned around the conserved tryptophan residue in TM6 
(Cherezov et al., 2007; Palczewski et al., 2000).  The antagonist ligand-binding 
pocket of the D3R was similar to 2-AR interacting with side chains of TM3, 5, 6 and 
7. The lipid ligand sphingosine-1-phosphate binds to an amphipathic binding pocket 
in the TM bundle however the extracellular side is covered by the receptor N-
terminus and ECLs 1 and 2. The entry of this ligand is through the lipid bilayer, 
between TM1 and 7 (Hanson et al., 2012). 
Ligand binding at family B GPCRs occurs predominantly at the N-terminal ECD. The 
peptide ligands of this family form an amphipathic α-helix at their C-terminus and 
form interactions with a hydrophobic ligand binding groove created by an N-
terminal α-helix and two antiparallel β-sheet structures of the ECD (Hollenstein et 
al., 2014). This allows the N-terminus of the ligand to interact with the receptor 
ECLs and TM bundle stabilising the active conformation through a “two-domain” 
model of ligand binding (Hoare, 2005). This will be discussed in greater detail in the 
family B GPCR section later in the review. 
Ligand binding of family C GPCRs occurs at the venus fly trap (VFT) domain of the 
large N-terminus. It was likened to that of the bacterial periplasmic binding protein 
(O'Hara et al., 1993). Understanding of the ligand binding mechanism was greatly 
enhanced with the mGlu1 receptor ECD structure in the presence and absence of 
glutamate (Kunishima et al., 2000). These bi-lobed ECDs exist in an open and closed 
conformation and each receptor dimer in a resting and active state. In an open 
conformation, the glutamate ligand makes contacts with the LB1 domain. In the 
closed conformation the ligand makes contacts with both LB1 and 2 domains. In the 
resting orientation, the dimers interact through LB1. Binding of the ligand (in this 
case glutamate) causes the lobes to reorganize allowing the LB2 to interact resulting 
in the activation of the receptor (Tsuchiya et al., 2002). The ligand binding affinity is 
not just based on the interactions between ligand and receptor but also the 
equilibrium constant between the open and closed conformations (Parmentier et 
al., 2002).  
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1.1.7.2 Binding affinity and the ternary complex model 
Research into the affinities of receptor agonists and antagonists in the β-adrenergic 
receptor system found that the affinity of antagonists remained the same in the 
presence of absence of guanine nucleotides. The affinity of agonists to the β-
adrenergic receptor reduced in the presence of guanine nucleotides (Maguire et al., 
1976; Williams & Lefkowitz, 1977). This led to the ternary complex model which 
described the interaction of the receptor to an additional membrane component 
which caused the high affinity state for ligand binding (De Lean et al., 1980). The 
effect of adding the guanine nucleotides was to de-stabilise the ternary complex 
causing the dissociation of both the ligand and the component protein. This 
component is the G protein.  
1.1.8 GPCR activation 
An active GPCR has adopted a conformation that allows the coupling and 
stabilisation of an effector molecule resulting in a downstream response 
(Venkatakrishnan et al., 2013). It was originally thought that a receptor behaves as a 
molecular “switch” existing in either an on or off conformation (Schwartz et al., 
2006). However current understanding is that GPCRs can exist in multiple 
conformational states allowing binding to different effectors, facilitating a range of 
downstream signalling responses (Kenakin & Miller, 2010). Ligand binding stabilises 
a particular receptor conformation. This can result in full activation of a signalling 
pathway (agonist), partial activation (partial agonist), binding to the receptor with 
no effect on basal signalling (antagonist) and stabilising the inactive receptor 
conformation (inverse agonist) (Hill, 2006). Ligand affinity is also dependent on the 
interaction of the receptor with its G protein described as the ternary complex 
model (De Lean et al., 1980). Ligand-specificity of a single receptor can also result in 
the activation of different signalling pathways with a mechanism described as 
biased agonism or functional selectivity (Kenakin, 2007). 
Two explanations for a conformation change in proteins induced by molecule 
binding have been proposed. The first is the conformational induction mechanism 
in which the binding of a molecule contributes energy to induce a conformational 
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change (Koshland, 1958). In terms of GPCRs this would mean the ligand binds to the 
low energy inactive state and induces a conformational change to the active state. 
The second is the conformational selection mechanism where molecules bind to 
pre-existing conformations, stabilising them and shifting the equilibrium in favour of 
these structures (Monod et al., 1965). Model simulations favored conformational 
selection as the mechanism for small molecule-protein interactions which include 
ligand-receptor interactions (Okazaki & Takada, 2008).  
1.1.8.1 Crystal structures of active GPCRs 
Understanding of the structural changes that occur between the inactive and active 
receptor were greatly enhanced with the publication of the β2-AR in complex with 
both an agonist and a G protein-like nanobody (Rasmussen et al., 2011a) and the 
β2-AR in complex with an agonist and the heterotrimeric G protein (Rasmussen et 
al., 2011b). The TM helices of these structures together with the inactive β2-AR 
structure are shown in Figure 1.5. The β2-AR-Nb80 structure was solved by 
immunizing a llama with purified agonist bound β2-AR reconstituted at high density 
into phospholipid vesicles (Rasmussen et al., 2011a). The differences between this 
active structure and the inactive structure are mainly on the cytoplasmic side, with 
outward movements of TM 5 and 6, inward movements of TM 3 and 7 and the 
formation of a two-turn α helix at ICL2. The largest conformational change was TM6 
with an 11.4Å movement of the helix at Glu2686.30. This was facilitated by a small 
rotation of the helix just before the conserved TM6 proline (Pro2886.50). The β2-AR-
Gs structure was solved by mixing purified GDP-Gs with purified β2-AR bound to a 
high affinity agonist (Rasmussen et al., 2011b). The GDP released when Gs formed a 
complex with the β2-AR was hydrolysed to prevent the disruption of the high 
affinity β2-AR-Gs interaction that can occur in presence of GTP and GDP. The main 
differences between the inactive and active structures are a 14Å outward 
movement of TM6 and a smaller outward movement and extension on TM5 on the 
intracellular side. The β2-AR active state structure is stabilised with extensive 
interactions with the Gαs subunit but there are no direct interactions with Gβγ. In 
this crystal structure there is a 127° displacement of the GαsAH domain with relation 
to GαsRas (Figure 1.6). In the Gαs-GTPγS crystal structure the nucleotide binding  
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Figure 1.5. Crystal structures of the β2-AR in an inactive (PDB 2RH1) and two active 
conformations (G protein bound PDB 3SN6 and nanobody stabilised PDB 3P0G).  
Each TM helix (including helix 8) has been highlighted a different colour. TM1 is red, TM2 is 
yellow, TM3 is green, TM4 is cyan, TM5 is blue, TM6 is magenta, TM7 is purple and H8 is 
light blue. The receptor is presented in three orientations all parallel to the plasma 
membrane with 120° rotations. 
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Figure 1.6. Crystal structures of the heterotrimeric G protein in different conformations. 
The top row is the Gs subunit bound to the non-hydrolysable GTPS (PDB 1AZT) presented 
in two different orientations, parallel to the plasma membrane. The middle row is the Gs 
subunit in the 2-AR-Gs crystal structure (PDB 3SN6). The bottom row presents all the 
components of the 2-AR-Gs crystal structure (PDB 3SN6). The GTPase (Gs Ras domain) is 
cyan with the GPCR interactions areas (from the PDB3SN6 structure) highlighted yellow. 
The N-terminal  helix is green. The -helical domain is magenta. The three switch regions 
are highlighted red and the bound GTPS presented in the structure in the top row is blue. 
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pocket is at the interface of these two domains (Sunahara et al., 1997). Guanine 
nucleotide binding stabilises these two domains and the crystal structures shows 
the flexibility of this protein.  
1.1.8.2 Mechanism of activation 
In the β2-AR and A2AR, ligand-binding pulls the extracellular sides of TM3, 5 and 7 
together (Lebon et al., 2011; Rasmussen et al., 2011b; Rosenbaum et al., 2011; Xu 
et al., 2011). This causes structural changes around P5.50 in TM5 resulting in 
intracellular movement of the helix (Sansuk et al., 2011). Rearrangement of the 
TM5-6 interface is coupled with rotation of TM6 near F6.44. This rotation causes a 
large intracellular movement of this kinked helix opening the cleft required for G 
protein-binding (Standfuss et al., 2011). TM6 is held close to TM3 in the inactive 
state through different mechanisms. One includes the interactions with the R3.50 of 
the DRY lock motif and a glutamate in TM6 (Palczewski et al., 2000). Another 
includes hydrophobic interactions between L3.43 and I6.40 occurring in the β2-AR and 
the M2 mAChR (Hulme, 2013). Release of TM6 allows interactions between TM7 
and TM1 and 2 to occur. This repositioning of TM7 prevents TM6 from moving back, 
stabilising the active receptor conformation (Scheerer et al., 2008). Inactive and 
active conformations of the β2-AR are presented in Figure 1.5. The two active 
structures depict the β2-AR bound to agonist and either in complex with the Gαsβγ 
protein (Rasmussen et al., 2011b) or stabilised by a G protein resembling a 
nanobody (Rasmussen et al., 2011a). 
In the active conformation, the cytoplasmic end of TM3 forms interactions with the 
heterotrimeric G protein. A key interaction is between the R3.50 of the DRY motif 
and a backbone carbonyl at the C-terminus of the G protein. A consensus interface 
of at least 8 residues has been identified in TM3, 5 and 6 that bind to the G protein. 
The receptor interaction areas of the G protein are highlighted in Figure 1.6. The N-
terminus of the G protein interacts with ICL2 (Choe et al., 2011; Deupi et al., 2012; 
Rasmussen et al., 2011b). The side chains of N7.49, Y7.53, R3.50 and GαsY391 have a 
linear orientation parallel to TM3 in the activated state with R3.50 being the upper 
insertion point of the G protein (Rasmussen et al., 2011b). Contrastingly, F3.58 in 
ICL2 has the deepest insertion into the G protein interacting with the N and C 
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terminal Gαs helices and residues in the β2 -β3 strand (Moro et al., 1993). Similar 
interactions were observed between an M3mAChR ICL2 leucine and the N-terminal 
helix of Gqα (Hu et al., 2010). The Gαs α5 helix also forms interaction with the TM5 
and 6 that have moved during activation (Rasmussen et al., 2011b). 
The activation of the family C GPCRs is initiated through the dramatic 
conformational change of the ECD dimer. Each monomer exists in an open and 
closed state and each dimer can exist in a resting and active conformation. Binding 
to the ligand stabilises the closed active conformation (although all combination 
have been observed) which brings the each LB2 domain into close proximity 
(Kunishima et al., 2000; Tsuchiya et al., 2002). This mechanism was confirmed with 
the GABAB receptor.  The introduction of N-glycosylation preventing the interaction 
of the LB2 domains resulted in a loss of receptor activation (Rondard et al., 2008). 
FRET analysis confirmed the movement of the TM helices of each monomer during 
receptor activation (Tateyama et al., 2004). 
In the mGlu1 receptor, binding of glutamate to one receptor monomers results in 
partial activation however binding of glutamate to each monomer caused a full 
activation (Kniazeff et al., 2004). However with the GABAB receptor, the ligand only 
binds to just the GABAB1 monomer, which is sufficient for receptor activation 
(Galvez et al., 2000; Kniazeff et al., 2002). Similarly the taste receptors share a T1R3 
subunit with ligand specificity determined by the T1R1/2 subunit of the dimer 
(Chandrashekar et al., 2006). 
1.1.9 GPCR signalling  
1.1.9.1 GPCR signalling components 
1.1.9.1.1 G proteins 
A G protein is a guanine nucleotide binding protein. They bind to GTP and cause the 
hydrolysis to GDP. The G proteins associated with GPCRs are heterotrimeric 
proteins consisting of an ,  and  subunit however small monomeric GTPases also 
exist (McCudden et al., 2005). Considering the quantity of GPCRs in the human 
genome, there are relatively few G proteins. There are 21 G subunits (16 genes), 6 
G subunits (5 genes) and 12 G subunits (Downes & Gautam, 1999). The G proteins 
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are divided into classes according to the G subunit. These are Gs, Gi, Gq and 
G12/13 (Simon et al., 1991). The class of subunit determines which signalling 
pathway becomes activated.  
The G subunit consists of two domains (Figure 1.6). A GTPase (Ras) domain and an 
-helical domain (Sunahara et al., 1997). The GTPase domain is conserved in all G 
protein families including monomeric G proteins and elongation factors. This 
domain hydrolyses GTP and interacts with the  subunits, the GPCR and effector 
proteins. This domain also contains three loops (switches) that undergo 
conformational changes following binding to GTP or GDP. The -helical domain is 
only found in G and forms a lid over the nucleotide-binding pocket. Modifications 
at the N-terminus are involved in membrane and proteins interactions. The G 
subunit has an N-terminal -helix followed by a seven bladed -propeller structure. 
The N-terminus of G interacts with the N-terminal helix of G and the C-terminus 
with blades 5 and 6 (Oldham & Hamm, 2008). This interaction is only dissociated 
under denaturing conditions (Schmidt et al., 1992). 
The best characterised contacts site of the G protein with an activated GPCR are 
through its C-terminal -helix (Janz & Farrens, 2004) however interactions also 
occur with the N-terminal helix and contact sites within the GTPase domain (Figure 
1.6). In the active structure of 2-AR, there are no direct contact sites between the 
GPCR and the G subunits however G does stabilise the N-terminal -helix of G 
(Rasmussen et al., 2011b).  
There are two proposed models by which the G protein couples with its receptor. 
The first is the “collision coupling” model, which predicts that the G protein 
encounters an activated receptor, binds and signals (Tolkovsky & Levitzki, 1978). 
The other is the “pre-coupled” model which predicts that the G protein binds to its 
receptor before agonist activation (Galés et al., 2006). The pre-coupling model 
explains the specificity between receptor and G protein coupling and the rapid 
response time in signalling however it does not account for the amplification of 
signalling (Hamm et al., 1987). The “collision coupling” model is supported by 
kinetic and live cell imaging data, however co-purification and co-
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immunoprecipitation experiments on inactive GPCRs and G protein and energy 
transfer experiments with labelled receptor and G proteins supports the “pre-
coupled” model (Hein & Bünemann, 2009). Emerging evidence suggest that 
receptors can function through both models and it depends both on the type of 
receptor and G protein involved (Jakubík et al., 2011). 
1.1.9.1.2 Arrestins 
There are four members of the arrestin family. Arrestin 1 and 4 are the visual 
arrestins, expressed in the rod and cone cells (Craft et al., 1994; Wilden et al., 
1986).  Arrestin 2 and 3 (alternatively named -arrestin 1 and -arrestin 2) interact 
with the non-visual GPCRs and are ubiquitously expressed (Attramadal et al., 1992; 
Lohse et al., 1990). The early view of the -arrestins was that they bound to the 
activated GPCR following serine/threonine (S/T) phosphorylation of the C-terminus 
or ICL3, blocking G protein binding resulting in desensitization of the receptor 
(Shenoy & Lefkowitz, 2003a). 
Arrestins share a similar structure (Figure 1.7) of an N and C-terminal domain with a 
central polar core, connected by a C-terminal tail (Han et al., 2001). In the inactive 
conformation the C-terminal tail lies along the N-terminal domain of the arrestin 
molecule. This is displaced by the receptor through interactions with its 
phosphorylated residues. Upon activation there is a conformation change of 
arrestin, with a substantial twisting of the N and C-terminal domains in relation to 
each other increasing the affinity to the activated receptor (Kim et al., 2013; Shukla 
et al., 2013). 
1.1.9.1.3 G protein-coupled Receptor Kinases (GRKs) 
G protein-coupled Receptor Kinases (GRKs) were first identified in rhodopsin 
following the discovery of rhodopsin phosphorylation following activation (Bownds 
et al., 1972; Kühn & Dreyer, 1972; Weller et al., 1975). Receptor phosphorylation 
was subsequently observed in the 2-AR (Sibley et al., 1985; Stadel et al., 1983). 
The kinase responsible for this phosphorylation was identified as the  adrenergic 
receptor kinase, which later became known as GRK2. Since then a further five GRKs 
have been discovered. These seven GRKs are split into three subfamilies. These are  
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Figure 1.7. Crystal structures of key GPCR signalling components.  
The top row is the Gs subunit interacting with its effector protein, adenylate cyclase. The 
GTPase (Gs Ras domain) is cyan with the GPCR interactions areas (from the PDB3SN6 
structure) highlighted yellow. The three switch regions are highlighted red. The adenylate 
cyclase is light blue and purple. The complex is presented in two orientations, parallel to 
the plasma membrane and perpendicular to the plasma membrane from the intracellular 
side. The second row is the crystal structure of GRK2 coupled with . GRK is cyan, with the 
RGS domain highlighted magenta, the kinase domain yellow, the AGC kinase C-terminus is 
green and the PH domain is red. The nucleotide-binding domain has been highlighted blue. 
The GRK2 crystal structure is in two orientations, planar to the membrane. In the second 
image the  subunits are absent. The bottom row is the crystal structure of the inactive 
and active conformations of -arrestin 1. In the inactive conformation the C-terminal tail 
lies along the N-terminal domain of the arrestin molecular. This is displaced by the receptor 
(GPCR phosphopeptide) in the active structure. 
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GRK1 and 7 (visual kinases), GRK2 (2 and 3) and GRK 4 (4, 5 and 6). GRK1 and 7 are 
expressed in the retinal rods and cones respectively. GRKs 2, 3 and 5 are expressed 
in mammalian tissues however GRK4 is limited to the cerebellum, kidney and testis 
(Pitcher et al., 1998). GRKs consist of an N-terminal helix that binds the kinase to 
the active GPCRs and is important feature for the kinase activity (Lodowski et al., 
2006; Palczewski et al., 1993), a Regulator of G protein Signalling (RGS) homology 
domain (HD), an S/T protein kinase domain (KD) and a C-terminus that contains 
different structural features that are responsible for membrane targeting (Figure 
1.7). These membrane-binding domains facilitate GRK function but are not required 
for phosphorylation (Mushegian et al., 2012). The kinase domain is inserted into a 
loop of the RH domain. The kinase domain consists of two lobes (small and large) 
with the active site in between (Lodowski et al., 2006), followed by a C-tail of which 
a central segment called the active site tether (AST) becomes ordered once the 
kinase adopts a closed active conformation (Kannan et al., 2007). This domain was 
crystallised in an open conformation in the presence of a nucleotide analogue, 
which is in contrast to other AGC kinases (Taylor et al., 2004). 
The N-terminal helix is amphipathic and contains conserved residues that do not 
appear to be orientated towards the kinase domains (Lodowski et al., 2006). It is 
thought that similar to G proteins, this region is disordered until in comes in contact 
with the GPCR (Huang & Tesmer, 2011). The N-terminal helix interacts with the 
kinase domain through conserved residues (Boguth et al., 2010). A hydrophobic 
patch at the N-terminus of the N-terminal helix is predicted to interact with the 
GPCR (Leitz et al., 2006) and a positively charged region adjacent to this helix is 
correctly positioned to interact with the lipid bilayer (Pitcher et al., 1996). 
1.1.9.2 G protein-dependent signalling 
In the inactive state, the G protein exists as a GDP bound G heterotrimer. The 
active conformation of a GPCR acts as a guanine nucleotide exchange factor (GEF) 
catalyzing the exchange of GDP to GTP (Gilman, 1987). The nucleotide binding site is 
separate from the receptor contact sites, therefore GDP release must be through 
conformation changes of the G protein (Natochin et al., 2001). These 
conformational chances may open up the gap between the GTPase and the helical  
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domains, releasing the bound GDP (Grishina & Berlot, 1998). GDP binding is 
stabilised through hydrophobic interactions with the C terminal helix and a -strand 
(Natochin et al., 2000). There is evidence showing that the opening of the 
nucleotide binding pocket is induced by a movement of the  domain, however 
there is no agreement as to the precise mechanism through which this occurs 
(Oldham & Hamm, 2008).The receptor bound, nucleotide free G subunit has equal 
affinity for both GTP and GDP (Heck & Hofmann, 2001). Binding of GTP occurs due 
to a higher GTP concentration in the cell (Bos et al., 2007). Binding of GTP causes 
conformational changes in the three switch regions (Figure 1.6). This results in a 
hydrophobic patch that binds to the  subunit becoming disrupted by charged 
residues, leading to dissociation of the complex (Lambright et al., 1996; Noel et al., 
1993). 
The exchange of GDP for GTP causes a conformational change of the G subunit 
resulting in the dissociation of the G protein from the receptor and also the G unit 
from  (Oldham & Hamm, 2008). Both of the dissociated G and  subunits can 
activate effector proteins resulting in second messenger molecules, which initiate a 
cellular response. Each class of the G subunit activates a specific pathway. Gs 
binds to adenylate cyclase (Figure 1.7) resulting in an increase in the second 
messenger cAMP (May et al., 1985; Pfeuffer et al., 1983). It has also been found to 
activate Ca2+ channels and inhibit Na+ channels (Mattera et al., 1989; Schubert et 
al., 1989). Gi inhibits adenylate cyclase resulting in a decrease in cAMP levels 
(Taussig et al., 1993). The Gq family (Gq, G11, G14, G15 and G16) activates the 
effector enzyme phospholipase C (PLC) which catalyses the hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP2) creating the second messengers 
inositol 1,4,5 triphosphate (IP3) and diacylglcerol (DAG) (Hepler & Gilman, 1992). IP3 
releases Ca2+ from intracellular stores and DAG activates protein kinase C (PKC) 
(Steinberg, 2008). The G12 subfamily consists of the G12 and G13 subunits 
(Strathmann & Simon, 1991). They are similar both in primary sequence and 
biochemical properties and ligands are able to activate both subtypes, however 
they do have specific physiological responses (Kozasa et al., 2011). They signal 
through the Rho family of GTPases, a family of peripheral membrane proteins. 
51 
 
These cycle between an inactive GDP bound and active GTP bound state that 
regulate cellular process such as morphology, migration, cell cycle and gene 
transcription (Aittaleb et al., 2010). 
The  component was originally thought to be a regulator of the G subunit, 
stabilising the GDP bound form and anchoring the heterotrimer to the membrane. 
However it was found that  could independently signal, first in yeast (Blumer & 
Thorner, 1991) and then in mammalian cells, acting on both adenylate cyclase and 
PLC (Camps et al., 1992; Tang & Gilman, 1991). 
1.1.9.3 G protein independent signalling 
-arrestins were first identified as being able to initiate signalling pathways 
independent of the G protein through the activation of MAPK signalling and the 
formation of -arrestin-src complexes (Daaka et al., 1998; Luttrell et al., 1999). 
Using agonists and mutants of the ATR1 which prevented G protein-coupling it was 
shown that the receptor could still activate MAPK through a -arrestin 2 dependent 
pathway (Wei et al., 2003). Signalling can also be temporally dependent with early 
ERK1/2 signalling through Gs and Gi and late ERK1/2 signalling through -arrestin1 
and 2 (Shenoy et al., 2006) and inverse agonists have been found to activate ERK1/2 
through -arrestin, independent of cAMP production (Azzi et al., 2003). -arrestins 
have also been found to signal through Akt (protein kinase B) (Beaulieu et al., 2005) 
and RhoA (Barnes et al., 2005). 
-arrestins are able to scaffold MAPK signalling components to the plasma 
membrane preventing their translocation to the nucleus. This changes the cellular 
effects from transcriptional regulation to cytoskeletal reorganization and 
chemotaxis. They can also bind regulatory units to inhibit signalling pathways, or 
converge on G protein dependent pathways to act synergistically (Defea, 2008).  
-arrestin ERK activation can also depend on the GRK that is activating the GPCR. 
GRK5 and 6 were required for -arrestin dependent ERK activation of the AT1AR, 
V2R and 2-AR. GRK2 and 3 attenuated signalling (Reiter & Lefkowitz, 2006).  
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1.1.9.4 GPCR phosphorylation, desensitization and internalisation 
GPCR phosphorylation was first described for rhodopsin following light activation 
(Bownds et al., 1972; Kühn & Dreyer, 1972) through an opsin kinase, which later 
became GRK1 (Weller et al., 1975). This effect was then described with the 2-AR  
(Sibley et al., 1985; Stadel et al., 1983) through a different kinase that became GRK2 
(Benovic et al., 1986). Phosphorylation of rhodopsin caused the binding of another 
protein (arrestin), which physically prevented the binding and subsequent signalling 
of the G protein. The discovery of an arrestin homologue which caused 
desensitization of 2-AR signalling led to a two-step mechanism of GPCR 
deactivation (Benovic et al., 1987). Rhodopsin is phosphorylated on serine and 
threonine residues on the intracellular C-terminus (Ohguro et al., 1993), however 
GPCRs can be also be phosphorylated on any of the ICLs (Tobin, 2008). Given this 
variety in both the domain being phosphorylated and the number of receptors to 
which the β-arrestins bind, it has been proposed that bulk negative charge is the 
important factor in arrestin binding (Gurevich & Gurevich, 2006). Recruitment of 
arrestin to a GPCR can be both phosphorylation dependent and independent (Min 
et al., 2002). GPCR binding to the arrestin disrupts an ionic lock in the arrestin and 
induces a conformational change, which creates a high affinity binding between the 
GPCR and arrestin. Binding of arrestin to the intracellular region of GPCRs forms a 
cap over the receptor preventing the coupling of the G protein resulting in receptor 
desensitisation (Gurevich & Gurevich, 2006). Subsequently it was found that -
arrestins can interact with cAMP phosphodiesterases enhancing their activity 
demonstrating a second mechanism of -arrestin desensitisation (Perry et al., 
2002). 
The S/T cluster of residues in the C-terminus is not present in all receptors and 
appears to influence -arrestin binding affinity.  Receptors have been split into two 
classes based on this feature (separate from the A-F/GRAFS classification systems). 
Class A receptors (eg. 2-AR, -opioid receptor, dopamine D1A receptor, and 1b-
AR) do not contain this S/T rich domain. They recruit -arrestin 2, traffic to clathrin 
coated pits and then dissociate, internalising without the -arrestin and recycle 
rapidly. Class B receptors (eg. angiotensin II type 1A receptor, neurotensin receptor 
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1 and vasopressin V2 receptor) recruit both -arrestin 1 and 2 with equal and higher 
affinity and internalise together forming stable endosomal vesicles (Oakley et al., 
2001; Oakley et al., 2000). 
Following desensitisation, the receptor becomes internalised. Internalisation allows 
the dephosphorylation and re-sensitisation of the receptor through recycling back 
to the cell surface, the down regulation of the receptor through the degradation 
pathway or the activation of intracellular signalling pathways. A common 
mechanism of endocytosis is through clathrin coated vesicles, however other routes 
such as caveolae or other uncoated vesicles have also been described (Claing et al., 
2002). In this process, arrestin acts as a scaffold molecule recruiting the 
components of the clathrin coated machinery to the GPCR. These include clathrin 
itself and the adapter protein AP2 (Lefkowitz & Shenoy, 2005). -arrestin is also 
able to recruit ubiquitin ligase, resulting in the ubiquitination of the -arrestin 
protein, essential for clathrin mediated endocytosis. This ubiquitination is transient 
for the class A endocytotic receptors and sustained for class B (Shenoy & Lefkowitz, 
2003b; Shenoy et al., 2001). 
1.1.9.5 GPCR recycling and degradation 
Once the GPCR becomes internalised, the receptor can follow one of two pathways. 
The first is a recycling of the receptor back to the cell surface; the second is 
degradation. There are C-terminal sequence motifs that direct the GPCR to a 
specific pathway. A four residue motif (DSLL) of the β2-AR was transferred into the 
δ-opioid receptor re-directing the post-endocytotic process from degradation to 
rapid recycling (Gage et al., 2001). The affinity of the receptor to arrestin also 
determines whether the GPCR is recycled or degraded (Oakley et al., 2001; Oakley 
et al., 2000). Post-endocytotic sorting to lysosomes is mediated by C-terminal tail 
motifs, regulatory binding partners and covalent modifications. The tyrosine-based 
sequence motif YXXϕ (ϕ = large hydrophobic residue) is involved in internalisation 
and may act as a lysosomal sorting motif for the protease-activated receptor-1 
(PAR1) (Paing et al., 2004). The same receptor was found to bind to the regulatory 
proteins SNX1, which functioned in lysosomal sorting and degradation (Gullapalli et 
al., 2006; Wang et al., 2002). The sorting protein GASP also associates with C-
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terminal tails directing receptors to lysosomes and degradation. Manipulation of 
GASP re-routed the receptor to be recycled back to the cell surface (Bartlett et al., 
2005; Simonin et al., 2004; Whistler et al., 2002). Ubiquitination is also a factor in 
receptor degradation. GPCRs that have been mutated to prevent ubiquitination 
were able to internalise following prolonged exposure to agonist but were not 
degraded (Shenoy et al., 2001). Conversely, when β-arrestin ubiquitination was 
blocked, internalisation was prevented with little effect on degradation.  
1.1.10 Dimerisation 
Early evidence for the dimerisation of GPCRs was obtained through biochemical and 
biophysical techniques. A common method was the co-immunoprecipitation of 
different epitope tagged GPCRs. This identified homodimers (Hebert et al., 1996), 
closely related heterodimers (Jones et al., 1998; Kaupmann et al., 1998; White et 
al., 1998) and more distantly related heterodimers (AbdAlla et al., 2000). Different 
approaches have also supported receptor dimerisation. This include BRET analysis 
of the β2-AR (Angers et al., 2000) and FRET, which was dependent on agonist 
stimulation (Cornea et al., 2001; Horvat et al., 2001). Recent structures of GPCRs 
have revealed a strong dimerisation interface between TM5 and 6 of each 
monomer and a slight interface between TM1, 2 and helix 8 (Manglik et al., 2012; 
Wu et al., 2010; Wu et al., 2012).  
These results provide evidence that GPCRs are able to dimerise, however do not 
reflect the stability or duration of this interaction. In the case of the crystal 
structures, the dimerisation may reflect properties of the crystal packing instead of 
physiological interactions. It was calculated that receptors with a Kd (dissociation 
constant) of 1µM had a half-life of <1s. For a dimer to be stable for the duration of 
time of short-lived GPCRs (2-20 hours), the monomers required an interaction with 
a Kd of 10-100pM which is unlikely to be achieved with hydrophobic interactions. 
Therefore receptors that exist as stable dimers are often covalently linked (for 
example class C GPCRs) (Gurevich & Gurevich, 2008). 
The ratio of G protein-coupling to monomeric and dimeric receptors was 
investigated in both family A and C GPCRs. In receptors of both families, it was 
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found that GPCR complexes signal through a single G protein (Bayburt et al., 2007; 
Margeta-Mitrovic et al., 2001; Whorton et al., 2007). The function of dimerisation 
remains unclear. The reduction in signalling efficiency of the neurotensin NTS1 
receptor upon dimerisation has led to speculation of a desensitization role (White 
et al., 2007). 
1.1.11 Biased agonism 
The early paradigm of a GPCR activating a single signalling pathway has changed 
with new evidence. There are now multiple examples of a single GPCR activating 
multiple signalling pathways.  These include 2-AR coupling to both Gs and Gi; the 
switch occurring following PKA phosphorylation (Daaka et al., 1997). The protease 
activated receptor (PAR1) is able to signalling through Gi, Gq and G12/13 
depending on the ligand stimulating the receptor (McLaughlin et al., 2005). 
Molecular dynamic modelling has presented an alternative view of receptor 
dynamics, which can account for this versatility of signalling. This represents 
receptor conformations as wells in an energy landscape. Binding to ligands or other 
signalling partners creates a new thermodynamic species with an altered energy 
landscape with different thermodynamically stable wells. This range in receptor 
conformations dictated by a binding partner can account for the difference in 
signalling response (Kenakin, 2011; Onaran & Costa, 1997).  It is therefore better to 
consider receptors as dynamic, moving through a range of conformations, each of 
which can be stabilised by ligands and initiate signalling responses (Kenakin & 
Miller, 2010). 
The ability of a single receptor to activate different signalling pathways through the 
binding of specific ligands is described as biased agonism or functional selectivity 
(Kenakin, 2007). 
1.1.12 Membrane environment 
The established view of the plasma membrane as a homogenous fluid structure, as 
proposed in the fluid mosaic model (Singer & Nicolson, 1972), is changing to reflect 
the findings of discrete membrane regions that confine lipids and proteins to 
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specific areas. These areas have been named lipid rafts, composed of sphingolipids 
and cholesterol (Simons & Vaz, 2004).  
Lipid rafts are important with respect to GPCRs as both the receptors and their 
downstream signalling components (specifically G proteins and RGS proteins) have 
been proposed to be targeted to them (Ostrom & Insel, 2004). This is achieved 
through the post-translational modifications, usually palmitoylation or other lipid 
additions (Barnett-Norris et al., 2005). 
The lipid environment surrounding the receptor can also influence its function. Both 
the lipid head and acyl chain composition effected rhodopsin activity (Gibson & 
Brown, 1993; Niu et al., 2004). 
1.1.13 Summary 
GPCRs are one of the largest and oldest family of proteins and are found 
throughout the eukaryotic domain. In humans there are over 800 different 
receptors binding to a diverse array of ligands. However given this diversity, they 
share a similar three dimensional architecture of an extracellular N-terminal 
domain, seven transmembrane spanning alpha helices connected by three 
extracellular loops and three intracellular loops and an intracellular C-terminus.  
Current understanding of GPCR structure and is of a complex process where the 
receptor exists in multiple conformations, stabilised by a variety of ligands inducing 
a number of signalling pathways.  
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1.2 Family B GPCRs 
The family B (or secretin) GPCRs are a group of around 15 receptors, which bind to 
peptide ligands. These receptors include the calcitonin receptor (CTR), calcitonin 
receptor-like receptor (CLR), corticotropin-releasing hormone receptor 1 and 2 
(CRHR1, CRHR2), growth hormone releasing hormone receptor (GHRH), gastric 
inhibitory polypeptide receptor (GIPR), glucagon receptor (GCGR), glucagon-like 
peptide 1 and 2 receptor (GLP1R and GLP2R), parathyroid hormone 1 and 2 
receptor (PTH1R and PTH2R), pituitary adenylate cyclase activating polypeptide 1 
receptor (PAC1R), secretin receptor (SCTR) and the vasoactive intestinal peptide 
receptor 1 and 2 (VIPR1 and VIPR2). These GPCRs are involved in a diverse range of 
physiological responses including vasodilation, stress, digestion and glucose 
homeostasis. This has made them important drug targets for a range of human 
diseases including diabetes, obesity, cancer, cardiovascular disease and migraine 
(Hollenstein et al., 2014). 
Family B GPCRs are characterised by their large (~100-160 residues) N-terminal 
extracellular domain (ECD), which is responsible for ligand binding. The TM domain 
consists of the seven TM-spanning α-helices common to all GPCRs. Signalling is 
predominantly through Gαs-coupled pathways, however Gq11, Gi and G protein-
independent signalling can occur (Hoare, 2005; Mahon et al., 2002; Walker et al., 
2010). Some family B GPCRs have associated receptor activity-modifying proteins 
(RAMPs) that participate in ligand binding or have indirect conformational effects 
on the receptor (McLatchie et al., 1998; Morfis et al., 2003). 
1.2.1 Evolution 
Family B GCPRs are thought to have originated in a split from the adhesion family 
~1000 million years ago (Nordström et al., 2009; Nordström et al., 2011). Genomic 
analysis found that protosome genes are most similar to the CT/CGRP and CRH 
receptor subfamilies indicating that these are likely to be the family B ancestral 
genes (Cardoso et al., 2006). The subsequent evolution of this GPCR family is likely 
to be a combination of species-specific gene duplications and duplication in 
ancestral gene precursors. 
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The family B GPCRs contain multiple exons and introns in their open reading frames, 
which generates multiple splice variants. Primary sequence alignment comparisons 
shows the greatest variability in the N- and C-terminal domains (<10% of amino 
acids conserved in two-thirds of family B GPCRs;(Markovic & Grammatopoulos, 
2009) . 
1.2.2 Ligands 
The endogenous peptide ligands of the family B GPCRs are hormones, 
neuropeptides and autocrine factors (Hoare, 2005). The peptide structure is often 
disordered in aqueous solution however the C-terminal portion of the ligand often 
becomes helical during receptor binding or under mild ambient conditions. This α-
helix is stabilised through intramolecular salt bridges (Runge et al., 2008) and C-
terminal amidation (Pioszak & Xu, 2008). This amidation is important for ligand 
binding affinity. Loss of the C-terminal amidation in both CGRP and CRH caused a 
dramatic loss in both ligand binding affinity and cAMP signalling potency (Banerjee 
et al., 2006; Hoare et al., 2004; O'Connell et al., 1993). The N-terminus of the α-
helix of each peptide is stabilised through an N-terminal capping motif. This is with 
the exception of the calcitonin family of peptides, which stabilise the α-helix with an 
intramolecular disulphide bond (Neumann et al., 2008). The N-terminal structure 
varies between ligands, with α-helical structures (PTH) and β-coil formations 
(PACAP) proposed (Inooka et al., 2001; Monticelli et al., 2002; Shimizu et al., 2001). 
Key residues govern ligand selectivity within receptor sub-families. CRHR2 selective 
ligands contain a proline at position 11. CRHR1 peptides had an arginine at position 
35 and an acidic amino acid at position 39. The equivalents of these were both 
alanine residues in the CRHR2 specific peptides (Mazur et al., 2004). In GLP-1 the N-
terminal histidine residue is vital for receptor binding affinity (Gallwitz et al., 1990; 
Hareter et al., 1997) however residues in the central part of the ligand and the C-
terminus are also important for ligand affinity and selectivity (Adelhorst et al., 1994; 
Hjorth et al., 1994; Mapelli et al., 2009).  
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1.2.3 The N-terminal ECD of family B GPCRs 
Until 2013 no crystal structures were solved for the TM domain of the family B 
GPCRs however structures for the soluble ECDs of a number of receptors have been 
published (both unbound and bound to ligand). Structures of the ECD of family B 
GPCRs unbound to a ligand have been solved for the CGRP receptor, AM receptor, 
CRHR1, CRHR2, GCGR, PAC1R, PTH1R and VIPR2 (Grace et al., 2004; Koth et al., 
2012; Kumar et al., 2011; Kusano et al., 2012; Pioszak et al., 2008; Pioszak et al., 
2010; ter Haar et al., 2010). Structures have also been solved for the ECD bound 
with either agonist or antagonist ligand for the CGRP receptor, CRHR1, CRHR2, 
GIPR, GLP1R, PAC1R and PTH1R (Grace et al., 2007; Grace et al., 2010; Parthier et 
al., 2007; Pioszak et al., 2008; Pioszak & Xu, 2008; Pioszak et al., 2009; Sun et al., 
2007; ter Haar et al., 2010; Underwood et al., 2010). A selection of these structures 
are shown in Figure 1.8. 
The ECD structures suggest a common fold that may be conserved throughout the 
receptor family. This consists of two central antiparallel β-sheets and an N-terminal 
α-helix connected by loop structures and stabilised by three intramolecular 
disulphide bonds. This similarity is surprising as the only sequence conservation in 
the family includes the six cysteine residues involved in the disulphide bonding and 
five additional residues responsible for domain stability (Perrin et al., 2007). The 
space between the two β-sheets acts as a ligand-binding groove that is occupied by 
hydrophobic residues from the amphipathic α-helix of the ligand, with the C-
terminus stopped through H-bonding between side chains. These hydrophobic 
interactions are vital for ligand binding, which are thought to induce conformational 
changes within the ECD leading to receptor activation (Hollenstein et al., 2014; 
Parthier et al., 2009). 
1.2.4 Extracellular loops of family B GPCRs 
The ECLs are important for ligand binding and receptor activation in a number of 
the family B GPCRs. In CLR both ECL1 and 3 contain residues involved in CGRP-
mediated receptor signalling (Barwell et al., 2011). 
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Figure 1.8. Structures of the ECDs of family B GPCRs.  
The first row shows ECDs in the absence of bound ligand and the second row are ECDs in complex with a peptide ligand. The GPCR ECD is highlighted blue, 
accessory proteins are highlighted pink and bound ligand is lilac. The GPCR ECDs in the first row are CGRP receptor (CLR + RAMP1, PDB 3N7P), AM receptor 
(CLR + RAMP2, PDB 3AQF), CRHR1 (PDB 3ESH), GCGR (PDB 4ERS), PAC1R (PDB 3N94), PTH1R (PDB 3L2J) and VIPR2 (PDB 2X57). The GPCR ECDs bound to 
peptide ligand in the second row are PAC1R + PACAP6-38 antagonist (PDB 2JOD), GIPR + GIP (PDB 2QKH), CRHR1 + CRH (PDB 3EHU), CRHR2 + UCN1 (PDB 
3N96), CRHR2 + UCN2 (PDB 3N95), CRHR2 + UCN3 (PDB 3N93), GLP1R + GLP-1 (PDB 3IOL), PTH1R + PTH (PDB 3C4M). 
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Residues in each of the ECLs of the CRHR1 domain are important for agonist binding 
(Grammatopoulos, 2012). Specifically in ECL2 residues W259 and F260 in the centre 
of the loop and three residues at the ECL2-TM5 interface (V266, Y267 and T268) 
interact with the agonist N-terminus but not the antagonist (Gkountelias et al., 
2009).  
In GLP1R ECL1 an aspartate was important for GLP-1 binding however this was 
maintained with an asparagine mutation suggesting that ligand-receptor interaction 
was mediated through hydrogen bonding instead of the negative charge of the WT 
residue (López de Maturana & Donnelly, 2002). A methionine-tyrosine pair in the 
centre of ECL1 were also important for interaction with the GLP-1 N-terminus 
(López de Maturana et al., 2004).   
1.2.5 TM domain of family B GPCRs 
The first crystal structures of the TM domain of family B GPCRs were published in 
2013 (Figure 1.9). These were for the CRHR1 (Hollenstein et al., 2013) and the GCGR 
(Siu et al., 2013). These two receptors share ~30% sequence homology and this 
similarity is reflected in the crystal structures. The TM domain of both receptors 
have a more open conformation on the extracellular side compared to the 
previously published family A GPCR structures. This creates a V-shaped structure as 
viewed parallel to the plasma membrane. One arm of the V-shape comprises TM2-5 
and the other comprises TM1, 6 and 7. When comparing the two structures, there is 
a conserved GWGxP motif in TM4 creating a network of interactions between TM2, 
3 and 4. There are also shared interactions between S1.50 in TM1 and S7.47, G7.50 and 
F/L7.51, stabilising the kink in TM7 (Wootten numbering system) (Hollenstein et al., 
2014). In the GCGR, Y4007.57 has hydrogen bond interactions with T3516.42 and 
E2453.50 creating a conformation similar to the family A GPCRs (Siu et al., 2013). 
A functional equivalent to the conserved D(E)RY motif of the family A GPCRs is 
predicted to exist in family B. In GLP1R there is a predicted network of hydrogen 
bonds between H1802.50, E2473.50, T3536.42 and water molecules. The proposed lock 
between TM3 and 6 in the inactive conformation of family A GPCRs could exist  
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Figure 1.9. Crystal structures of the CRH1R (PDB 4K5Y) and GCGR (PDB 4L6R).  
The N-terminal extracellular domain (ECD) and extracellular loops (ECLs) are highlighted 
magenta, the seven transmembrane helices (7TM) are highlighted cyan and the 
intracellular loops (ICLs) and intracellular C-terminal domain is highlighted yellow. Each 
structure is presented twice, in a parallel orientation to the membrane, rotated 180°. 
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between water-connected hydrogen bonds of E2473.50 and T3536.42 (Wootten et al., 
2013).  
The tyrosine of the conserved family A NPxxY motif, which has a functional role in 
the activation of β2-AR (Rasmussen et al., 2011b) is conserved in the family B 
GPCRs. In the GCGR crystal structure, Y400 is location in a similar position (Siu et al., 
2013) and the equivalent residue is important for receptor activation for GLP-1R 
and the CGRP receptor (Vohra et al., 2013; Wootten et al., 2013). 
In the family B GPCRs, there are three conserved proline residues within TM4, 5 and 
6. Alanine substitution of the TM6 proline resulted in a significant reduction in 
cAMP signalling compared with WT for both CTR and CLR (Bailey & Hay, 2007; 
Conner et al., 2005).  
Molecular modelling of CLR suggested that this proline produced a pronounced TM 
bend where the intracellular end of TM6 was positioned close to TM3 (Conner et 
al., 2005). However some of the most compelling evidence on the requirement of 
the proline residue and its effect on the TM helix came with modelling predictions 
that the introduction of a proline, three residues above (P343A-G346P) would not 
result in a correctly orientated kink in the helix but the introduction of a proline 
four residues above (P343A-I347P) would. This was experimentally verified (Conner 
et al., 2005). 
Even though these results show the importance of these proline residues, not all 
data supports this. In the study of human hCTR, (Bailey & Hay, 2007) salmon 
calcitonin was also tested and the substitution of the proline residues for alanine 
did not result in a significant reduction in cAMP signalling or receptor binding.  
1.2.6 Intracellular domains of the family B GPCRs 
The ICLs are the main interaction points with the downstream signalling 
components of the GPCR signalling cascade. Each of the ICLs have a functional role 
however there are key conserved motifs throughout the receptor family. These 
include a KL motif in ICL3 involved in G protein-coupling in the secretin, GLP and 
VPAC receptors. There is also a basic-X-X-basic motif found at the ICL3-TM6 junction 
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that is conserved between both the family A and B GPCRs (Chan et al., 2001; Hilairet 
et al., 2001; Mathi et al., 1997). 
Research into the ICL domains of CLR identified a minor role of K167 and L169 in 
ICL1 in signalling through the coupled Gαs protein however mutation of R173 to 
either A or E dramatically reduced signalling. Mutations of Y236 and L237 in ICL2 
reduced cell surface expression by 70%. The ICL3 is the largest loop region. I312 is 
proximal to TM5 and I312A causes a dramatic reduction in cAMP accumulation and 
also a decrease in CGRP affinity and internalisation. K319A and L320A did not differ 
from the wild type. K333 and R336 form the basic-X-X-basic motif. K333A shows no 
effect however R336 causes a >10 fold reduction in pEC50. R336E and R336Q did not 
differ from the wild type, which suggests that polarity over charge is the significant 
factor with regards to the interactions of this residue (Conner et al., 2006a). 
Using synthetic peptides of GLP1R, it was shown that the N-terminus of ICL3 
couples to Gαs and the C-terminus couples with Gi/o (Hällbrink et al., 2001). Basic 
and hydrophobic residues in ICL3 were important in a Gαs-mediated cAMP response 
(Mathi et al., 1997; Takhar et al., 1996). Analysis of the other two ICLs only found 
one residue (R176) in ICL1 to be important for cAMP activation. 
The intracellular C-terminus has been shown to be involved in G protein-coupling, 
cell surface localisation and agonist-driven desensitisation in family A GPCRs (Chen 
et al., 2004; Piserchio et al., 2005) with a key feature being the proposed helix 8 
domain first observed in the rhodopsin crystal structure (Palczewski et al., 2000). 
Deletion of this domain in the CGRP receptor found no significant effect on the 
cAMP response, however the residues of the helix proximal to the TM7 domain 
were required for cell surface expression of the receptor. The distal residues of the 
C-terminus were required for internalisation (Conner et al., 2008). 
1.2.7 Ligand binding at the family B GPCRs 
An early study into these receptors used PTH-calcitonin ligand and receptor 
chimeras (Bergwitz et al., 1996). A ligand peptide constructed of the C-terminal PTH 
and N-terminal calcitonin bound and activated a chimeric receptor containing the 
N-terminal extracellular domain of PTH and the TM segment of the calcitonin 
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receptor. Experiments using the reciprocal ligands and receptors resulted in the 
same outcome. 
Studies using truncated versions of the ligands found that removal of the N-
terminus formed competitive antagonists (Gardella & Jüppner, 2001; Gelling et al., 
1997; Hinke et al., 2001; Nutt et al., 1990; Rivier et al., 1984; Thorens et al., 1993). 
C-terminal truncations are able to activate the receptor with a significantly reduced 
affinity (Al-Sabah & Donnelly, 2003b; Gelling et al., 1997; Hoare et al., 2004; Perrin 
et al., 2003). A chimeric receptor construct that replaced the N-terminal ECD 
domain of the CRHR1 with the N-terminus of the CRH peptide ligand resulted in a 
dramatic increase in constitutive activity (Nielsen et al., 2000). 
These results have led to a “two-domain” model of ligand binding. This proposes 
that the C-terminus of the peptide ligand binds to the GPCR N-terminal ECD. This 
allows the presentation of the N-terminal section of the ligand to the ECLs and the 
TM domain resulting in the subsequent activation of the receptor (Hoare, 2005). 
 The structures of the receptor ECD with bound peptide ligand shows a common 
binding pattern. The family B ligands generally bind through interactions between 
hydrophobic interactions of the amphipathic α-helix of the peptide ligand and 
hydrophobic binding pockets between the two β-sheets of the ECD (Figure 1.8). 
However comparison of the binding of CRH, PTH, GIP and exendin-4 with their 
cognate receptors does reveal differences. An extra residue in the β1-β2 loop of the 
CRHR causes a shift in peptide binding compared with the other three ligands 
resulting in little overlap within the binding interface (Grace et al., 2007; Parthier et 
al., 2007; Pioszak & Xu, 2008; Runge et al., 2008). There is also a difference 
between the “anchor” point of the CRH ligand and receptor and of the other 
peptides. For the CRH complex, CRH is anchored by interactions of the CRH C-
terminus with the β1-β2 loop, loop 3 and Y99 of the ECD. The PTH ligand is 
anchored by interactions of the N-terminal portion of the peptide and the N-
terminal α-helix of the PTHR ECD. These differences result in a distinct interface for 
the binding of the ligands to their receptors, providing insights into the specificity of 
these receptors.  
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The affinity of the ligand to its receptor has also been estimated for the PTH1, PTH2, 
CRH1, CRH2 and GLP-1 receptors (Al-Sabah & Donnelly, 2003b; Hoare et al., 2004; 
Hoare & Usdin, 2001; López de Maturana et al., 2003; Perrin et al., 2003). These 
studies found that the affinity of the ligand to the N-terminal ECD was between 1-
100nM, however the interaction with the TM domain is ~10μM for PTH1 and CRH 
(Hoare et al., 2004; Shimizu et al., 2001). These results complement the two-
domain model with the initial ligand-receptor binding between the C-terminal 
ligand and N-terminal receptor ECD occurring with higher affinity which enables the 
lower affinity N-terminal ligand/TM receptor domain interaction to occur. 
Research on the secretin receptor found that modified N-terminal secretin peptides 
that only bound to the receptor N-terminus still activated the receptor. These 
peptides used acetylation of the N-terminus of photolabelled probes which 
removed the charge of the N-terminal amino group. These bound to the ECD of the 
receptor instead of TM6, however TM6 binding was recovered when a basic residue 
was added to the N-terminus of the ligand. All these ligands remained full agonists. 
Peptides corresponding to the secretin receptor’s N-terminus activated the full 
length receptor. Further studies found that a secretin receptor epitope agonist 
bound near to the top of the TM6-ECL3 interface indicating that upon ligand 
binding, a conformational change in the N-terminal ECD causes a folding of this 
domain to interact with TM6 and activate its receptor (Dong et al., 2006; Dong et 
al., 2005). 
Looking within the CRH family of peptides reveals factors involved in the specificity 
of ligand binding. Even though the sequences between CRH receptor peptides CRH 
and UCNI, II and III are very similar, there are distinct differences between their 
binding to the CRHR1 and CRHR2 receptors. CRH has a 10-40 fold higher affinity for 
CRHR1 than to CRHR2, and CRH and UcnI exhibit ~10 fold higher estimated affinity 
for the CRHR1 ECD than UcnII and III (Hauger et al., 2006). Even with high sequence 
similarity, this substantial affinity difference has been proposed to be due to 
differences in two residues within the peptide. R35 is present in both CRH and UcnI, 
CRH contains E39 and UcnI has a similar negatively charged D39. UcnII and III have 
an alanine in both positions. This difference in ligand side chain properties can be 
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reciprocated with an E104 residue in the CRHR1 ECD and a P100 in CRHR2. This 
provides an explanation into the specificity of these ligands to their respective 
receptors (Pal et al., 2010). 
1.2.8 Activation of family B GPCRs by their agonists 
Zn(II)-binding experiments utilise the ability of histidine to co-ordinate transition 
metal ions to determine proximity of different receptor regions (Sheikh et al., 
1996). Selected receptor residues are substituted with histidine and are activated in 
the presence or absence of Zn2+. Experiments utilising this technique in the family A 
β2-AR and the family B PTHR found that even though these receptors are only 16% 
identical, both required the movement of TM6 in relation to TM3 for the receptor 
to activate the G protein (Sheikh et al., 1999). This suggests that even with the 
differences in sequence, structure and ligand binding, receptors from these two 
families share a common three-dimensional structure and activation mechanism.  
During the N-terminal ECD conformational changes induced by ligand binding, 
which may guide the ligand towards the binding pocket, the receptor N-terminus 
itself may interact with its TM domain to stabilise or enhance this interaction, which 
would explain why peptides based on receptor epitopes are able to activate 
receptors (Dong et al., 2006; Dong et al., 2005). Through ionic and hydrophobic 
interactions, the ligand brings the TM6 ECL domain towards that of TM3, stabilising 
the active conformation. 
In family A GPCRs, TM6 and 7 have a proline-induced bend, shown to straighten 
during receptor activation (Schwartz et al., 2006). There is no TM7 proline in the 
family B GPCRs however there is a TM6 proline that straightens during activation 
(Conner et al., 2005). This TM bend is energetically unstable and has to be held in 
the inactive position through an ionic “lock” mechanism. This is a role of the DRY 
motif in family A and it has been proposed that residues in TM2 and 3 of family B 
GPCRs may act in the same way (Frimurer & Bywater, 1999). 
1.2.9 Signalling pathways of family B GPCRs 
The promiscuity of family B GPCR signalling has been observed in multiple 
receptors. The CRHRs can activate Gαs, Gαo, Gαq11, Gαi and Gαz (Grammatopoulos et 
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al., 1999; Grammatopoulos et al., 2001). Mutations of Ucn1 between residues 6-15 
altered the signalling between Gαs and Gαi pathways, indicating a capability of 
biased signalling induced through small modifications of the peptide ligand 
(Beyermann et al., 2007). Both ICL3 and the C-terminus of CRHR1 are important for 
G protein-binding (Grammatopoulos et al., 1999; Papadopoulou et al., 2004). In 
GLP1R, the N-terminus of ICL3 was responsible for Gαs coupling and the C-terminus 
for Gi/o (Hällbrink et al., 2001). The CGRP receptor predominantly signals through 
Gαs however it has also been found to signal through Gαi, Gαq11 and G protein-
independent pathways (Walker et al., 2010). 
1.2.10 Desensitisation and recycling 
Following activation, the family B GCPRs may undergo phosphorylation mediated 
desensitisation, internalisation and recycling similar to family A GPCRs.  
CLR is phosphorylated by GRKs at S/T residues within the C-terminus. This recruits 
-arrestin leading to subsequent desensitisation and internalisation (Conner et al., 
2008). In CRHR1 there are S/T clusters in both ICL3 and the last 30 amino acids of 
the C-terminus that can be phosphorylated by GRKs, PKA and PKC (Oakley et al., 
2007; Papadopoulou et al., 2004; Teli et al., 2005). GRK phosphorylation is required 
for efficient coupling to β-arrestin but recruitment can still occur without 
phosphorylation (Oakley et al., 2007). In GLP1R, phosphorylation occurs at four 
serine doublets at the end of the C-terminus resulting in desensitisation and 
internalisation (Widmann et al., 1996). 
1.2.11 Summary 
Family B GPCRs are a small but physiologically important class of GPCRs binding to 
peptide ligands. The ECD structures are best understood, with a common fold of an 
N-terminal α-helix following by two antiparallel β-sheet structures forming a 
hydrophobic ligand-binding groove that binds to an amphipathic α-helical peptide 
ligand. Recent crystal structures of the CRHR1 and GCGR TM domain’s confirm that 
these receptors consist of the seven TM spanning α-helix bundle seen with the 
family A GPCRs. A notable difference is that the family B structures are more open 
on the extracellular side. Ligand binding and activation is predicted to follow a 
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“two-domain” mechanism. In this model the C-terminus of the peptide ligand 
adopts an α-helical structure binding to the receptor ECD through hydrophobic 
interactions. This facilitates binding of the N-terminus of the ligand to the ECLs and 
TM bundle of the receptor resulting in receptor activation.  
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1.3 CGRP and the CGRP receptor 
1.3.1 Introduction 
Calcitonin gene-related peptide (CGRP) is a 37 amino acid neuropeptide with potent 
vasodilatory effects (Poyner et al., 2002). CGRP is a member of the calcitonin family 
of peptides (with calcitonin, adrenomedullin, amylin and AM2/intermedin). These 
are all ligands to several receptors constructed from two family B GPCRs, the 
calcitonin receptor (CTR) and the calcitonin receptor-like receptor (CLR) (Pal et al., 
2012). With the exception of calcitonin, the peptide receptors are a heterodimer 
consisting of a GPCR unit (CTR or CLR) and one of three single transmembrane 
accessory proteins (RAMP 1, 2 or 3) (Poyner et al., 2002). The CGRP receptor is a 
heterodimer between CLR and RAMP1 (Walker et al., 2010).  
The calcitonin family of peptides are expressed throughout the body, in peripheral 
tissues and the central and peripheral nervous system. Other than vasodilation 
(CGRP and adrenomedullin), the effects of these peptides include reduced food 
intake (amylin) and a decrease in bone readsorption (calcitonin) (Walker et al., 
2010). This has led to significant pharmaceutical interest in their mechanism of 
action. 
1.3.2 Calcitonin family of peptides 
The calcitonin peptide family consists of six members. These include calcitonin (CT), 
amylin, (AMY), two isoforms of CGRP (α and β), adrenomedullin (AM) and 
adrenomedullin 2/intermedin (AM2). They have weak primary sequence homology 
however share secondary structure characteristics of an N-terminal loop stabilised 
by a disulphide bond followed by a region of amphipathic α-helix and a C-terminal 
amidation (Poyner et al., 2002). 
Calcitonin is a 32 amino acid peptide expressed predominantly in the thyroid C cells 
resulting in reduced blood calcium levels (Copp & Cheney, 1962; Hirsch et al., 1963). 
This occurs through inhibition of bone resorption and enhancing calcium excretion 
through the kidney (Friedman & Raisz, 1965; Warshawsky et al., 1980). Calcitonin is 
formed from the post-transcriptional splicing of exon 4 to 1-3 from the calcitonin 
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gene (Amara et al., 1982; Rosenfeld et al., 1984). There is evidence that calcitonin is 
also expressed in the prostate gland and the central nervous system (Davis et al., 
1989; Fischer et al., 1983). 
Amylin (or Islet Amyloid Polypeptide, IAPP) is a 37 amino acid peptide expressed in 
the β-cells of the pancreas (Clark et al., 1987; Mosselman et al., 1988). It is 
expressed alongside insulin through similar promoter regions that bind to the same 
transcription factor (German et al., 1992). It has autocrine and paracrine effects on 
insulin and glucagon secretion, reduces appetite and the rate of gastric emptying. 
However it is also able to aggregate into pancreatic islet amyloid deposits, which 
are associated with type 2 diabetes (Westermark et al., 2011). 
CGRP is a 37 amino acid peptide expressed in the peripheral and central nervous 
system (van Rossum et al., 1997) and in the cardiovascular, respiratory and 
gastrointestinal system (Brain & Grant, 2004). There are two isoforms of CGRP (α 
and β). α-CGRP is created from the post-transcriptional splicing of exons 5 and 6 to 
1-3 from the calcitonin gene (Rosenfeld et al., 1984). β-CGRP is transcribed from a 
separate gene to α-CGRP however shares sequence homology with the α-CGRP 
precursor mRNA (Amara et al., 1985). 
AM is a 52 amino acid peptide, which (like CGRP) is a potent vasodilator. AM can 
also inhibit oxidative stress, inflammation, apoptosis, atherosclerosis and promote 
angiogenesis and lymphangiogenesis (Ishimitsu et al., 2006; Kitamura et al., 1993; 
Kuwasako et al., 2011). AM is predominantly expressed in endothelial and smooth 
muscle cells (Sugo et al., 1994a; Sugo et al., 1994b; Sugo et al., 1995).  
A second, related peptide called AM2 (also called intermedin/IMD) was 
independently discovered by two groups in 2004 (Roh et al., 2004; Takei et al., 
2004). Its distribution is similar to that of AM, expressed in peripheral tissues and in 
the CNS, with highest levels in the kidney, hypothalamus and stomach (Hong et al., 
2012). It acts through both the CGRP and AM receptors, however it has highest 
affinity for the AM2 receptor. AM2 has vasodilatory effects on blood vessels 
throughout the body, however it increases sympathetic activity when administered 
centrally (Hong et al., 2012). 
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1.3.3 CGRP 
1.3.3.1 Peptide 
CGRP exists as two isoforms. One isoform of the peptide (α-CGRP) is formed from 
the alternative splicing of the calcitonin gene (Amara et al., 1982). A second isoform 
(β-CGRP) is expressed from a different gene, which differs from human α-CGRP by 
three amino acids. Rat α-CGRP and β-CGRP differ by one amino acid (Steenbergh et 
al., 1985). Unless stated, CGRP will be in reference to the alpha isoform for the rest 
of this thesis.  
The first seven residues of the CGRP peptide form an N-terminal loop stabilised by a 
disulphide bond between cysteine residues at positions 2 and 7. Removal of this 
loop forms the CGRP8-37 antagonist. Within and adjacent to the loop, positions 1, 4, 
8 and 9 influence agonist activity. Alanine at position 5 and threonine at position 6 
are particularly important (Hay et al., 2014). Residues 8 – 18 form an amphipathic 
alpha helix, which terminates in a beta turn (Boulanger et al., 1995). The remainder 
of the peptide is thought to contain at least one further beta turn around residues 
33-34 (Sagoo et al., 1991). The C-terminal phenylalanine at position 37 is amidated 
(Poyner et al., 1992). 
αCGRP contains up to 88% α-helix when dissolved in 50% trifluoroethanol however 
removal of the N-terminal seven residues resulted in a large change in secondary 
structure, with a dramatic loss in α-helix (9% α-helix) and an increase in β-sheet and 
random coiling to compensate for this (Robinson et al., 2009).  
1.3.3.2 Expression 
The CGRP receptor is expressed in the central nervous system (CNS) in discrete 
areas such as the striatum, amydala, colliculi and cerebellum, however an extensive 
amount of research has been in the trigeminovascular system, with CGRP 
immunoreactivity detected in trigeminal nerve fibres and ganglion cells, and the CLR 
and RAMP1 components detected in arterial blood vessels, mononuclear cells and 
Schwann cells in rat (Lennerz et al., 2008). αCGRP is more abundant and found in 
areas of the central and peripheral nervous system. βCGRP is located in the gut, in 
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sites including those of enteric nerves (Mulderry et al., 1988) and the pituitary gland 
(Petermann et al., 1987). 
1.3.3.3 Physiology 
The major physiological effect of CGRP is vasodilation, caused by the release of 
CGRP from sensory nerve fibres, which innervate smaller arteries, passing into the 
vascular smooth muscle layer (Brain & Grant, 2004). Vasodilation occurs through 
direct action on the smooth muscle cells, via a cAMP dependent pathway, however 
in some vasculature, this occurs through endothelium-sensitive and NO-sensitive 
mechanisms (Gray & Marshall, 1992; Raddino et al., 1997). Despite these 
physiological effects of CGRP it is not involved in the control of systemic blood 
pressure. The effects are instead more local, acting on the microvasculature, 
regulating responsiveness and protecting organs from injury (Smillie & Brain, 2011). 
As well as vasodilation, CGRP has been linked to inflammation and nociception and 
it is thought to be through these effects that migraine can occur (Durham, 2008). 
CGRP is expressed in unmyelinated c nerve fibres which are present throughout the 
body and are associated with immune cells such as dendritic cells, mast cells and T 
cells. A role of CGRP as a key mediator of neuro-immune communication is 
emerging, with the c fibres having both sensory and local effects (Assas et al., 2014).  
1.3.3.4 Pathophysiology 
CGRP is involved in migraines. The origin of a migraine is thought to be in the CNS, 
most likely the brain stem, initiated by a range of contributing factors such as stress, 
environmental agents, or hormones, which then activate trigeminal neurons 
(Goadsby et al., 2002). The link with CGRP is seen with an increase in CGRP levels in 
the cranial circulation during migraine or cluster headache attacks (Fanciullacci et 
al., 1995; Gallai et al., 1995; Goadsby et al., 1990; Juhasz et al., 2003). Anti-migraine 
compounds stop this increase (Fanciullacci et al., 1995; Goadsby & Edvinsson, 
1993). CGRP antagonists are able to prevent neurogenic vasodilation that has been 
initiated either through the activation of trigeminal C-fibre nociceptors or agents 
known to trigger migraines (Goadsby et al., 1988; Nicoletti et al., 2008). 
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During myocardial ischemia, CGRP release stops the development of myocardial 
infarction (Franco-Cereceda & Liska, 2000). Ischemic preconditioning through a 
brief coronary artery occlusion releases CGRP which is cardio protective during 
prolonged coronary artery occlusion. This effect is repeated with exogenous CGRP 
and blocked with CGRP antagonists (Chai et al., 2006).  There is evidence that CGRP 
has a protective effect in hypertension (Smillie & Brain, 2011). 
1.3.4 GPCR components 
1.3.4.1 Calcitonin receptor (CTR) 
CTR (the GPCR component of both the calcitonin and amylin receptors) was first 
cloned from a porcine cDNA library (Lin et al., 1991). It showed high affinity for 
salmon calcitonin and homology to the PTH receptor. Following this, hCTR was 
cloned from a ovarian carcinoma cell line (Gorn et al., 1992). This was 73% identical 
to the porcine receptor but contained a 16 amino acid insert in ICL1. A second 
human isoform was then cloned which did not contain the 16 amino acid insert. 
This isoform was found to be the most abundant, expressed at relatively constant 
levels in a variety of tissues including the kidney, brain, lung, stomach, placenta 
ovary and bone marrow. The insert positive receptor was mainly found in the ovary 
and placenta (Kuestner et al., 1994). 
A receptor for amylin was discovered when CTR was found to form dimers with 
RAMP1 and 3 (Christopoulos et al., 1999; Muff et al., 1999). A CTR-RAMP2 
heterodimer consisting of the insert positive had a greater capacity for amylin that 
the insert negative CTR (Tilakaratne et al., 2000).   
1.3.4.2 Calcitonin receptor-like receptor (CLR) 
CLR (the GPCR component of both the CGRP and AM receptors) was initially cloned 
from rat cDNA in 1993 (Njuki et al., 1993) and from human soon after (Flühmann et 
al., 1995). CGRP was not considered the ligand for this receptor until successful 
binding and cAMP accumulation experiments were shown in a HEK293 stable cell 
line, which expressed hCLR (Aiyar et al., 1996). The reason for this was not 
discovered for another two years, when RAMP1 was identified in the HEK293 cells 
and was shown to be necessary for cell-surface expression and CGRP-binding of CLR 
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(McLatchie et al., 1998). This research also found that RAMP2 (or RAMP3) could 
combine with CLR forming functional receptors for AM. 
CLR forms a heteromeric complex with RAMPs in the endoplasmic reticulum/Golgi, 
and maintains this complex throughout the receptor life cycle, from cell surface 
trafficking to receptor activation, signalling, internalisation and the subsequent 
recycling to the membrane or degradation (Bomberger et al., 2005; Kuwasako et al., 
2000; Sexton et al., 2001). CLR has three N-glycosylation sites required for cell 
surface expression (N66, N118, N123) (Bühlmann et al., 2000; Kamitani & Sakata, 
2001). Historically, the labelling of the CLR residues did not include the 22 amino 
acid signal peptide, however in recent years this sequence has been included in the 
literature. 
1.3.5 RAMPs 
1.3.5.1 Discovery 
CLR was shown to be the GPCR for CGRP through CGRP binding and cAMP 
production in HEK293 cells stably transfected with hCLR (Aiyar et al., 1996), 
however CLR alone was not sufficient to be a receptor for CGRP. Through a cDNA 
library screen, a single cDNA was isolated called receptor activity modifying protein 
1 (RAMP1) that resulted in a CGRP response. Following this discovery, analysis of 
sequence databases identified two similar proteins, RAMPs 2 and 3 (McLatchie et 
al., 1998). 
1.3.5.2 RAMPs with CLR and CTR 
Although they share less than 30% sequence homology, all three RAMPs possess a 
similar secondary structure with a large extracellular N-terminus (~100 amino 
acids), a single TM spanning domain (22 amino acids), and a short intracellular C-
terminus (~10 amino acids) (McLatchie et al., 1998). Co-expression of CLR and one 
RAMP is essential for complete cell surface expression of the receptor (Kuwasako et 
al., 2000; McLatchie et al., 1998). RAMP1 has a bundle of three -helices in the 
extracellular N-terminus (Figure 1.10) that interact predominantly with an N-
terminal -helix of CLR through electrostatic and hydrophobic interactions and 
hydrogen bonding (ter Haar et al., 2010). A QSKRT sequence in the RAMP1 C- 
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Figure 1.10. Crystal structure of the CGRP receptor ECD.  
This consists of the N-terminal ECD of CLR and the N-terminus of RAMP1. CLR is cyan and 
RAMP1 magenta. The top row presents the receptor complex in two orientations. The exact 
orientation with respect to the membrane is currently unknown. The bottom row has the 
side chains of key structural and functional residues highlighted and labelled. The receptor 
complex is presented in two different orientations. 
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terminus appears to function as a Golgi retention motif that is sterically inhibited 
upon association with CLR (Steiner et al., 2002). RAMP2 appears to interact with 
CLR in a similar way to that of RAMP1, with contacts between CLR and RAMP2 -
helices (Kusano et al., 2012). However, while the overall structure is the same, the 
difference in amino acid residues between RAMP1 and RAMP2 produces a variation 
in the heterodimer interface (Kusano et al., 2012). RAMP1 was not found to be 
glycosylated; however RAMP2 is glycosylated at N130, which facilitates trafficking 
to the cell surface (Aldecoa et al., 2000; Flahaut et al., 2002). The RAMP3 structure 
has yet to be solved. 
1.3.5.3 RAMPs with other GPCRs 
Other family B GPCRs have also been shown to interact with RAMPs. The VPAC1 
receptor resulted in significant translocation of each RAMP to the cell surface, 
however there was no substantial difference in ligand binding affinity or receptor 
signalling with the RAMPs compared with wild type, except for an increase in 
phosphotidylinositol (PI) response with RAMP2 following stimulation with various 
VPAC1 agonists. Parathyroid hormone 1 (PTH1) or glucagon receptors increased cell 
surface expression of RAMP2 and the PTH2 receptor translocated RAMP3 
(Christopoulos et al., 2003). The pharmacology of the CRHR1 receptor can be 
altered by RAMP-association, particularly for the effects on Emax of its Gαi response 
(Wootten et al., 2012). 
1.3.6 CLR and RAMP1 
1.3.6.1 Structure – extracellular domain 
There is no available crystal structure of the full CGRP receptor or its individual 
components, however the structure of a complex formed between the N-terminal 
extracellular domains (ECDs) of CLR and RAMP1 has been solved (Figure 1.10) (ter 
Haar et al., 2010). The N-terminal domain of CLR appears to be similar to that of 
other family B GPCRs (Hollenstein et al., 2014). It consists of an N-terminal -helix 
(αC1) followed by an unstructured region extending to a long finger-like motif with 
a tryptophan residue (W72) at the tip, stabilised by two disulphide bonds (C48/C74 
and C65/C105). There is a third disulphide bond between C88/C127 (Kusano et al., 
78 
 
2012; ter Haar et al., 2010). After the tryptophan finger, there are two antiparallel 
beta sheets with the loop between them forming the base of the ligand-binding site 
closest to the TM domain of the receptor (Figure 1.11).  
The N-terminal domain of RAMP1 has a three helix bundle (αR1 - 3) stabilised by 
three disulphide bonds (Figure 1.11). These disulphide bonds are located between 
the αR1 and αR2 helices (C40/C72), the N-terminus and the αR2 – αR3 loop 
(C27/C82) and connecting the αR1–αR2 loop to the C terminus (C57/C104). Alanine 
substitution of RAMP1 residues C40, C57, C72, or C104 significantly reduced cell 
surface expression of the CGRP receptor, while the deletion of C27 or the 
substitution of C82 by alanine did not affect the receptor function (Steiner et al., 
2003). There is a kink in the αR1 helix caused by L39 due to a disruptive pattern of 
hydrogen bonds. The interactions between the helices are mainly between 
hydrophobic residues, a property that is shared by intramolecular interacting sites 
across the three RAMP sequences (Kusano et al., 2008).  
In the crystal structure of the ectodomain complex of the CGRP receptor (ter Haar 
et al., 2010), the -helix bundle of RAMP1 was perpendicular to the -helix of the 
CLR N-terminus (Figure 1.10). The essential points of structural interaction occur 
between the N-terminal alpha helix of CLR (αC1) and the second and third alpha 
helices (with some adjacent residues) of the N-terminus of RAMP1 (αR2 and αR3 
respectively) (Figure 1.11). A notable non-helix interaction is the hydrophobic bond 
between CLR R119 and RAMP1 F83, stabilising the top of the ECD complex (ter Haar 
et al., 2010). 
1.3.6.2 CGRP model structure 
Until the recent publications of the CRHR1 and GCGR crystal structures (Hollenstein 
et al., 2013; Siu et al., 2013), the absence of defined structural information for the 
family B GPCRs has led to difficulty in producing accurate receptor models. 
The most recent technique applied to modelling CLR used a novel approach using 
the plant GPCR GCR1, which has sequence homology to both family A and B GPCRs, 
to bridge to gap between the lack of sequence homology between these two 
receptor families. This has allowed the CLR sequence to be fitted to family A crystal 
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Figure 1.11. Schematic diagram showing the CLR and RAMP1 components of the CGRP 
receptor.  
Key amino acids involved in structural interactions are displayed, together with the type of 
interaction involved. Figure adapted from Woolley & Conner, 2013. 
80 
 
structures, most notably the active β2-AR G protein complex (Vohra et al., 2013). 
This CLR model was further refined with the incorporation of a substantial amount 
of mutagenesis data, particularly within the TM domain. 
In TM1 residues K1.61 and L1.63 comprise the KKLH1.64 motif shared in family A and B 
GPCRs (Vohra et al., 2013). In the CLR model K1.61 was proposed to interact with Gβ 
but also with E8.49. L1.63 interacts with V8.50 which stabilises F7.53 (comprising an 
alternative version of the NPxxY motif) in the inactive conformation.  
The TM5/ICL3 interface contains an I/LxxL5.65 motif that is often involved in G 
protein-coupling (Scheerer et al., 2008). A KxxK6.35 motif in TM6 has a similar 
function following movement of this helix during receptor activation. 
In TM3, there are a number of conserved residues. These include E3.46 and YLH3.51. 
The YLH motif forms the family B equivalent of the DRY3.51 motif present in many 
family A GPCRs (Tams et al., 2001). Mutagenesis of these residues has a less 
pronounced effect to that observed with the DRY motif, however the YLH motif 
forms a hydrophobic network with residues in ICL2 maintaining the inactive 
conformation and E3.46 can interact with R1732.39 and H1772.43 in TM2 suggesting a 
similar functional role to that in family A GPCRs. ICL2 was also expected to make Gs 
contacts. R1732.39 makes contact with T6.37 in the inactive conformation to form a 
polar lock. 
1.3.6.3 Ligand binding 
CGRP-binding and activation of its receptor is expecting to follow the “two domain” 
model of ligand binding, described in the previous section (Hoare, 2005). The C-
terminus of CGRP is thought to bind to the N-terminal ECD of CLR and the 
extracellular N-terminus of RAMP1, allowing the presentation of the N-terminal 
loop of CGRP to the extracellular loops and juxtamembrane regions of CLR (Conner 
et al., 2007a; Watkins et al., 2012). This stabilises the active conformation of the 
receptor, possibly orientated by the disulphide loop forming a similar structure to 
the N-cap motif found in many peptide ligands for family B GPCRs (Neumann et al., 
2008). This model is strengthened by the fact the CGRP8-37 peptide is not able to 
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activate the receptor, however its reduction in binding affinity indicates that the 
interaction of the N-terminal loop residues are also important for receptor binding. 
The binding affinity of CGRP varies between species, and the cell type that was 
being tested. CGRP binds to the CGRP receptor with nanomolar affinity. The CGRP8-
37 antagonist has a 3-10 fold reduction in binding affinity (Poyner et al., 2002). The 
structural domains of CGRP are all important for ligand binding affinity. These 
include the N-terminal loop (residues 1-7), the central α-helix (residues 8-18) and 
the C-terminus (residues 28-37) (Poyner et al., 1998; Robinson et al., 2009). The C-
terminal amidation of phenylalanine is also important. Loss of this amidation does 
not disrupt ligand structure, however it does result in a decrease in the affinity to 
the receptor, even if the alanine at position 36 is amidated instead (Banerjee et al., 
2006; O'Connell et al., 1993).  
A lot of information has become available with the publication of the crystal 
structure of the CGRP receptor ECD complex with the non-peptide antagonists 
Olcegepant (BIBN4096BS) and Telcagepant (MK- 0974) (ter Haar et al., 2010). Both 
Olcegepant and Telcagepant are more effective for humans and primates than for 
other mammals including dogs and rodents (Hershey et al., 2005; Salvatore et al., 
2008). Both synthetic antagonists bind to a hydrophobic binding pocket formed 
between the CLR ECD and the RAMP helices. Important CLR residues are R38, I41 
and M42 in the αC1 helix, and W72, F92, D94, R119, T122 and Y124 in the 
remainder of the N-terminal domain. Important RAMP1 residues are D71, W74, F83 
and W84 (Figure 1.12) (ter Haar et al., 2010).   
From studies prior to the crystal structure, it was observed that the CLR N-terminus 
contains several areas involved in CGRP binding (Figure 1.12). One particular cluster 
within this sequence is I32, G35 and T37. Alanine substitutions of these residues 
increase CGRP potency. A further cluster of I41, A44, Q45, C48 and Y49 has also 
been shown to be important in receptor function (Barwell et al., 2010). The 
involvement of C48 is through disulphide bonding. CLR forms an alpha helix from 
G35 to M53 along which I41, Q45 and Y49 are expected to lie on the same face. Q45 
and Y49 are seen in the crystal structure to interact with RAMP1. I41 of CLR is 
positioned too far from RAMP1 to make a significant hydrophobic interaction, and  
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Figure 1.12. Schematic diagram showing the CLR and RAMP1 components of the CGRP 
receptor.  
Key amino acids involved in ligand binding are displayed, together with the type of 
interaction involved. Figure adapted from Woolley & Conner, 2013. 
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A44 also faces away from RAMP1, therefore these residues may be directly involved 
in CGRP binding (ter Haar et al., 2010).  
The CLR N-terminus also contains a highly conserved aspartate residue (D70). 
Alanine and glutamate substitutions abolished signalling and substitution to 
asparagine maintained pEC50, however reduced Emax to 24% of WT. These 
substitutions reduced co-immunoprecipitation with RAMP1 suggesting that this 
residue is involved in binding to RAMP1 (Ittner et al., 2004).  
In RAMP1, mutations of Y66A, L69A and T73A in helix 2, P85A, N86A in the loop 
from helix 2 to helix 3, and H97A and F101A in helix 3 all impaired cAMP production 
(Figure 1.12). The crystal structure shows that RAMP1 Y66 forms hydrogen bonds 
with CLR Q45 and hydrophobic binds with CLR M42 and Y46. RAMP1 H97 forms 
hydrogen bonds with CLR Q50 and hydrophobic bonds with CLR Y49. RAMP1 F101 
forms hydrogen bonds with Q50 and hydrophobic bonds with Y46, again vital for 
receptor signalling. L69 is a key residue of helix 2 involved in the hydrophobic core 
of the RAMP1 helices (Kusano et al., 2008; Simms et al., 2009; ter Haar et al., 2010). 
Within RAMP1, it has been speculated that a cluster of residues at the C-terminal 
end of helix 2 (R67, D71, W74, E78 and W84) could form a CGRP binding site 
(Kusano et al., 2008). RAMP1 R67 and D71 form structural interactions with CLR 
residues M42 and R38 respectively, however R67, D71, W74 and W84 all form 
interactions with the Olcegepant antagonist. The RAMP1 W74 and W84 residues 
form a hydrophobic binding pocket into which, both the Olcegepant and 
Telcagepant antagonists extend (ter Haar et al., 2010). W74 has also been shown to 
be an important residue in species selectivity (Mallee et al., 2002) however 
substitution experiments of this residue found it only affected synthetic antagonist 
binding but not binding or signalling with the CGRP ligand or CGRP8-37 antagonist 
(Hay et al., 2006; Moore et al., 2010; Qi et al., 2011). Alanine substitution of RAMP1 
W84 resulted in a 20-30-fold reduction in CGRP potency compared with wild type, 
and also reduced the effect of the Telcagepant and CGRP8-37 antagonists (Moore et 
al., 2010).  
The structure of the CLR N-terminus aligns well to the GIP and PTH receptor 
domains. Based on comparisons with other family B GPCR N-terminal domain 
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structures, it was also hypothesised that the CGRP peptide may bind with similar 
orientation to GIP or PTH, allowing the peptide C-terminus to come into close 
contact with the F83-P85 loop of RAMP1. It was proposed that these interactions 
could result in the specificity of the receptor to its preferred ligand (CGRP or AM) 
(ter Haar et al., 2010).  
1.3.6.4 Receptor activation 
The binding of the C-terminus of CGRP to the complex formed between the N-
terminus of both CLR and RAMP1 is thought to result in the presentation of the N-
terminal loop formed by residues 1-7 of CGRP to the ECL domains and the TM 
bundle resulting in activation of the receptor. This follows the proposed “two 
domain” model of family B GPCR ligand binding (Hoare, 2005).  
Within the N-terminal loop of CGRP, residues 5 and 6 (alanine and threonine 
respectively) are particularly important for receptor activation. Substitution of A5 to 
cysteine causes large decreases in both affinity and efficacy especially compared to 
the 10 fold loss in binding affinity observed with the CGRP8-37 antagonist. 
Substitution of T6 to cysteine or alanine resulted in small decreases in ligand affinity 
but a dramatic loss in potency and efficacy. This was not recovered with the 
conservative serine substitution which is identical to threonine except for the 
absence of a methyl group on the β-carbon. This shows the specificity of the ligand 
binding pocket at this position, constraining both the hydroxyl and the methyl 
group of CGRP T6 (Hay et al., 2014). 
Alanine-scanning mutagenesis of ECL1 and ECL3 of CLR has revealed key residues 
responsible for CGRP stimulated receptor activation (Figure 1.13). In ECL1, alanine-
substitution of three non-polar residues (L195A, V198A and A199L) reduced cAMP 
signalling (between 11- and 30-fold reductions of pEC50 values). These three, close 
residues in ECL1 are located at the top of TM2 in their model and are predicted to 
face into the TM bundle either binding directly with the CGRP ligand or indirectly 
affecting CGRP binding through disruption of the receptor structure or its 
interaction with its localised environment (Barwell et al., 2011).  
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Figure 1.13. Key residues of the ECLs, ICLs and TM domain involved in CGRP mediated receptor binding and activation.  
Schematic diagram showing key residues of the CLR extracellular, intracellular and TM domain. Figure adapted from Woolley & Conner, 2013. 
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Unusually, an increase in cAMP signalling was found in the A203L (~11 fold) and 
A206L (9 fold) mutants, proposed to be within the loop region of ECL1. Addition of 
the hydrophobic side chain of leucine promotes receptor activation, potentially by 
assisting CGRP docking to the receptor-binding pocket, or by stabilising the active 
conformation of the receptor. 
Two further mutations (H219A and C212A) also reduced cAMP signalling by 
approximately 10-fold. The C212 residue is thought to reside at the top of TM3 and 
has been shown to interact with C282 of ECL2. Whilst this was proposed to be 
functionally important for ligand-binding in the CLR/RAMP2 AM receptor 
(Kuwasako et al., 2003), a double mutant combining C212A and C282A was wild-
type suggesting this is not functionally relevant, and rather an artefact of 
evolutionary redundancy (Woolley et al., 2013). A similar effect occurred in the 
GLP1R. Substitution of the TM3 cysteine to alanine (C226A) reduced ligand potency, 
and the double alanine substitution (C226AC296A) restored WT signalling.  
However the single ECL2 cysteine alanine substitution (C296A) also restored WT 
signalling. Substitution of the ECL2 cysteine to leucine (C226AC296L) reduced ligand 
potency indicating that it is the bulky nature of the free ECL2 side chain that caused 
the disruption in receptor activation (Mann et al., 2010). H219 is located in TM3 of 
the CLR model (Barwell et al., 2011) alongside L220 and L222. Alanine substitutions 
of these residues result in a decrease in cAMP signalling (L220A ~25 fold, L222 ~6 
fold). Models of CLR and the understanding of the activation mechanisms of family 
A and B GPCRs, has led to the prediction that TM3 could undergo subtle rotational 
movement upon activation, taking part in interhelical interactions, or directly 
interacting with CGRP itself (Barwell et al., 2011; Conner et al., 2005; Sheikh et al., 
1999).   
In an experiment substituting ECL3 of CLR with that of the VPAC receptor, there was 
little effect on CGRP potency or efficacy. This indicates that ECL3 does not have a 
substantial involvement in CGRP-mediated receptor activation (Kuwasako et al., 
2012). However, pEC50 values were decreased by ~30 fold for E357A and ~10 fold 
for I360A (Barwell et al., 2011). I360A is predicted to be located in the middle of 
ECL3, close to ECL2. The reduction in signalling caused by this mutation could be 
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due to direct CGRP binding, or due to an association with ECL2, stabilising this 
domain.  E357 is located near the top of TM6 and along with L351A have a reduced 
cell surface expression (10-30% of wild type). It was found that RAMP3 dimerises 
with the secretin receptor at TM6 and TM7 (Harikumar et al., 2009). The authors 
suggested that most residues that resulted in a decrease in cell surface expression 
were in TM6, ECL3 and TM7 with their side chains facing out towards the lipid 
environment. It is possible that these could be the sites of RAMP1 interaction, 
leading to successful cell surface expression and CGRP activation.   
Proline residues found within α-helices can cause a break in the helix, with 
structural and functional effects. Proline residues are found within TM4, 5 and 6 
throughout all family B GPCRs. Alanine substitution of the CLR TM4 and 5 prolines 
(P263 and P297 respectively) had no effect on receptor function, however the 
mutation P343A (and to a lesser extent P353A) in TM6 had a significantly decreased 
pEC50. Modelling suggested that the kink formed in the alpha helix by P343 brought 
the C-terminus of TM6 closer to that of TM3. A P343A-I347P double mutation 
designed to reintroduce the proline kink in the same orientation of the helix 
restored signalling to that of wild-type (Conner et al., 2005).  
1.3.6.5 Receptor signalling 
Basic residues in ICL1 have key roles in transducing the signalling response (Figure 
1.13). K167A and R173A both reduce cAMP accumulation; with R173E having a 
much greater effect. Alanine substitution of the hydrophobic residue L169A also 
reduced cAMP accumulation (Conner et al., 2006a). This indicates that both the 
polarity of charge and hydrophobicity are important for the interaction resulting in 
G protein-mediated stimulation of cAMP. However it is not yet certain whether this 
is through direct G protein interactions or stabilising of a G protein-binding pocket. 
ICL2 also has residues important for the localisation of the receptor at the cell 
surface and the subsequent G protein-mediated cAMP signal transduction. H238 
and K249 both cause a ~10 fold reduction in cAMP signalling. H238A also has ~90% 
reduction in cell surface expression, highlighting its importance for membrane 
localisation, however K249A retains wild type surface expression and agonist 
affinity indicating a direct involvement in downstream signalling.  The double 
88 
 
mutant V245A/F246A and the single mutant W254A both had a small reduction in 
cAMP signalling (<5 fold) however both of these sets of mutants resulted in an 
approximate 50% reduction in cell surface expression, (Conner et al., 2006b). The 
double mutant Y236A/L237A had no effect on signalling however cell surface 
expression was reduced by 70% (Conner et al., 2006a). 
Within ICL3, I312A (proximal to TM5) caused a 68% reduction in cAMP 
accumulation and 5-fold reduction in binding affinity and a 30% reduction in 
internalisation. K333 and R336 form the conserved basic-x-x-basic motif. K333A has 
cAMP signalling identical to WT however R336A resulted in a >10 fold reduction in 
pEC50 (Conner et al., 2006a).  
Unusually, the CGRP receptor has a second accessory protein required for signalling 
to occur. The CGRP receptor component protein (RCP) is a peripheral membrane 
protein that couples the CLR/RAMP1 complex to the cellular signalling pathway 
(Evans et al., 2000). Cell culture studies with the CGRP receptor have shown that a 
loss of RCP expression correlates with a loss in signalling, however this is not seen 
with the β2-adrenergic receptor (β2AR) and the adenosine receptor, indicated that 
RCP is only involved with certain GPCRs (Evans et al., 2000; Prado et al., 2001). 
Yeast two hybrid assays determined that RCP interacts with the ICL2/TM3 region of 
CLR but not the remaining three intracellular domains (Egea & Dickerson, 2012). 
1.3.6.6 Receptor recycling 
The deletion of the entire C-terminus of CLR, including the predicted helix 8 domain, 
did not significantly change CGRP-mediated cAMP levels from that of wild type, 
suggesting that this region of the receptor is not involved in Gαs-coupling (Figure 
1.13). This deletion did limit cell surface expression to 10% of wild type, which was 
recovered once helix 8 was re-introduced. This indicates a possible role of helix 8 
for successful cell surface expression. This could occur through interaction with 
RAMP1, already predicted to associate with TM6 and 7, however this is not certain. 
Deletion of the C-terminus up to helix 8 prevents internalisation, which is recovered 
by the extension of the C-terminus. This involvement in internalisation is thought to 
be through the phosphorylation and subsequent recruitment of β-arrestin to the C-
terminus (Conner et al., 2008). 
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Following activation, CGRP co-internalises with the receptor into early endosomes, 
which contain the metalloendopeptidase endothelin-converting enzyme 1 (ECE-1) 
that was found to degrade CGRP at endosomal pH5.5. This degradation of CGRP 
allows the recycling of the receptor to the cell surface. Addition of CGRP caused the 
recruitment of beta-arrestin 2 after two minutes followed by endocytosis into the 
same endosomes. Inhibition of ECE-1 or endosomal acidifications did not have an 
effect on receptor internalisation, but did prevent the recycling of the receptor to 
the membrane surface and the release of beta-arrestin 2 back to the cytosol (Padilla 
et al., 2007). 
The fate of receptor recycling depends on the duration of the CGRP-mediated 
activation. The receptor internalises after 10 minutes of CGRP mediated activation, 
and is located in early endosomes for the first hour of ligand stimulation. After this 
time, the trafficking of the receptor complex starts to move to lysosomes. Following 
a one hour stimulation with 0.1µM CGRP, the CLR RAMP1 heterodimer started to 
recycle back to the cell surface after 2 hours, with almost total recovery after 6 
hours. This correlated with Ca2+ resensitisation at 80% after 6 hours, and 95% after 
8 hours (compared with control), however an inhibitor of endosomal acidification 
abolished this (Cottrell et al., 2007).  Prolonged exposure to CGRP directs the 
receptor complex to lysosomes, however the kinetics of degradation differ between 
CLR and RAMP1. The CLR component shows no detectable degradation following 
CGRP exposure for 5 hours and degrades by 54% after 16 hours of CGRP exposure. 
RAMP1 degrades by 45% after just 5 hours. This degradation is independent of the 
ubiquitination pathway. 
1.3.7 Summary 
CGRP is a 37 amino acid neuropeptide with potent vasodilatory, inflammatory and 
nociceptive effects. The CGRP receptor is unique in that it consists of a heterodimer 
between the family B GPCR, CLR, and a single transmembrane accessory protein, 
RAMP1. 
CGRP binding to the receptor is expected to follow the standard family B “two 
domain” model of binding, with the amphipathic α-helix of the middle and C-
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terminal section of the ligand forming interactions with a hydrophobic binding 
groove formed between the CLR ECD and RAMP1. This is thought to present the N-
terminus of the ligand to the ECLs and TM domain of the receptor. With CGRP (and 
the calcitonin family of peptides) this is an N-terminal loop formed by a disulphide 
bond between two cysteine residues. ECL1 and 3 are both involved in ligand based 
receptor activation however ECL2 has not yet been studied.  
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1.4 Aims of the study 
The purpose of this research is to gain further understanding into the structure and 
function of the CGRP receptor using biochemical analysis.  The major focus of this 
research is the ECL2 domain. As discussed in the GPCR section of the introduction, 
this is a highly variable GPCR domain with a prominent role in ligand binding and 
receptor activation for many receptors. However, until this point, ECL2 has not been 
investigated in the CGRP receptor.  
The hypothesis of the ECL2 study is that this domain of the CGRP receptor has 
structural and functional importance for ligand binding and receptor activation. 
Within this loop certain residues will be vital in creating the loop structure or 
directly binding to the CGRP ligand and will be identified. The electrochemical 
properties of these residues will have functional effects and these properties can be 
studied.  
This investigation of ECL2 used mutagenesis techniques to manipulate individual 
residues of this loop and used cell signalling, ligand binding and cell surface 
expression assays to determine the effect of this mutagenesis on receptor function. 
The first results chapter describes the results of alanine substitution mutagenesis 
on each individual residues of ECL2. The second results chapter describes a 
comprehensive set of further substitution mutagenesis of residues identified as 
functionally important in results chapter 1 to gain detailed understanding into the 
molecular effects at these positions. The final results chapter looks at intracellular 
interactions occurring during CGRP receptor signalling. 
92 
 
 Materials and Methods 2
2.1 Materials 
2.1.1  Peptides and hormone analogues. 
The natural agonist human Calcitonin Gene Related Peptide-1 (hCGRP-1) was 
purchased from Merck (Watford, UK). The human alpha CGRP (8-37) 
trifluoroacetate salt antagonist was purchased from BACHEM (St Helens, UK).  
2.1.2 Chemicals 
All chemicals were purchased from Fisher (Loughborough, UK) at analytical grade 
quality unless otherwise stated. 
2.1.3 Molecular biology reagents 
Restriction endonucleases XbaI, EcoRI, KpnI and DpnI were obtained from New 
England Biolabs (NEB, Hitchin, UK). Pfu DNA polymerase and deoxynucleotide 
triphosphates (dNTPs) were purchased from Promega (Southampton, UK). Alkaline 
phosphatase (Calf intestinal phosphatase, CIP), T4 polynucleotide kinase and T4 
DNA ligase enzymes were obtained from NEB (Hitchin, UK). For plasmid purification 
from bacterial suspensions, the Wizard SV Miniprep kit was purchased from 
Promega and the PowerPrep High Purity Plasmid Maxiprep System was purchased 
from Insight Biotechnology Ltd (Middlesex, UK). 1kb ladder was purchased from 
NEB (Hitchin, UK) and 100bp ladder was purchased from Promega (Southampton, 
UK). 
2.1.4  Cell tissue culture 
Dulbecco’s modified Eagle’s medium (DMEM), phosphate buffered saline (PBS) and 
0.25% Trypsin-EDTA was purchased from Gibco (Paisley, UK). Cell culture 
plasticware was purchased from BD Biosciences (Oxford, UK). Polyethyleneimine 
solution for transfection was purchased from Sigma (Dorset, UK).  
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2.1.5 Plasmid vectors 
The mammalian expression vector plasmid used was pcDNA3.1- (5427bp) from 
Invitrogen (Paisley, UK) (Figure 2.1). This plasmid features the following elements: a. 
CMV promoter to permit high level protein expression, b. T7 promoter/priming site 
for in vitro transcription in the sense orientation and sequencing through insert, c. 
multiple cloning site for insertion of gene, d. BGH reverse priming site, e. BGH 
polyadenylation sequence for efficient transcription termination and mRNA 
polyadenylation, f. f1 origin for rescue of single stranded DNA, g. SV40 early 
promoter and origin for efficient, high level expression of the neomycin resistance 
gene and episomal replication in cells expression SV40 large T antigen, h. neomycin 
resisitance gene (ORF) for selection of stable transfectants in mammalian cells, i. 
SV40 early polyadenylation signal for efficient transcription termination and 
polyadenylation of mRNA, j. pUC origin for high copy number replication and 
growth in E.coli , k. ampicillin resistance gene for selection of vector in E.coli , l. ORF, 
ribosome binding site, m. bla promoter (P3).  
2.1.6 DNA constructs 
The hCLR and hRAMP1 and rGαs DNA sequences were kindly provided in the 
pcDNA3.1- vector by David Poyner at Aston University. The hCLR construct 
contained an N-terminal signal peptide and an HA tag (Figure 2.2).  
2.1.7 Oligonucleotides 
Oligonucleotides were synthesised in 25 µmol amounts from Invitrogen (Paisley, 
UK) or Sigma (Dorset, UK). Lyophilised primers were reconstituted to a 100 µM 
stock concentration in sterile H2O and stored at -20°C. Oligonucleotide sequences 
for the ECL2 alanine substitution are detailed in Table 2.1. Oligonucleotide 
sequences for the ECL2 further mutagenesis are detailed in Table 2.2. 
Oligonucleotide sequences for the ICL and C-terminus cloning are detailed in Table 
2.3. Oligonucleotide sequences for the CLR-Gαs fusion construct are detailed in 
Table 2.4. 
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Figure 2.1. Plasmid vector map of the mammalian expression vector pcDNA3.1 (+/-). 
Plasmid vector map as described from www.invitrogen.com. Key features have been 
annotated. The +/- plasmids contain the same features except the orientation of the 
multiple cloning site (MCS). 
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cggccgcgtcgacggaattgcgccaccatggccttaccagtgaccgccttgctcctgccg 
 R  P  R  R  R  N  C  A  T  M  A  L  P  V  T  A  L  L  L  P  
ctagccttgctgctccacgccgccaggccggattacgcgtcttacccgtatgacgtccca 
 L  A  L  L  L  H  A  A  R  P  D  Y  A  S  Y  P  Y  D  V  P  
gattacgcatcgctgggaggcccttcactcgagggatccgcagaattagaagagagtcct 
 D  Y  A  S  L  G  G  P  S  L  E  G  S  A  E  L  E  E  S  P  
gaggactcaattcagttgggagttactagaaataaaatcatgacagctcaatatgaatgt 
 E  D  S  I  Q  L  G  V  T  R  N  K  I  M  T  A  Q  Y  E  C  
taccaaaagattatgcaagaccccattcaacaagcagaaggcgtttactgcaacagaacc 
 Y  Q  K  I  M  Q  D  P  I  Q  Q  A  E  G  V  Y  C  N  R  T  
tgggatggatggctctgctggaacgatgttgcagcaggaactgaatcaatgcagctctgc 
 W  D  G  W  L  C  W  N  D  V  A  A  G  T  E  S  M  Q  L  C  
cctgattactttcaggactttgatccatcagaaaaagttacaaagatctgtgaccaagat 
 P  D  Y  F  Q  D  F  D  P  S  E  K  V  T  K  I  C  D  Q  D  
ggaaactggtttagacatccagcaagcaacagaacatggacaaattatacccagtgtaat 
 G  N  W  F  R  H  P  A  S  N  R  T  W  T  N  Y  T  Q  C  N  
gttaacacccacgagaaagtgaagactgcactaaatttgttttacctgaccataattgga 
 V  N  T  H  E  K  V  K  T  A  L  N  L  F  Y  L  T  I  I  G  
cacggattgtctattgcatcactgcttatctcgcttggcatattcttttatttcaagagc 
 H  G  L  S  I  A  S  L  L  I  S  L  G  I  F  F  Y  F  K  S  
ctaagttgccaaaggattaccttacacaaaaatctgttcttctcatttgtttgtaactct 
 L  S  C  Q  R  I  T  L  H  K  N  L  F  F  S  F  V  C  N  S  
gttgtaacaatcattcacctcactgcagtggccaacaaccaggccttagtagccacaaat 
 V  V  T  I  I  H  L  T  A  V  A  N  N  Q  A  L  V  A  T  N  
cctgttagttgcaaagtgtcccagttcattcatctttacctgatgggctgtaattacttt 
 P  V  S  C  K  V  S  Q  F  I  H  L  Y  L  M  G  C  N  Y  F  
tggatgctctgtgaaggcatttacctacacacactcattgtggtggccgtgtttgcagag 
 W  M  L  C  E  G  I  Y  L  H  T  L  I  V  V  A  V  F  A  E  
aagcaacatttaatgtggtattattttcttggctggggatttccactgattcctgcttgt 
 K  Q  H  L  M  W  Y  Y  F  L  G  W  G  F  P  L  I  P  A  C  
atacatgccattgctagaagcttatattacaatgacaattgctggatcagttctgatacc 
 I  H  A  I  A  R  S  L  Y  Y  N  D  N  C  W  I  S  S  D  T  
catctcctctacattatccatggcccaatttgtgctgctttactggtgaatctttttttc 
 H  L  L  Y  I  I  H  G  P  I  C  A  A  L  L  V  N  L  F  F  
ttgttaaatattgtacgcgttctcatcaccaagttaaaagttacacaccaagcggaatcc 
 L  L  N  I  V  R  V  L  I  T  K  L  K  V  T  H  Q  A  E  S  
aatctgtacatgaaagctgtgagagctactcttatcttggtgccattgcttggcattgaa 
 N  L  Y  M  K  A  V  R  A  T  L  I  L  V  P  L  L  G  I  E  
tttgtgctgattccatggcgacctgaaggaaagattgcagaggaggtatatgactacatc 
 F  V  L  I  P  W  R  P  E  G  K  I  A  E  E  V  Y  D  Y  I  
atgcacatccttatgcacttccagggtcttttggtctctaccattttctgcttctttaat 
 M  H  I  L  M  H  F  Q  G  L  L  V  S  T  I  F  C  F  F  N  
ggagaggttcaagcaattctgagaagaaactggaatcaatacaaaatccaatttggaaac 
 G  E  V  Q  A  I  L  R  R  N  W  N  Q  Y  K  I  Q  F  G  N  
agcttttccaactcagaagctcttcgtagtgcgtcttacacagtgtcaacaatcagtgat 
 S  F  S  N  S  E  A  L  R  S  A  S  Y  T  V  S  T  I  S  D  
ggtccaggttatagtcatgactgtcctagtgaacacttaaatggaaaaagcatccatgat 
 G  P  G  Y  S  H  D  C  P  S  E  H  L  N  G  K  S  I  H  D  
attgaaaatgttctcttaaaaccagaaaatttatataattgagaattc 
 I  E  N  V  L  L  K  P  E  N  L  Y  N  -  E  F   
 
Figure 2.2. DNA and translated sequence of hCLR with an N-terminal signal peptide and 
HA tag.  
The start codon is highlighted green, the signal peptide magenta, the HA tag is cyan and the 
mature hCLR sequence is yellow.  
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Mutant F/R Primer sequence 5' - 3' 
A271L F  CCTGCTTGTATACATCTCATTGCTAGAAGC  
  R  GCTTCTAGCAATGAGATGTATACAAGCAGG  
I272A F  GCTTGTATACATGCCGCTGCTAGAAGCTTATATTAC  
  R  GTAATATAAGCTTCTAGCAGCGGCATGTATACAAGC  
A273L F  GTATACATGCCATTCTTAGAAGCTTATATTAC  
  R  GTAATATAAGCTTCTAAGAATGGCATGTATAC  
S275A F  CATGCCATTGCTAGAGCCTTATATTACAATGAC 
  R  GTCATTGTAATATAAGGCTCTAGCAATGGCATG 
L276A F  GCCATTGCTAGAAGCGCATATTACAATGAC 
  R  GTCATTGTAATATGCGCTTCTAGCAATGGC 
I284A F  GACAATTGCTGGGCCAGTTCTGATACCC 
  R  GGGTATCAGAACTGGCCCAGCAATTGTC 
S286A F  CAATTGCTGGATCAGTGCTGATACCCATCTCCTC 
  R  GAGGAGATGGGTATCAGCACTGATCCAGCAATTG 
D287A F  GCTGGATCAGTTCTGCTACCCATCTCCTCTAC 
  R  GTAGAGGAGATGGGTAGCAGAACTGATCCAGC 
H289A F  CAGTTCTGATACCGCTCTCCTCTACATTATCC  
  R  GGATAATGTAGAGGAGAGCGGTATCAGAACTG  
L290A F  GTTCTGATACCCATGCCCTCTACATTATCC  
  R  GGATAATGTAGAGGGCATGGGTATCAGAAC  
L291A F  CTGATACCCATCTCGCCTACATTATCCATGG  
  R  CCATGGATAATGTAGGCGAGATGGGTATCAG  
Y292A F  CCCATCTCCTCGCCATTATCCATGGC  
  R  GCCATGGATAATGGCGAGGAGATGGG  
I293A  F  CCCATCTCCTCTACGCTATCCATGGCCC  
  R  GGGCCATGGATAGCGTAGAGGAGATGGG  
I294A F  CTCCTCTACATTGCCCATGGCCCAATTTG  
  R  CAAATTGGGCCATGGGCAATGTAGAGGAG  
 
Table 2.1. Primer sequences for the alanine substitution site directed mutagenesis of the 
ECL2 domain of the CGRP receptor.  
The codon being mutated is highlighted in red. 
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Mutant F/R Primer sequence 5' - 3' 
A273G F GCTTGTATACATGCCATTGGTAGAAGCTTATATTACAATG 
  R CATTGTAATATAAGCTTCTACCAATGGCATGTATACAAGC 
R274G F CATGCCATTGCTGGAAGCTTATATTAC 
  R GTAATATAAGCTTCCAGCAATGGCATG 
Y277F F GCTAGAAGCTTATTTTACAATGACAATTGC 
  R GCAATTGTCATTGTAAAATAAGCTTCTAGC 
Y277L F GCCATTGCTAGAAGCTTATTATACAATGACAATTGCTGG 
  R CCAGCAATTGTCATTGTATAATAAGCTTCTAGCAATGGC 
Y278F F GCTAGAAGCTTATATTTCAATGACAATTGCTGG 
  R CCAGCAATTGTCATTGAAATATAAGCTTCTAGC 
Y278L F GCTAGAAGCTTATATTTAAATGACAATTGCTGG 
  R CCAGCAATTGTCATTTAAATATAAGCTTCTAGC 
D280E F GCTTATATTACAATGAGAATTGCTGGATCAG 
  R CTGATCCAGCAATTCTCATTGTAATATAAGC 
D280L F GCTTATATTACAATCTCAATTGCTGGATCAG 
  R CTGATCCAGCAATTGAGATTGTAATATAAGC 
D280N F GCTTATATTACAATAACAATTGCTGGATCAG 
  R CTGATCCAGCAATTGTTATTGTAATATAAGC 
D280S F GCTTATATTACAATAGCAATTGCTGGATCAG 
  R CTGATCCAGCAATTGCTATTGTAATATAAGC 
D280T F GCTTATATTACAATACCAATTGCTGGATCAG 
  R CTGATCCAGCAATTGGTATTGTAATATAAGC 
N281K F GCTTATATTACAATGACAAATGCTGGATCAGTTCTG 
  R CAGAACTGATCCAGCATTTGTCATTGTAATATAAGC 
W283F F CAATGACAATTGCTTTATCAGTTCTGATACCC 
  R GGGTATCAGAACTGATAAAGCAATTGTCATTG 
W283H F TTACAATGACAATTGCCATATCAGTTCTGATACCC 
  R GGGTATCAGAACTGATATGGCAATTGTCATTGTAA 
I284F F CAATGACAATTGCTGGTTCAGTTCTGATACCCATC 
  R GATGGGTATCAGAACTGAACCAGCAATTGTCATTG 
I284L F CAATGACAATTGCTGGCTCAGTTCTGATACCCATC 
  R GATGGGTATCAGAACTGAGCCAGCAATTGTCATTG 
I284Q F CAATGACAATTGCTGGCAGAGTTCTGATACCCATC 
  R GATGGGTATCAGAACTCTGCCAGCAATTGTCATTG 
S285D F GACAATTGCTGGATCGATTCTGATACCCATCTCC 
  R GGAGATGGGTATCAGAATCGATCCAGCAATTGTC 
S285N F GACAATTGCTGGATCAATTCTGATACCCATCTC 
  R GAGATGGGTATCAGAATTGATCCAGCAATTGTC 
S285T F GACAATTGCTGGATCACTTCTGATACCCATCTC 
  R GAGATGGGTATCAGAAGTGATCCAGCAATTGTC 
S285Y F GACAATTGCTGGATCTATTCTGATACCCATCTCC 
  R GGAGATGGGTATCAGAATAGATCCAGCAATTGTC 
 
Table 2.2. Primer sequences for the further substitution site directed mutagenesis of the 
ECL2 domain of the CGRP receptor.  
The codon being mutated is highlighted in red. 
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Mutant F/R Primer sequence 5' - 3' 
D287E F GCTGGATCAGTTCTGAGACCCATCTCCTCTAC 
  R GTAGAGGAGATGGGTCTCAGAACTGATCCAGC 
D287L F GACAATTGCTGGATCAGTTCTCTTACCCATCTCCTCTACATTATCC 
  R GGATAATGTAGAGGAGATGGGTAAGAGAACTGATCCAGCAATTGTC 
D287S F GCTGGATCAGTTCTTCTACCCATCTCCTCTAC 
  R GTAGAGGAGATGGGTAGAAGAACTGATCCAGC 
T288D F GCTGGATCAGTTCTGATGACCATCTCCTCTACATTATCC 
  R GGATAATGTAGAGGAGATGGTCATCAGAACTGATCCAGC 
T288N F GCTGGATCAGTTCTGATAACCATCTCCTCTACATTATCC 
  R GGATAATGTAGAGGAGATGGTTATCAGAACTGATCCAGC 
T288S F GCTGGATCAGTTCTGATTCCCATCTCCTCTACATTATCC 
  R GGATAATGTAGAGGAGATGGGAATCAGAACTGATCCAGC 
T288V F GGATCAGTTCTGATGTCCATCTCCTCTAC 
  R GTAGAGGAGATGGACATCAGAACTGATCC 
L290AL291A F CAGTTCTGATACCCATGCCGCCTACATTATCCATGGCC 
  R GGCCATGGATAATGTAGGCGGCATGGGTATCAGAACTG 
L290AY292A F GATACCCATGCCCTCGCCATTATCCATGGCCC 
  R GGGCCATGGATAATGGCGAGGGCATGGGTATC 
L291AY292A F CTGATACCCATGCCGCCGCCATTATCCATGGCCC 
  R GGGCCATGGATAATGGCGGCGGCATGGGTATCAG 
L291AI293A F CCCATCTCGCCTACGCTATCCATGGCCC 
  R GGGCCATGGATAGCGTAGGCGAGATGGG 
L290N F CAGTTCTGATACCCATAACCTCTACATTATCCATG 
  R CATGGATAATGTAGAGGTTATGGGTATCAGAACTG 
L291N F CTGATACCCATCTCAACTACATTATCCATGG 
  R CCATGGATAATGTAGTTGAGATGGGTATCAG 
Y292S F CCCATCTCCTCTCCATTATCCATGGCCC 
  R GGGCCATGGATAATGGAGAGGAGATGGG 
I294G F CTCCTCTACATTGGCCATGGCCCAATTTG 
  R CAAATTGGGCCATGGCCAATGTAGAGGAG 
 
Table 2.2 (cont). Primer sequences for the further substitution site directed mutagenesis 
of the ECL2 domain of the CGRP receptor.  
The codon being mutated is highlighted in red. 
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Mutant F/R Primer sequence 5' - 3' 
ICL1 F  CTAGA ATG AAGAGCCTAAGTTGCCAAAGG TAG G 
  R  AATTC CTA CCTTTGGCAACTTAGGCTCTT CAT T 
ICL2 F  TCGT TCTAGA ATG CTACACACACTCATTG 
  R  TCGT GAATTC CTA CATTAAATGTTGCTTC 
ICL3 F  TCGT TCTAGA ATG CGCGTTCTCATCACC 
  R  TCGT GAATTC CTA TCTCACAGCTTTCATG 
H8 F  CTAGA ATG GGAGAGGTTCAAGCAATTCTGAGAAGAAACTGGAAT TAG G 
  R  AATTC CTA ATTCCAGTTTCTTCTCAGAATTGCTTGAACCTCTCC CAT T 
C-terminus F  TCGT TCTAGA ATG CAATACAAAATCCAATTTGG 
  R  TCGT GAATTC CTA ATTATATAAATTTTCTGG 
 
Table 2.3. Primer sequences for the cloning of the CLR ICLs, H8 and C-terminus into the 
pcDNA3.1- vector.   
The primers have been designed with a 5’ XbaI restriction site (magenta) and a 3’ EcoRI site 
(green). A start codon (red) and a stop codon (blue) have been included in the primers. 
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Mutant F/R Primer sequence 5' - 3' 
CLRSTOPA F GAAAATTTATATAATGCAGAATTCCACCACAC  
CLRSTOPA  R GTGTGGTGGAATTCTGCATTATATAAATTTTC  
rGNASE F TGAC GAATTC ATGGGCTGCCTCGGC  
rGNASK R TGAC GGTACC TTAGAGCAGCTCGTATTGGCG  
GNASND F GATGAACGTGCCAGACTTTGACTTCCCACC 
GNASND R GGTGGGAAGTCAAAGTCTGGCACGTTCATC  
 
Table 2.4. Primer sequences for the cloning of the Gαs gene intro the CLR construct at the 
3’ terminus.  
The codon being mutated is highlighted in red. The Gαs amplification primers have been 
designed with a 5’ EcoRI site restriction site (magenta) and a 3’ KpnI site (green). 
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2.1.8 Antibodies 
For the cell surface expression ELISA, the monoclonal anti-HA antibody produced in 
mouse and the anti-mouse IgG (whole molecule)-peroxidase antibody produced in 
goat were both purchased from Sigma (Dorset, UK). 
2.1.9 cAMP signalling  
To measure cellular cAMP levels a Perkin Elmer Lance® TR-FRET based cAMP assay 
and 96 well white optiplates were purchased from Perkin Elmer (Cambridge, UK).  
2.1.10 ELISA 
For the detection of peroxidase activity in enzyme immunoassays SIGMAFAST™ 
OPD (o-Phenylenediamine dihydrochloride) was purchased from Sigma (Dorset, 
UK). 
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2.2 Methods 
2.2.1 Primer design for site directed mutagenesis (SDM) 
Primers were designed to include the required codon change with an extended 5’ 
and 3’ sequence of 10-15 nucleotides to allow for primer annealing and extension. 
Where possible, primers were terminated with a cytosine or guanine nucleotide to 
facilitate stronger binding to the template DNA strand. 
2.2.2 Primer design for PCR amplification 
Primers were designed to include a flanking restriction site with appropriate 
restriction site and a short random base pair sequence at the terminus to facilitate 
restriction digest. Start and stop codons were include if required. 
2.2.3 QuikChange site directed mutagenesis 
100 ng of plasmid DNA was used as a template with sense and antisense 
nucleotides at a final concentration of 200 nM each. A final concentration of 800 
µm dNTPs and a total amount of 3 units of Pfu polymerase were added to a total 
reaction volume of 50 µl. The final 1x reaction buffer consisted of 20 mM Tris-HCl 
(pH 8.8 at 25 °C), 10 mM KCl, 10 mM (NH4)SO4, 2 mM MgSO4, 0.1 % Triton® X-100 
and 0.1 mg/ml nuclease-free BSA.  The reaction mix was denatured at 95 °C for 30 s, 
annealed at 55 °C for 30 s and extended at 72 °C for 16 min for 16 cycles in a 
Biometra T3000 thermocycler. 20 units DpnI was added to the reaction mix for 5 
hours at 37 °C to digest methylated template DNA. The template DNA used was 
hCLR with an N terminal HA tag in the pcDNA3.1- vector. 
2.2.4 PCR amplification 
10 ng of plasmid DNA was used as a template with sense and antisense nucleotides 
at a final concentration of 200 nM each. A final concentration of 800 µm dNTPs and 
a total amount of 3 units of Pfu polymerase were added to a total reaction volume 
of 50 µl. The final 1x reaction buffer consisted of 20 mM Tris-HCl (pH 8.8 at 25 °C), 
10 mM KCl, 10 mM (NH4)SO4, 2 mM MgSO4, 0.1 % Triton® X-100 and 0.1 mg/ml 
nuclease-free BSA.  The reaction mix was denatured at 95 °C for 30 s, annealed at 
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50 °C for 30 s and extended at 72 °C for 1 min for 30 cycles in a Biometra T3000 
thermocycler. 
2.2.5 Annealing and kinase treating primers 
ICL1 and H8 primers (Table 2.3) were designed ready for insertion into the 
pcDNA3.1- vector. Sense and antisense nucleotides were added at a final 
concentration of 5 M to a total volume of 50 l. The primer mix was denatured at 
95 °C for 5 min and annealed at 50 °C for 15 min. Before ligation the annealed 
primers were phosphorylated with T4 polynucleotide kinase. 5 M primers were 
mixed with 0.5 mM ATP and 10 units T4 polynucleotide kinase in a total reaction 
volume of 30 l. The final 1x reaction buffer consisted of 70 mM Tris-HCl, 10 mM 
MgCl2 and 5 mM DTT (pH 7.6 @ 25 °C). The reaction was incubated at 37 °C for 15 
min and heat inactivated at 65 °C for 10 min. 
2.2.6 Restriction endonuclease digestion 
~1 g DNA was digested using 20 units restriction endonuclease in a total reaction 
volume of 50 l. The final 1x reaction buffer consisted of 50 mM Potassium Acetate, 
20 mM Tris-acetate, 10 mM Magnesium Acetate and 1 mM DTT (pH 7.9 @ 25 °C). 
The reaction mix was incubated at 37°C for 3 hours. After 2 hours 10 units of calf 
intestinal phosphatase (CIP) was added to the plasmid vector digest and incubated 
at 37 °C for 1 hour. 
2.2.7 Gel electrophoresis 
Agarose gels were prepared by adding 0.8-2% (w/v) agarose to 1x TBE buffer (89 
mM Tris, 89 mM Boric acid, 2 mM EDTA, pH 8) and heating with regular stirring to 
dissolve. Ethidium bromide (0.2 µg/ml) was added and stirred to mix. The gel was 
poured and allowed to set. DNA samples were prepared with NEB 6x loading dye, to 
a final concentration of 2.5 % Ficoll-400, 11 mM EDTA, 3.3 mM Tris-HCl (pH 8.0 @ 
25 °C), 0.017 % SDS and 0.015 % bromophenol blue. 0.5 µg 1kb ladder (NEB) or 0.65 
µg 100bp ladder (Promega) was loaded and the gel was electrophoresed at 100-
150V until sufficient separation had occurred. The gel image was captured using a 
GelDoc 2000 UV transilluminator with Quantity One software (Biorad, UK). To 
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extract DNA, fragments were excised from the gel and purified using a gel 
extraction kit (Qiagen). 
2.2.8 Ligation 
A vector:insert ratio of 1:3 (100 ng vector) was added to 400 units T4 ligase in a 
total reaction volume of 20 l. The final 1x reaction buffer consisted of 50 mM Tris-
HCl, 10 mM MgCl2, 1 mM ATP and 10 mM DTT (pH 7.5 @ 25 °C). The reaction mix 
was incubated at 16 °C for 16 hours. 
2.2.9 Preparation of competent cells 
Top 10 cells were streaked onto an LB agar plate (no antibiotic) and grown at 37 °C, 
16 hours. A single colony was used to inoculate 5ml LB medium and incubated at 37 
°C, 220 rpm for 16 hours. The 5ml culture was used to inoculate 400 ml LB medium 
and grown at 37 °C, 220 rpm until the OD590 had reached 0.35-0.4. The culture was 
incubated on ice for 10 min, and cells were pelleted at 4000 x g, 4 °C for 15 min. 
Cells were resuspended in 80ml of ice cold 60 mM CaCl2, 15 % (v/v) glycerol, 10 mM 
pipes pH 7 and pelleted at 4000 x g, 4 °C for 15 min. Cells were resuspended in 80 
ml of ice cold 60 mM CaCl2, 15 % (v/v) glycerol, 10 mM pipes pH 7, 4 °C and 
incubated on ice for 30 min. Cells were pelleted at 4000 x g, 4 °C for 15 min. Cells 
were resuspended in 16 ml 60 mM CaCl2, 15 % (v/v) glycerol, 10 mM pipes pH 7, 4 
°C, aliqotted into pre-cooled microcentrifuge tubes and stored at -80 °C. 
2.2.10 Transformation 
Competent Top10 cells were defrosted on ice and DNA was added (not exceeding 
1/10 of the competent cell volume), mixed and incubated for 10 min, 4 °C. The 
Top10 cells and DNA mix was exposed to heat shock at 42 °C for 60 s followed by 
incubation on ice for 5 min. The Top10 cells were grown in 1ml LB medium for 1 
hour at 37°C. Cells were pelleted at 2000 x g for 5 min and resuspended in 50-150 µl 
LB medium and plated onto LB agar + 100 µg/µl ampicillin and incubated at 37 °C 
for 16hours. 
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2.2.11 DNA amplification and purification 
To obtain a plasmid DNA yield of ~10 µg to use for sequencing or molecular 
biological processes, a transformed Top10 colony was picked and grown in 3-5 ml 
Lbroth + 100 µg/µl ampicillin at 37 °C, 220 rpm for 16 hours. The cells were pelleted 
by centrifugation at 4000 x g for 5 min and DNA was purified using a Wizard® Plus 
SV Miniprep kit (Promega). To obtain a plasmid DNA yield of 250-1000 µg to use for 
mammalian cell transfections a transformed Top10 colony was picked and grown in 
3-5 ml Lbroth + 100 µg/µl ampicillin at 37 °C, 220 rpm for 8 hours. This culture was 
used to inoculate 150 ml Lbroth + 100 µg/µl ampicillin and incubated at 37 °C, 220 
rpm for 16 hours. The cells were pelleted by centrifugation at 4000 x g for 5 min and 
DNA was purified using a PowerPrep High Purity Plasmid Maxiprep System (Insight 
Biotechnology Ltd). 
2.2.12 Sequencing 
DNA sequencing was done by GATC biotech (Köln, Germany). Samples were 
prepared by adding 500 ng DNA and 5 µM sequencing primer to a final volume of 
10 µl. DNA sequences were obtained using Applied Biosystems sequence scanner 
software and alignments were created using EMBL-EBI ClustalW2 multiple sequence 
alignment software. 
2.2.13  Cell culture and transfection 
Cos7 cells were grown in Dulbecco's Modified Eagle Medium (DMEM) 
supplemented with 10 % (v/v) fetal bovine serum (FBS) at 37 °C in a humidified 95 % 
air/5 % CO2 atmosphere. Cos7 cells were subcultured to maintain a cellular 
confluence between 10 % and 80 % using 0.25 % (w/v) Trypsin - 0.53 mM EDTA 
solution. Cell stocks (4x106 per vial) were maintained by freezing the cells in DMEM 
+ 10 % FBS + 5 % dimethyl sulfoxide (DMSO) and storing in liquid nitrogen. For 
cAMP assays, cells were seeded in 6 well plates at 5 x 10-5 cells per well and grown 
for 24 hours before PEI transfection. For cell surface expression ELISAs, cells were 
seeded in 24 well plates at 8x10-4 cell per well and grown for 24 hours before PEI 
transfection.   
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2.2.14 PEI transfection  
Cells were transfected using a mixture (per 1 µg DNA) of 6 µl of 1 µg/µl 
polyethyleneimine PEI (pH7.4) and 50 µl DMEM (serum free) and incubating for 10 
min at room temperature. 300 µl DMEM + 10 % FBS was added and the transfection 
mix was added to the cells. Following incubation (37 °C, 95 % air/5 % CO2) for 3 
hours, DMEM + 10 % FBS was added to an appropriate final volume. 6 well plates 
were treated with 2 µg DNA per well, 24 well plates were treated with 0.5 µg of 
DNA per well and 100 mm dishes were treated with 10 µg of DNA per dish. 
2.2.15 Perkin Elmer Lance® cAMP TR-FRET signalling assay 
The Perkin Elmer Lance® cAMP TR-FRET assay was used. The assay was optimised 
for cos7 cells transiently transfected with the CGRP receptor. 
2.2.15.1 Optimisation of the Perkin Elmer Lance® cAMP assay 
The cAMP assay protocol was optimised from the Perkin Elmer Lance® cAMP assay 
manual. The optimisation included testing the consistency of data output across a 
Perkin Elmer 96 well optiplate (using cAMP standards), the reproducibility of the 
assay over different days (using cAMP standards), the optimal cell amount per well 
and the optimal CGRP stimulation concentration range. The results from this 
optimisation are shown in Figure 2.3. The assay buffer (stimulation buffer, SB) was 
PBS + 0.1 % BSA + 0.5 mM IBMX. A logarithmic decrease of cAMP standards were 
diluted in SB over a concentration range of 10-6 to 10-12 M with SB as a basal. The 
cAMP standards were loaded in triplicate at two different positions on a 96 well 
optiplate. The top graph in Figure 2.3 describes the response. Each set of standards 
produced an identical output. This shows the consistency across a 96 well plate. The 
cAMP standards were loaded in triplicate on separate days to measure the 
reproducibility of the assay. The second graph describes these results. These curves 
are almost identical showing the reproducibility of the assay. The cAMP output of a 
range of cos 7 cell amounts was tested using a dose-dependent stimulation with 
forskolin across a concentration range of 10-4 to 10-10 M using SB as a basal. The 
cAMP standards across the previously described concentration range were loaded  
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Figure 2.3. Optimisation of the Perkin Elmer Lance® cAMP TR-FRET signalling assay. 
The cAMP assay protocol was optimised from the Perkin Elmer Lance® cAMP assay manual. 
The cAMP standard curve same plate graph loaded cAMP standards in triplicate at two 
different positions on a 96 well plate. The cAMP standard curve different day graph shows 
cAMP standards loaded in triplicate in the same plate position on separate days. The 
forksolin stimulation graph tested varying amounts of cos 7 cells/well (1000/well, 
2000/well, 5000/well and 10,000/well) and dose dependently stimulated with forskolin. 
The CGRP stimulation graph tested varying amounts of cos 7 cells/well (2000/well, 
6000/well and 12,000/well) and dose dependently stimulated with CGRP.   
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to enable the cell concentration that produced a forskolin response over the linear 
part of the cAMP standard curve to be chosen. These results are shown in the third 
graph. 1000 cells/well produced a response close to the top end of the cAMP 
standard curve. 10,000 cells/well produced a response close to the bottom end. 
2000 cells/well and 5000 cells/well both produced a response in the linear cAMP 
standard range. 2000 cells/well produced a response over a slightly larger range. 
The cAMP output of a range of cos 7 cell amounts was tested using a dose-
dependent stimulation with CGRP across a concentration range of 10-6 to 10-12 M 
using SB as a basal. A cAMP standard curve was loaded. These results are shown in 
the final graph. Again, the higher cell number (12,000 cells/well) produced a cAMP 
response at the bottom end of the cAMP standard curve. 2000 cells/well and 6000 
cells/well both produced a response in the linear part of the cAMP standard curve 
with a similar window between the highest and lowest cAMP response. 2000 
cells/well were chosen to use in the assay due to the slightly higher signalling 
window observed with the forskolin stimulation. The concentration range of CGRP 
(10-6 to 10-12 M with SB as a basal) was sufficient to produce a basal and Emax 
signalling response with a pEC50 between 9.2 and 10.2. This concentration range 
should be sufficient to stimulate substitutions with an increased or reduced 
signalling potency. 
2.2.15.2 Perkin Elmer Lance® cAMP assay optimised protocol 
48 hours following transfection, cells were removed from the plate with  0.25 % 
(w/v) Trypsin - 0.53 mM EDTA solution, washed with PBS and resuspended in assay 
stimulation buffer (SB, PBS + 0.1 % BSA + 0.5 mM IBMX). The cells were counted 
with a hemocytometer and the appropriate cell number pelleted at 500 x g, 4 min, 
to be resuspended in SB + 1/100 AlexaFluor® 647-anti cAMP antibody at an assay 
concentration of 2000 cells/10 µl. 2000 cells/well (10µl) were loaded onto a 96 well 
white optiplate and were dose dependently stimulated in triplicate with a 
logarithmic increase of CGRP diluted in SB from 10-6 M to 10-12 M with SB as a basal 
in a 10 µl volume at a x2 final concentration. The plate was incubated in the 
absence of light for 30 min before 20 µl/well of detection mix was added. The plate 
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was incubated in the absence of light for a further 60 minutes. FRET was recorded 
by excitation at 320 nm and emission at 665 nm. 
2.2.16 Cell surface expression ELISA 
48 hours following transfection cells were stimulated with DMEM + 10 % FBS ± 10-7 
M CGRP for 45-60 min. The stimulation media was removed by aspiration and the 
cells were fixed with 3.7 % formaldehyde in PBS (250 µl/well), room temperature 
for 15 min. Cells were washed with PBS (500 µl/well, x3). Cells were blocked with 1 
% bovine serum albumin (BSA) in PBS (500 µl/well), room temperature for 45 min, 
shaking. Blocking buffer was removed by aspiration and cells were incubated with 
mouse α-HA primary antibody (1:2000 in 1 % BSA in PBS, 200 µl/well) room 
temperature, 1 hour, shaking. Cells were washed with PBS (500 µl/well, x3). Cells 
were re-blocked with 1 % BSA in PBS (500 µl/well), room temperature for 15 min, 
shaking. Blocking buffer was removed by aspiration and cells were incubated with 
mouse α-mouse IgG peroxidase secondary antibody (1:2000 in 0.5 % BSA in PBS, 
200 µl/well) room temperature, 1 hour, shaking. Cells were washed with PBS (500 
µl/well, x3). SIGMAFAST™ OPD (o-Phenylenediamine dihydrochloride) substrate 
was prepared by adding 1 silver tablet and 1 gold tablet in 20 ml H2O. Cover in foil 
until use. OPS was added to the cells (200 µl/well) and incubated in the dark for 5-
30 min (until sufficient colour change has occurred). Following the incubation the 
plate was read immediately at 450 nm. The reaction can be stopped with the 
addition of 50 µl of 3 M HCl or 3 M H2SO4 solution per 200 µl of solution and read at 
492 nm. 
2.2.17 Experimental repeats 
The number of experimental repeats is denoted by the N number. This refers to an 
experiment prepared on a separate day, using a new passage of cells and a fresh 
transfection. For practical reasons the cell stocks, the plasmid DNA and the 
transfection reagent remain consistent between experimental repeats.  
2.2.18 Data analysis of cAMP FRET based signalling assay 
Data from cAMP signalling were analysed by fitting a sigmoidal dose response curve 
to the WT CLR data. The minimum and maximum values were taken and used to 
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normalise the WT CLR and mutant receptor data to 0 % and 100 % respectively. A 
sigmoidal dose response curve was fitted to the normalised values, which produced 
pEC50 values for the WT CLR and mutant receptors and basal and Emax values of the 
mutant receptor compared to WT CLR. Experimental repeats were undertaken (n ≥ 
3) and pEC50, basal and Emax values for each mutant were analysed using a paired t 
test to test for statistical significance.  
2.2.19 Data analysis of the cell surface expression ELISA 
Data from the cell surface expression ELISA were analysed by normalising the 
unactivated WT CLR and mutant receptor raw data to the basal and WT CLR 
maximum (minimum and maximum respectively). Experimental repeats were 
undertaken (n ≥ 3) and WT CLR and mutant receptor cell surface expression values 
were analysed using a paired t test to test for statistical significance. 
2.2.20 Data analysis of the internalisation ELISA 
Data from the internalisation ELISA were analysed by normalising each WT CLR and 
mutant receptor data set to basal and the individual unactivated receptor maximum 
(minimum and maximum respectively). Experimental repeats were undertaken (n ≥ 
3) and the activated (internalised) WT CLR and mutant receptor cell surface 
expression values were analysed using a paired t test to test for statistical 
significance. 
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 Alanine substitution analysis of the 3
extracellular loop two domain of the CGRP 
receptor  
3.1 Introduction 
The extracellular loop 2 (ECL2) domain in all GPCR families is of structural and 
functional importance (Wheatley et al., 2012). This was first identified through 
chimeric receptor experiments and mutagenesis studies of this domain (Fitzpatrick 
& Vandlen, 1994; Olah et al., 1994; Walker et al., 1994). Even in receptors with 
known TM ligand binding pockets, the ECLs were implicated in early stage ligand 
binding and presentation to the TM binding site (Colson et al., 1998; Perlman et al., 
1997). In other cases, effects of residues in ECL2 were speculated to be direct ligand 
binding due to a flexibility of the loop (Kim et al., 1996). 
The unique properties of ECL2 were highlighted in the crystal structure of 
Rhodopsin (Figure 3.1) which discovered an antiparallel β-sheet structure formed by 
the loop and extended deep into the centre of the TM bundle (Palczewski et al., 
2000). The role of ECL2 in this receptor was further understood using NMR 
spectroscopy that revealed an interaction between ECL2 and TM 5, 6 and 7 which 
constrained the receptor in the inactive state, until receptor activation resulted in 
movement of ECL2 and TM5 allowing an inward movement of TM6-ECL3-TM7 
(Ahuja et al., 2009). 
The high resolution structure of the human β2-adrenergic receptor (β2-AR) showed 
a more complex structure of ECL2 compared with the other ECLs (Figure 3.1) 
(Cherezov et al., 2007). In contrast with the structure of Rhodopsin, ECL2 of the β2-
AR was exposed at the surface, contained an extra helical segment and an intra-
loop disulphide bond as well as the familiar disulphide bond with TM3. The loop 
also made contacts with ECL1 and had a glycosylation site. These crystal structures 
highlighted the unique nature of ECL2 with respect to receptor function and show 
that it as an important domain to be investigated.   
112 
 
 
Figure 3.1. Crystal structures of the two archetypal family A GPCRs with the ECL2 domain 
highlighted.  
Bovine rhodopsin (PDB 1F88) and the β2-adrenergic receptor (PDB 2RH1). Each receptor is 
presented in two orientations. The GPCR unit is cyan, ECL2 is magenta. (Cherezov et al., 
2007; Palczewski et al., 2000). 
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Following the crystal structure publication of the β2-AR, a number of other 
mammalian GPCR structures were published. A selection of these is presented in 
Figure 3.2 with the ECL2 domains highlighted. These structures reveal the high 
degree of variation in both the length and structure of ECL2 compared with the 
ECL1 and ECL3 domains which are much more restricted and uniform. However 
given this variation, there are features that are conserved between receptor 
subfamilies. The rhodopsin and sphingosine-1-phosphate 1 (S1P1) receptors both 
have ECL2 domains that occlude the ligand binding pocket indicating the route of 
entry for the hydrophobic ligands (Hanson et al., 2012; Palczewski et al., 2000). 
Water-soluble ligand GPCRs have an open ECL2 conformation however there are 
structural differences. Aminergic and adenosine receptors have an α-helix structure 
(Cherezov et al., 2007; Jaakola et al., 2008) whereas the peptide binding opioid and 
chemokine receptors have a β-sheet (Granier et al., 2012; Manglik et al., 2012; Park 
et al., 2012; Wu et al., 2010; Wu et al., 2012). 
In 2013, the first two family B GPCR structures were published (Hollenstein et al., 
2013; Siu et al., 2013). These structures are presented in Figure 3.3 with the ECL2 
domains highlighted. In comparison with the ECL2 domains of the family A GPCRs in 
Figure 3.1 and Figure 3.2, the structures of these loops are different again. Neither 
the corticotropin-releasing hormone receptor 1 (CRHR1) nor the glucagon receptor 
(GCGR) have the β-sheet or α-helix of Rhodopsin or β2-AR. Instead there is a loop 
structure for both receptors that extends from TM4 towards the middle of the TM 
bundle before twisting 90° to cover over the binding pocket and twisting back 90° to 
form TM5 which are more representative of the muscarinic and dopamine 
receptors (Chien et al., 2010; Haga et al., 2012; Kruse et al., 2012). Both structures 
are similar however the CRHR1 ECL2 domain is longer and more pronounced. Each 
structure confirms that the ECL2 cysteine forms a disulphide bond with the cysteine 
at the top of TM3, a feature conserved in most family A and family B GPCRs. In the 
GCGR structure, ECL2 begins at the F289, three residues to the C-terminus of the 
conserved basic residue at the start of ECL2. The loop is 12 residues and ends at 
N300. In CRHR1 ECL2 begins at Y253, three residues to the C-terminus of the 
conserved basic residue. ECL2 is longer than GCGR (17 residues) and ends at D269.  
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Figure 3.2. Crystal structures of selected GPCRS with the ECL2 domain highlighted.  
Each receptor is presented in two different orientations. The GPCR unit is cyan, ECL2 is 
magenta. Human A2A Adenosine Receptor (A2AR) Bound to an antagonist, human 
dopamine d3 receptor (D3R) in complex with a d2/d3 selective antagonist, human M2 
muscarinic acetylcholine receptor (M2R) bound to an antagonist, rat M3 muscarinic 
acetylcholine receptor (M3R) in complex with antagonist, human sphingosine 1-phosphate 
1 receptor (S1P1R) complex with antagonist, mouse  µ -opioid receptor (µ-OR) bound to a 
morphinan antagonist, mouse δ opioid receptor (δ-OR) bound to antagonist, human κ-
opioid receptor (κOR) bound with antagonist, human CCR5 chemokine receptor bound to 
antagonist, human CXCR4 chemokine GPCR bound with antagonist. 
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Figure 3.3. Crystal structures of the two family B GPCRs with the ECL2 domain highlighted. 
Corticotropin releasing hormone receptor 1 (CRH1R, PDB 4K5Y) and the Glucagon receptor 
(GCGR, PDB 4L6R). Each receptor is presented in two orientations. The GPCR unit is cyan, 
ECL2 is magenta (Hollenstein et al., 2013; Siu et al., 2013). 
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Crystal structures have been vital in gaining understanding into receptor structure 
and conformations, interactions with both ligands and downstream signalling 
partners and possible mechanisms of activation. However they are limited in that 
they only provide a snapshot of one particular receptor conformation at a single 
moment in time. GPCR signalling is a dynamic and complex process. Different 
ligands stabilise different receptor conformations, activating certain signalling 
pathways and inhibiting others. Signalling can even occur through non G protein-
mediated pathways, for example using β-arrestin to activate MAPK signalling (Azzi 
et al., 2003). There are cases where one ligand may act as an agonist for one 
signalling pathway and an antagonist or inverse antagonist for another (Baker et al., 
2003; MacKinnon et al., 2009; Rajagopal et al., 2013).  
This fluidity in receptor conformation and signalling means it is important to do 
more than just study the receptor through static observations. Biochemical and 
biophysical analysis together with computer modelling has been essential in 
complementing and refining the information from the crystal structures. Various 
methods have been employed to study receptor function. Site directed mutagenesis 
and chimeric proteins have identified key domains and residues of ECL2 that have 
functional importance (Bergwitz et al., 1996; Conner et al., 2007b; Runge et al., 
2003).  
The scanning cysteine accessibility method (SCAM) introduces cysteine mutations 
into the receptor and uses their reactivity to cysteine reagents to determine their 
exposure to the aqueous environment (Javitch et al., 2002). Disulphide trapping 
experiments have been used to study ligand-receptor proximities for family B 
GPCRs. This technique introduces cysteine residues into the ligand and the 
extracellular parts of the receptor and tests the ability of these mutants to form 
disulphide bonds. This provides insight into those ligand-receptor residues that are 
in close proximity to each other (Dong et al., 2012; Monaghan et al., 2008). Zn2+ 
cross linking of endogenous and introduced histidine residues has also been used to 
determine the proximity of receptor domains and motifs (Elling & Schwartz, 1996). 
Ligand receptor contact can also be investigated using photoaffinity cross linking 
(Assil-Kishawi & Abou-Samra, 2002; Dong et al., 2004; Kraetke et al., 2005). 
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The first complete alanine scan of the ECL2 domain was of the family A V1A 
Vasopressin receptor (Conner et al., 2007b). This study identified key aromatic 
residues located throughout the loop that were required for ligand binding and 
intracellular signalling. An alanine scan of the cannabinoid receptor 1 (CB1) ECL2 
domain identified residues in the N-terminus of the loop important for cell surface 
expression (Ahn et al., 2009). Residues in the C-terminus were important for agonist 
binding but not inverse agonist binding. 
SCAM was used to investigate the ECL2 domain of the angiotensin II type 1 receptor 
in different receptor states (Unal et al., 2010). In the unliganded receptor a segment 
either side of the conserved disulphide bond was available suggesting an open 
conformation. Upon binding to an agonist or inverse agonist, ECL2 acted like a lid 
albeit in different conformations. ECL2 was involved in slowing down the rate of 
dissociation of ligands but also adopted different conformations according to the 
functional state of the receptor. This dynamic effect of ECL2 was also observed with 
the M2mAChR, where a reduction of loop flexibility caused by the addition of a 
disulphide bond between ECL2 and TM7 reduced the ligand binding affinity (Avlani 
et al., 2007).  
ECL2 has also been proposed as a site for allosteric enhancement of agonist 
signalling (Kennedy et al., 2014; Peeters et al., 2012). In the M2 crystal structure 
bound to the positive allosteric modulator LY2119620, the allosteric side was 
situated above the orthosteric binding pocket and involved interactions with the 
ECLs. ECL2 interactions were hydrogen bonding with E172 and stacking interactions 
with Y177 (Kruse et al., 2013). This domain has not just been implicated in the 
activation process; constitutive activity resulting from mutagenesis has led to 
speculation that this domain may constrain the receptor in its inactive state through 
interactions with the TM domain (Klco et al., 2005). In the melanocortin receptor, 
ECL2 is much shorter and does not interact with the TM core, leading to a higher 
constitutive activity (Holst & Schwartz, 2003). 
The importance of ECL2 in family B GPCRs has been shown with ECL2 alanine scans 
of both the glucagon-like peptide-1 receptor (GLP1R) and CRHR1 (Gkountelias et al., 
2009; Koole et al., 2012). In particular the alanine scan of the GLP1R revealed that 
118 
 
more than half of the 23 residues of ECL2 investigated had a significant reduction in 
cAMP pEC50 values upon stimulation with the high affinity agonist GLP-1(7-36)NH2. 
A large number had involvement in ligand binding affinity and the initiation of other 
signalling cascades. The GCGR crystal structure publication included results from 
mutagenesis which revealed a number of positions within the ECL2 domain that are 
important for receptor signalling (Siu et al., 2013).  
Cross-linking experiments identified contact sites between the CRH1R and 
radiolabelled sauvagine (Assil-Kishawi & Abou-Samra, 2002). Disuccinimidyl 
suberate (DSS) was used to form cross links between ε amino groups of lysine 
residues that have a molecular distance of 11.4 Å. This technique revealed that 
K257 in the ECL2 domain is in close proximity to K16 of the ligand sauvagine.  
The predicted ECL sequences of each family B GPCR have been aligned in Figure 3.4. 
The full protein sequence for each GPCR was aligned and the ECLs were assigned 
according to the predicted sequence from the Uniprot database. Identical and 
similar residues have been identified. With the exception of the PTH receptors, ECL1 
and ECL2 are of similar length across the family (~20 amino acids) and ECL3 is 
shorter (~10 amino acids). There is also very little sequence homology in each ECL 
across the family. In ECL1 there is only the conserved cysteine found at the top of 
TM3. Following this cysteine is always a basic residue. At the start of ECL1 is a 
conserved hydrophobic residue. ECL2 has the most conserved residues with a 
cysteine, tryptophan (CW) motif located in the middle of the loop. There is also a 
conserved carboxylic acid or carboxamide amino acid positioned 3 residues before 
the cysteine. At the start of the loop is a conserved basic residue. There is no 
conservation in ECL3. What is apparent, comparing these predicted loop regions 
with the ECLs in the GCGR and CRHR1 crystal structure is the variability between 
predicted domains and observed domains.   
 The primary sequences of the calcitonin family of ligands have been aligned in 
Figure 3.5. The level of amino acid conservation between ligands that activate the 
same receptor is surprisingly low. The current understanding in family B activation 
is that the C-terminus of the peptide ligand has affinity for the extracellular N-
terminus of the receptor which allows the presentation of the N-terminal domain to   
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ECL1 
hCLR      HLTAVA-----------------------NNQALVATNPVSCK 213 
hCTR      HLVEVV-----------------------PNGELVRRDPVSCK 236 
hCRHR1      FVVQLT-----------------------MSPEVHQSNVGWCR 218 
hCRHR2 FLLQL------------------------VDHEVHESNEVWCR 185 
hGHRHR     KDAALF------------------HSDDTDHCS---FSTVLCK 203 
hGIPR     RDRLLP------------RPGPYLG-DQALALWN--QALAACR 217 
hGLP1R     KDAALKW-----------MYSTAAQQHQWDGLLS-YQDSLSCR 227 
hGLP2R     KDVVFYN-----------SYSKRPDNENGWMSYLS-EMSTSCR 261 
hGLR       IDGLLRT-----------RYSQKIGDDLSVSTWLSDGAVAGCR 225 
hPACR    KDWILY------------------AEQDSNHC---FISTVECK 227 
hPTH1R     KDAVLYSGATLDEAERLTEEELRAIAQAPPPPATAAAGYAGCR 282 
hPTH2R      KDRVVHAHIGVKELESLIMQDD--PQNSIEATSVDKSQYIGCK 237 
hSCTR       KDAVLF------------------SSDDVTYCD---AHRAGCK 216 
hVIPR1      KDLALF------------------DSGESDQCS---EGSVGCK 216 
hVIPR2      KDDVLY------------------SSSGTLHCPDQPSSWVGCK 203 
                  .                                    *: 
 
ECL2 
hCLR  RSLYYNDNCWIS--SDTH 289 
hCTR  RAVYFNDNCWLS--VETH 312 
hCRHR1 KLYYDNEKCWFGKRPGVY 296 
hCRHR2 KLYYENEQCWFGKEPGDL 263 
hGHRHR KLAFEDIACWDL-DDTSP 280 
hGIPR  RYLYENTQCWER-NEVKA 294 
hGLP1R KYLYEDEGCWTR-NSNMN 304 
hGLP2R RAHLENTGCWTT-NGNKK 338 
hGLR  KCLFENVQCWTS-NDNMG 302 
hPACR  RLYFDDTGCWDM-NDSTA 304 
hPTH1R RATLANTGCWDL-SS-GN 358 
hPTH2R RATLADARCWEL-SA-GD 313 
hSCTR  RHFLEDVGCWDI-NANAS 293 
hVIPR1 RIHFEDYGCWDT-IN-SS 292 
hVIPR2 RLYLEDTGCWDT-NDHSV 279 
              :    :  **         
 
ECL3 
hCLR   RP---EGKIAEEVYD 366 
hCTR   RP---SNKMLGKIYD 389 
hCRHR1  NPG--EDEVSRVVFI 374 
hCRHR2  NPG--EDDLSQIMFI 341 
hGHRHR  L----PDNAGLGIRL 358 
hGIPR  VTEEQARGALRFAKL 374 
hGLP1R  VMDEHARGTLRFIKL 384 
hGLP2R  ITDDQVEGFAKLIRL 418 
hGLR   VTDEHAQGTLRSAKL 382 
hPACR  S----PENVSKRERL 382 
hPTH1R  TPYTEVSGTLWQVQM 441 
hPTH2R  LPHS-FTGLGWEIRM 395 
hSCTR  S----PEDA-MEIQL 370 
hVIPR1  F----PDNFKPEVKM 370 
hVIPR2 F----PISISSKYQI 357 
 
Figure 3.4. Sequence alignment of family B ECLs as determined by the Uniprot database.   
* indicates positions that have a fully conserved residue. : indicates conservation between 
groups of strongly similar properties. . indicates conservation between groups of weakly 
similar properties. The online EMBL-EBI multiple sequence analyser was used to analyse the 
family B sequences. 
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Calcitonin family 
αCGRP       --------------ACDTATCVTHRLAGLLSRSGGVVKN-NFVPTNV-GSKAF 
βCGRP       --------------ACNTATCVTHRLAGLLSRSGGMVKS-NFVPTNV-GSKAF 
CT          --------------CGNLSTCMLGTYTQDFNKFH-------TFPQTAIGVGAP 
Amylin       --------------KCNTATCATQRLANFLVHSSNNFGA-ILSSTNV-GSNTY 
ADM         YRQSMNNFQGLRSFGCRFGTCTVQKLAHQIYQFTDKD-KDNVAPRSKISPQGY 
ADM2       ------TQAQLLRVGCVLGTCQVQNLSHRLWQLMGPAGRQDSAPVDPSSPHSY 
                                 .**     :  : :                .     
 
CLR peptides 
CGRP1    --------------ACDTATCVTHRLAGLLSRSGGVV-KNNFVPTNVGSK-AF 
CGRP2       --------------ACNTATCVTHRLAGLLSRSGGMV-KSNFVPTNVGSK-AF 
ADM         YRQSMNNFQGLRSFGCRFGTCTVQKLAHQIYQFTDKD-KDNVAPRSKISPQGY 
ADM2        ------TQAQLLRVGCVLGTCQVQNLSHRLWQLMGPAGRQDSAPVDPSSPHSY 
                          .*  .** .:.*:  : :      :.: .* .  *  .: 
 
 
CTR peptides 
CT           -CGNLSTCMLGTYTQDFNKFHTFPQTAI-------GVGAP-- 
Amylin       KCNT-ATCAT----QRLANFLVHSSNNFGAILSSTNVGSNTY 
              * . :**      * : :* .. .. :        **:    
 
 
Figure 3.5. Sequence alignment of the calcitonin family peptides.  
The online EMBL-EBI multiple sequence analyser was used to analyse all the family B GPCR 
sequences together and family B subfamilies separately. * indicate positions which have a 
fully conserved residue. : indicates conservation between groups of strongly similar 
properties. . indicates conservation between groups of weakly similar properties. 
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a ligand binding pocket created by the ECLs and TM bundle facilitating the 
activation of the receptor (Hoare, 2005). Following this mechanism, variation in the 
C-terminal sequence of the peptide would explain variations in affinity between the 
ligands and their receptors. However it would be expected that activation through a 
shared ligand binding pocket would require a similar set of amino acids between 
ligands.    
The ECL1 and ECL3 domains of CLR have been studied using alanine substitution 
analysis (Barwell et al., 2011). This study showed that a hydrophobic cluster of 
residues at the top of TM2 (L195, V198 and A199) were involved in CGRP-binding 
and cAMP production. Within ECL1, cAMP pEC50 signalling was enhanced through 
A203L and A206L substitutions. In TM3, H219, L220 and L222 were shown to be 
important. Investigation of ECL3 identified a role for I260 in receptor activation with 
a predicted proximity to ECL2. L351 and E357 in TM6 are important for cell surface 
expression.  
The ECL2 domain of CLR has yet to be investigated. It is likely that this domain is 
important as suggested by the structures obtained for both family A and B GPCRs 
and the key involvement in receptor function in the alanine scans of this loop in 
other receptors. This makes determining the role of ECL2 of CLR a priority for 
understanding how this receptor functions. The purpose of this chapter is to 
investigate the structure and function of the CLR ECL2 domain through the effect of 
alanine substitution mutagenesis on cellular expression and CGRP-mediated 
receptor signalling, internalisation and binding.  
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3.2 Methods 
The general methods used are described in section 2. Method details that are 
specific to the work in this chapter will be described in this section. 
3.2.1 Mutagenesis to create alanine-substitution mutants 
The individual alanine substitutions of ECL2 were created using the primers 
described in Table 2.1 and an N-terminal HA tagged hCLR construct in the 
mammalian expression vector pcDNA3.1- as a template, following the QuikChange 
site directed mutagenesis protocol (2.2.3). Following DpnI degradation of the 
template DNA, the product was transformed into chemically competent Top10 
E.coli cells (2.2.10). Colonies were picked and grown in 3-5 ml Lbroth + 100 µg/µl 
ampicillin at 37 °C, 220 rpm for 16 hours and the amplified plasmid DNA was 
purified using a Wizard® Plus SV Miniprep kit (Promega) (2.2.11). The purified DNA 
was electrophoresed alongside a pre-DpnI treated sample (2.2.7) to confirm 
successful degradation of the template DNA and was sent for sequencing (2.2.12) to 
confirm successful mutagenesis. 
3.2.2 cAMP signalling of alanine substitutions 
Cos7 cells were co-transfected with either WT CLR or the alanine-substitution CLR 
together with RAMP1. Transfected cells were dose dependently stimulated with 
CGRP across a concentration range of 10-12 to 10-6M. Assay buffer was used as a 
basal stimulation. A sigmoidal dose response curve was fitted to the raw data, 
which were normalised to WT CLR using the minimum and maximum values 
obtained from the fitted curve. In deciding which values would be most appropriate 
to represent the WT CLR basal and Emax data points (allowing comparison between 
WT CLR and alanine-substitution CLR), the minimum and maximum values of the 
curve represented a consistent average of these points across experimental 
repeats. The alternative for the basal point was to take the individual cAMP value at 
the basal concentration. The alternative for Emax was to take either the highest 
cAMP data point or the cAMP produced with 10-6M CGRP (the highest assay CGRP 
concentration). Using average values from the fitted curve minimised the error 
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from potentially erroneous single data points and allowed consistency with data 
analysis across experimental repeats. Alanine-substitution CLR data were 
normalised to WT CLR and a sigmoidal curve was fitted to the normalised data. 
Minimum, maximum and pEC50 values were taken from the fitted curve.  
3.2.3 Radioligand binding experiments 
The radioligand binding experiments described in section 3.3.5 were carried out by 
Professor David Poyner at Aston University as part of a continued collaboration. 
This was for practical reasons as the radioactivity lab at Aston University is set up 
for radiolabelled CGRP work. 
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3.3 Results 
3.3.1 Identification of ECL2 
The ECL2 domain of CLR was originally predicted (from SwissProt) to start from 
arginine at position 274 and extend to the threonine at position 288. In discussions 
with collaborators at Aston University, who have previously combined mutagenesis 
and computer modelling to study ECL1 and ECL3 of the CGRP receptor (Barwell et 
al., 2011), it was decided that the TM-ECL2 boundary was an important feature of 
ECL2 to be included in the study. The first part of this investigation was to create 
single alanine substitutions of all the residues of ECL2 including the predicted N- 
and C-terminal extensions of the loop.  
Alanine was chosen as an appropriate substitution due to the relatively inert 
properties of its methyl side chain. This removed the properties of the wild type 
(WT) side chain without creating amino acid deletions of the loop. Glycine was 
considered as an alternative possibility however its hydrogen atom side chain can 
introduce flexibility to the secondary structures it comprises. This property can 
result in hinge-like conformations in proteins. It was therefore decided for this 
study that alanine would be the most suitable amino acid replacement. In the event 
that the WT residue was an alanine, leucine was chosen as an alternative 
substitution. Leucine has a short branched hydrophobic extension to the methyl 
side chain of alanine creating a different steric effect without the disruption being 
too extreme. Leucine was therefore considered an appropriate conservative 
mutation of alanine.    
3.3.2 Selecting receptor activation assays 
Upon agonist binding, the ECL2 domain of the CGRP receptor is predicted to form 
intermolecular interactions with the CGRP peptide and/or intramolecular 
interactions within the receptor stabilising the active receptor conformation and 
initiating the downstream signalling process through the coupled G protein. 
Following receptor activation the C-terminus of CLR is phosphorylated by GRKs 
leading to the recruitment of β-arrestin and the subsequent de-activation and 
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internalisation of the receptor (Conner et al., 2008; Cottrell et al., 2007; Padilla et 
al., 2007). Signalling assays are a reliable and accurate method of measuring 
receptor activation. Commercially available assays can detect second messengers 
(such as cAMP or Ca2+) or are sensitive reporter assays that can monitor activity of 
response elements or target genes. The Perkin-Elmer Lance® cAMP detection kit 
offers high performance and robust detection of cell based cAMP and was therefore 
chosen to measure receptor-mediated cAMP production. To ensure that the 
receptor is successfully expressed at the cell surface and that any observed change 
in cAMP production is not because of an alteration in cell surface expression levels, 
an ELISA was used which detected the HA tag fused to the extracellular N-terminus 
of CLR. In a study manipulating extracellular domains of a receptor, any changes in 
cAMP levels are likely to be due to ligand-receptor interactions and a reduction in 
receptor signaling may correlate with a loss of ligand binding. Binding affinities of 
key mutants were determined using radioligand binding experiments. The final part 
of receptor activation is the attenuation of signaling and the subsequent 
internalisation, leading to the recycling of the receptor back to the cell surface or 
degradation. Receptor internalisation following CGRP stimulation can be quantified 
using the cell surface expression ELISA.  
3.3.3 cAMP signalling of alanine substitutions 
The effect of alanine substitution on receptor activation at each individual position 
of ECL2 from A271 to I294 was measured using a TR-FRET-based cAMP assay to 
measure levels of the second messenger cAMP signalling.  
The results are summarised in Table 3.1 and a representative cAMP signalling curve 
for each alanine substitution is presented in Figure 3.6 to Figure 3.9. These results 
will be described separately according to the pEC50, basal and Emax values to allow 
each component of the receptor signalling data to be clearly presented. 
3.3.3.1 pEC50 values 
The pEC50 values from the data set in Table 3.1 shows the pEC50 mean and SEM for 
the alanine-substitution and WT CLR and separates substitution mutants with a 
significant reduction compared to WT according to the level of disruption (<10 fold,  
126 
 
ECL2 
substitution 
pEC50 (alanine) pEC50 (WT CLR) pEC50 Basal (alanine) Emax (alanine) 
Mean SEM N Mean SEM N difference t-test Mean SEM N t-test Mean SEM N t-test 
A271L -10.21 0.61 3 -10.20 0.59 3 0.01 0.8891 7.37 6.74 3 0.3885 107.80 2.19 3 0.0709 
I272A -10.21 0.58 3 -10.20 0.59 3 0.01 0.86 -1.09 5.02 3 0.85 105.30 3.39 3 0.26 
A273L -9.99 0.25 3 -10.46 0.33 3 -0.47 0.034* 4.63 2.13 3 0.16 104.10 5.66 3 0.54 
R274A -8.00 0.24 3 -10.18 0.34 3 -2.18 0.0054** -0.15 3.96 3 0.9731 99.35 3.17 3 0.8574 
S275A -8.66 0.11 3 -8.81 0.19 3 -0.16 0.36 3.86 4.86 3 0.51 91.27 8.96 3 0.43 
L276A -8.70 0.19 3 -8.81 0.19 3 -0.12 0.05 8.06 3.25 3 0.13 106.50 7.29 3 0.46 
Y277A -8.90 0.49 4 -9.79 0.38 4 -0.89 0.0121* -4.29 4.52 4 0.4129 96.46 7.63 4 0.6746 
Y278A -8.75 0.08 5 -9.83 0.16 5 -1.08 0.006** -0.91 7.54 5 0.91 93.48 12.01 5 0.62 
N279A -9.65 0.27 4 -9.85 0.19 4 -0.20 0.23 -1.23 6.14 4 0.85 93.49 3.20 4 0.13 
D280A -8.01 0.13 3 -9.90 0.04 3 -1.90 0.0067** 9.73 2.58 3 0.064 103.40 5.97 3 0.062 
N281A -9.93 0.29 5 -9.84 0.26 5 0.10 0.5182 10.67 1.01 5 0.0005*** 112.50 4.07 5 0.0374* 
C282A -9.58 0.06 3 -10.71 0.13 3 -1.13 0.0119* 9.64 9.26 3 0.4072 104.00 3.26 3 0.345 
W283A -8.17 0.04 3 -10.71 0.13 3 -2.54 0.0042** 6.27 7.32 3 0.4818 105.50 3.11 3 0.2189 
I284A -7.70 0.10 3 -8.81 0.18 3 -1.11 0.012* 14.92 8.28 3 0.214 114.70 9.63 3 0.267 
S285A -9.41 0.27 5 -10.11 0.19 5 -0.70 0.018* 15.20 4.55 5 0.023* 93.40 6.56 5 0.037* 
S286A -8.98 0.17 3 -8.91 0.24 3 0.07 0.63 8.42 8.74 3 0.437 104.20 9.62 3 0.702 
D287A -8.58 0.56 4 -9.30 0.42 4 -0.71 0.0475* 14.41 7.98 4 0.1689 119.00 5.43 4 0.0394* 
T288A -8.46 0.28 4 -9.85 0.35 4 -1.39 0.0021** 17.44 5.17 4 0.043* 116.10 3.86 4 0.025* 
H289A -9.82 0.10 3 -9.85 0.26 3 -0.03 0.86 8.45 12.96 3 0.58 106.90 15.86 3 0.71 
L290A -9.72 0.17 3 -10.58 0.19 3 -0.86 0.019* 5.35 7.83 3 0.57 105.10 1.75 3 0.1 
L291A -9.93 0.23 3 -10.58 0.19 3 -0.65 0.013* 12.50 5.44 3 0.15 105.90 1.76 3 0.078 
Y292A -9.60 0.48 4 -10.07 0.36 4 -0.47 0.0347* 17.04 7.50 4 0.1075 110.50 0.75 4 0.0008*** 
I293A -10.34 0.22 3 -10.58 0.19 3 -0.24 0.13 10.53 8.97 3 0.36 109.10 3.85 3 0.14 
I294A -10.94 0.26 4 -10.56 0.13 4 0.38 0.0679 22.75 2.84 4 0.004** 110.80 1.83 4 0.0098** 
 
 
 
 
Reduced pEC50(>10 fold)/basal/Emax value Reduced pEC50(<10 fold) Increased pEC50/basal/Emax  value 
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Table 3.1. Summary of the pEC50, basal and Emax mean and SEM values for the ECL2 individual alanine substitutions and the WT receptor.  
Cos7 cells transfected with WT and alanine substitution receptor were dose dependently stimulated with CGRP and levels of the cAMP second messenger 
were detected using a TR-FRET based cAMP assay. A sigmoidal dose response curve was fitted to the data using GraphPad Prism software. The alanine 
substitution data were normalised to WT, taking the maximum and minimum values obtained from the WT dose response curve.  The number of 
experimental repeats is denoted in the N column and the significance was obtained through paired t-test. *p < 0.05, ** p < 0.01, ***p <0.001. 
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Figure 3.6. Representative cAMP signalling curves for A271L. I272A, A273L, R274A, S275A 
and L276A substitutions. 
Cos7 cells transfected with WT and alanine substitution receptor were dose dependently 
stimulated with CGRP and levels of the cAMP second messenger were detected using a TR-
FRET based cAMP assay. A sigmoidal dose response curve was fitted to the data using 
GraphPad Prism software. The alanine substitution data were normalised to WT, taking the 
maximum and minimum values obtained from the WT dose response curve.   
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Figure 3.7. Representative cAMP signalling curves produced for Y277A, Y278A, N279A, 
D280A, N281 and C282A substitutions.  
Cos7 cells transfected with WT and alanine substitution receptor were dose dependently 
stimulated with CGRP and levels of the cAMP second messenger were detected using a TR-
FRET based cAMP assay. A sigmoidal dose response curve was fitted to the data using 
GraphPad Prism software. The alanine substitution data were normalised to WT, taking the 
maximum and minimum values obtained from the WT dose response curve.   
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Figure 3.8. Representative cAMP signalling curves for W283A, I284A, S285A, S286A, 
D287A and T288A substitutions. 
Cos7 cells transfected with WT and alanine substitution receptor were dose dependently 
stimulated with CGRP and levels of the cAMP second messenger were detected using a TR-
FRET based cAMP assay. A sigmoidal dose response curve was fitted to the data using 
GraphPad Prism software. The alanine substitution data were normalised to WT, taking the 
maximum and minimum values obtained from the WT dose response curve.     
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Figure 3.9. Representative cAMP signalling curves for H289A, L290A, L291A, Y292A, I293A 
and I294A substitutions. 
Cos7 cells transfected with WT and alanine substitution receptor were dose dependently 
stimulated with CGRP and levels of the cAMP second messenger were detected using a TR-
FRET based cAMP assay. A sigmoidal dose response curve was fitted to the data using 
GraphPad Prism software. The alanine substitution data were normalised to WT, taking the 
maximum and minimum values obtained from the WT dose response curve. 
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>10 fold). The mean and SEM of the log difference between the substitution mutant 
pEC50 and the WT pEC50 values are summarised graphically in Figure 3.10. 14 out of 
the 24 amino acids of ECL2 had a significant reduction in pEC50 value compared with 
WT. Of these, seven have a greater than 10 fold reduction in pEC50 value compared 
with WT (R274A, Y278A, D280A, C282A, W283A, I284A and T288A) with the 
remainder having a less than 10 fold reduction (A273L, Y277A, S285A, D287A, 
L290A, L291A, Y292A). 
What is clear from the results is the extent to which the entire loop is involved in 
receptor activation. Between A273L and Y292A, only six out of the 20 residues 
(S275A, L276A, N279A, N281A, S286A and H289A) have no significant reduction in 
receptor signalling. However, with the exception of R274A (with ~100 fold reduction 
in pEC50) the remaining 6 substitutions with a greater than 10 fold reduction in 
cAMP signalling (Y278A, D280A, C282A, W283A, I284A and T288A) are located 
within the middle of the loop. The greatest reductions have occurred with 
substitutions D280A (~100 fold) and W283A (~300 fold). T288A has a more modest 
reduction of ~20 fold with the remaining substitutions much closer to a 10 fold 
reduction in signalling. Alanine substitutions resulting in a less than 10 fold 
reduction in pEC50 are distributed throughout the loop. This includes the most N-
terminal residue of ECL2 to have a significant reduction in signalling (A273L, ~3fold). 
Three residues are located in the middle of the loop (Y277A, S285A and D287A) with 
a pEC50 reduction of between 5-10 fold. There is a cluster of three amino acids at 
the C-terminus of the loop that each had a small but significant reduction in 
signalling (L290A, L291A and Y292A).   
C282 is predicted to form a disulphide bond with C212 at the top of TM3. To further 
investigate the reduction in cAMP signalling observed with the ECL2 C282A 
substitution, the TM3 cysteine was substituted to alanine (C212A) and a double 
alanine substitution was made (C212A/C282A). The single alanine substitution 
C212A had a similar reduction in cAMP signalling to that of C282A (pEC50 values: WT 
9.62+0.76, C212A 8.10+0.43, n = 3, p < 0.05, Student’s t-test). The double alanine 
substitution (C212A/C282A) however had a WT response (pEC50 values: WT 
9.49+0.11 n = 3, C212A/C282A 9.41+0.09, n = 3) (Woolley et al., 2013). 
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Figure 3.10. A graphical summary of the log difference in pEC50 values of the ECL2 alanine 
substitution and the WT receptor detailed in Table 3.1. 
A negative change indicates a decrease in potency of the alanine substitution. Cos7 cells 
transfected with WT and alanine substitution receptor were dose dependently stimulated 
with CGRP and levels of the cAMP second messenger were detected using a TR-FRET based 
cAMP assay. A sigmoidal dose response curve was fitted to the data using GraphPad Prism 
software. The alanine substitution data were normalised to WT, taking the maximum and 
minimum values obtained from the WT dose response curve.  Significance was obtained 
using a paired t-test. *p < 0.05, ** p < 0.01, ***p <0.001. 
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3.3.3.2 Basal signalling 
The basal values of the alanine substitutions described in Table 3.1 are illustrated 
graphically in Figure 3.11. Four substitutions (N281A, S285A, T288A and I294A) had 
a significant increase in basal signalling compared with WT. The greatest increase 
was observed with I294A (22.75% greater than WT). The remaining substitutions 
had an increase of basal signalling between 10-18% of WT. 
3.3.3.3 Emax 
The data for the Emax signalling of the alanine substitutions normalised to the WT 
receptor (WT normalised to 100%) described in Table 3.1 are summarised in Figure 
3.12. As Figure 3.12 clearly shows, all alanine-substituted CLR Emax data have 
broadly similar values to that of WT. However five substitutions (N281A, D287A, 
T288A, Y292A and I294A) showed a significant increase in Emax. The greatest 
increase was observed with D287A (119% that of WT). The other substitutions have 
Emax values between 110-116% that of WT. S285A is the only substitution to have a 
significantly reduced Emax compared with WT at 93.4%.  
3.3.4 Cell surface expression of alanine substitutions 
A cell surface expression ELISA was used to compare the cell surface expression of 
the alanine substitution mutant with WT.  
The results of the cell surface expression ELISA are shown in Table 3.2 and 
summarised graphically in Figure 3.13. The majority (19 out of 24) of the alanine 
substitutions did not have a significant difference in cell surface expression 
compared with the WT receptor. This confirms that mutation of these residues to 
alanine has not resulted in a loss of receptor surface expression and trafficking. Five 
of the 24 substitutions (C282A, W283A, I284A, S285A and H289A) had a significant 
reduction in cell surface expression to that of the WT receptor. The lowest of which 
is S285A with receptor expression levels at 55% of WT. C282A, W283A and I284A all 
have receptor expression between 60-70% of WT and H289A is ~75%. It has been 
previously shown that cell surface expression levels below 55% WT had no 
deleterious effect on CGRP-mediated cAMP signalling (Bailey & Hay, 2007; Conner 
et al., 2006a). Therefore while these mutants might be of interest when it comes to  
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Figure 3.11. A graphical summary of the basal mean and SEM value of the ECL2 alanine 
substitution following normalisation to the WT receptor.  
Cos7 cells transfected with WT and alanine substitution receptor were dose dependently 
stimulated with CGRP and levels of the cAMP second messenger were detected using a TR-
FRET based cAMP assay. A sigmoidal dose response curve was fitted to the data using 
GraphPad Prism software. The alanine substitution data were normalised to WT, taking the 
maximum and minimum values obtained from the WT dose response curve.   Significance 
was obtained using a paired t-test. *p < 0.05, ** p < 0.01, ***p <0.001. 
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Figure 3.12. A graphical summary of the Emax mean and SEM value of the ECL2 alanine 
substitution following normalisation to the WT.  
Cos7 cells transfected with WT and alanine substitution receptor were dose dependently 
stimulated with CGRP and levels of the cAMP second messenger were detected using a TR-
FRET based cAMP assay. A sigmoidal dose response curve was fitted to the data using 
GraphPad Prism software. The alanine substitution data were normalised to WT, taking the 
maximum and minimum values obtained from the WT dose response curve.   Significance 
was obtained using a paired t-test. *p < 0.05, ** p < 0.01, ***p <0.001. 
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ECL2 
mutant n 
%  WT cell surface 
expression 
p value (WT and 
mutant + CGRP) 
A271L 3 99.11±7.45 0.9165 
I272A 3 134.8±12.19 0.104 
A273L 3 104.20±3.95 0.3986 
R274A 4 93.21±6.08 0.3458 
S275A 4 78.90±14.14 0.2325 
L276A 3 89.95±8.97 0.3795 
Y277A 4 82.82±9.81 0.1782 
Y278A 6 97.71±20.59 0.916 
N279A 4 82.93±13.86 0.306 
D280A 4 83.48±18.57 0.4241 
N281A 4 103.30±24.79 0.9027 
C282A 3 67.80±2.06 0.0041** 
W283A 3 69.80±1.00 0.0011** 
I284A 4 62.77±8.12 0.0195* 
S285A 8 54.65±6.51 0.0002*** 
S286A 4 74.05±12.79 0.1355 
D287A 4 95.77±10.76 0.7207 
T288A 3 94.23±2.30 0.1283 
H289A 3 74.83±0.13 <0.0001** 
L290A 3 83.18±7.38 0.1504 
L291A 3 103.70±4.07 0.4558 
Y292A 3 93.90±4.54 0.3114 
I293A 3 103.70±7.69 0.6798 
I294A 3 100.80±9.15 0.9347 
 
Table 3.2 Summary of the cell surface expression mean and SEM values of the ECL2 
alanine substitution and the WT receptor following normalisation to the WT receptor. 
Cos7 cells were transfected with WT and alanine substitution receptor and cell surface 
expression was measured by ELISA. Following expression, cells were fixed with 
formaldehyde and blocked with 1% BSA in PBS. The WT and alanine substitution receptor 
cell surface expression was measured using a primary α-HA antibody probing for an N-
terminal HA tag on the extracellular N-terminus of the receptor. An α-mouse secondary 
antibody conjugated to HRP was used and the absorbance of an OPD substrate was 
measured at 450nm. Data were normalised to the blank mean and WT mean to produce 
relative minimum and maximum values respectively. Mean + SEM were taken of the 
normalised data and significance determined using a paired t-test. *p < 0.05, ** p < 0.01, 
***p <0.001. 
Reduced cell surface expression value 
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Figure 3.13. Graphical summary of the cell surface expression mean and SEM values of 
the ECL2 alanine substitution normalised to the WT CGRP receptor.  
Cos7 cells were transfected with WT and alanine substitution receptor and cell surface 
expression was measured by ELISA. Following expression, cells were fixed with 
formaldehyde and blocked with 1% BSA in PBS. The WT and alanine substitution receptor 
cell surface expression was measured using a primary α-HA antibody probing for an N-
terminal HA tag on the extracellular N-terminus of the receptor. An α-mouse secondary 
antibody conjugated to HRP was used and the absorbance of an OPD substrate was 
measured at 450nm. Data were normalised to the blank mean and WT mean to produce 
relative minimum and maximum values respectively. Mean + SEM were taken of the 
normalised data and significance determined using a paired t-test. *p < 0.05, ** p < 0.01, 
***p <0.001. 
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the trafficking of the receptor about the cell, the effect of this is unlikely to be 
sufficient to cause any observed disruption in receptor signalling. 
3.3.5 Radioligand binding of alanine substitutions 
Alanine substitutions in the middle of ECL2 that had the greatest reduction in cAMP 
signalling were subjected to radioligand binding analysis to determine the effect of 
the mutation on binding affinity. Following the extension of the ECL2 investigation 
into the TM4/ECL2 and ECL2/TM5 interface, the radioligand binding experiments of 
the new mutants were unsuccessful and have not been included.  
The radioligand binding experiments were carried out by Professor David Poyner at 
Aston University as part of a continued collaboration. Cos7 cells were co-
transfected with either WT CLR or alanine-mutant CLR together with RAMP1. 
Radioligand binding was done on the cell membranes using [125I] iodohistidyl-
human alpha CGRP. The results are shown in Table 3.3. pKd values were determined 
using the radioligand at a single concentration. Saturation binding to determine Bmax 
was not done. 
Six out of the eight alanine substitutions investigated had a significantly reduced 
binding affinity to CGRP (R274A, Y278A, D280A, C282A, W283A and T288A). The 
greatest effect was observed with the S285A substitution which had non-detectable 
levels of binding. The largest reductions in binding affinity were observed with 
R274A and Y278A, each having ~30 fold reduction in ligand binding affinity. W283A 
has ~10 fold reduction with the remainder (D280A, C282A and T288A) less than 10 
fold compared with WT. Only Y277A had no significant variation in binding 
compared with WT.  
3.3.6 Internalisation of alanine substitutions 
Activation of the receptor eventually leads to the phosphorylation of the C-
terminus, recruitment of β-arrestin and the internalisation of the receptor (Conner 
et al., 2008). To determine the effect that the alanine substitution of ECL2 has on 
this downstream process, the cell surface expression ELISA was used to measure 
internalisation levels.  
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Mutant pKd 
WT 9.18±0.05 
R274A 7.77±0.25 ** 
Y277A 8.99±0.53 
Y278A 7.75±0.39** 
D280A 8.39±0.64* 
C282A 8.47±0.07* 
W283A 8.13±0.25** 
S285A Undetectable 
T288A 8.32±0.43* 
 
Table 3.3. Radioligand binding of selected alanine substitutions with reduced pEC50 
values.  
Values are mean and SEM from three determinations. pKd values determined from 125[I]-
CGRP radioligand binding. *, ** significantly different from WT, p <0.05 and p <0.01, as 
assessed by paired Student’s t-test. 
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The internalisation results are described in Table 3.4 and summarised graphically in 
Figure 3.14. The WT CLR and alanine substitutions were stimulated with 10-7M 
CGRP to measure the effect on internalisation at ~99% WT CLR occupancy. 18 of the 
24 alanine substitutions had internalisation levels similar to that of the WT receptor 
(~60-70% internalisation). Six residues had a significant reduction in internalisation 
level (R274A, Y278A, D280, C282A, W283A and T288A). Of these, two are only 
slightly reduced (Y278A and T288A) with ~50% of the receptor internalising. 
However for the remaining four substitutions (R274A, D280A, C282A and W283A), 
receptor internalisation has been almost completely abolished. 
Two mutants have a significantly increased level of receptor internalisation (L276A 
and S285A), with an increase of ~10% that of WT. 
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ECL2 
mutant n 
Cell surface expression Internalisation 
difference 
p value (WT and 
mutant + CGRP) WT Mutant 
A271L 3 33.30 ± 3.07 30.46 ± 0.91 2.84 0.538 
I272A 3 33.30 ± 3.07 36.65 ± 1.20 -3.35 0.3447 
A273L 3 31.97 ± 3.06 34.31 ± 1.50 -2.34 0.6577 
R274A 4 44.02 ± 1.29 91.02 ± 3.58 -47 0.0008*** 
S275A 4 42.67 ± 1.59 27.28 ± 6.99 15.39 0.1171 
L276A 3 40.52 ± 1.55 31.57 ± 2.23 8.95 0.0398 * 
Y277A 4 40.43 ± 1.29 38.10 ± 1.98 2.33 0.4493 
Y278A 6 37.26 ± 3.80 52.70 ± 3.63 -15.44 0.0058 ** 
N279A 4 41.38 ± 4.33 34.71 ± 1.51 6.67 0.1258 
D280A 5 40.20 ± 2.06 91.18 ± 5.68 -50.98 0.0007 *** 
N281A 4 40.07 ± 2.66 36.05 ± 3.70 4.02 0.1778 
C282A 3 26.62 ± 2.71 90.70 ± 3.13 -64.08 0.0066 ** 
W283A 3 26.62 ± 2.72 105.8 ± 3.43 -79.18 0.0056 ** 
I284A 4 41.07 ± 3.85 36.08 ± 4.28 4.99 0.4553 
S285A 8 34.30 ± 2.71 26.76 ± 2.11 7.54 0.0355 * 
S286A 4 37.99 ± 2.67 30.98 ± 7.13 7.01 0.3558 
D287A 4 40.52 ± 1.55 37.23 ± 3.35 3.29 0.2268 
T288A 3 30.78 ± 1.88 48.55 ± 3.44 -17.77 0.0098 ** 
H289A 3 37.90 ± 1.00 31.19 ± 3.25 6.71 0.0973 
L290A 3 33.66 ± 2.17 35.74 ± 3.80 -2.08 0.3872 
L291A 3 36.23 ± 0.96 42.35 ± 1.15 -6.12 0.0656 
Y292A 3 30.96 ± 4.38 40.74 ± 0.65 -9.78 0.1222 
I293A 3 30.36 ± 3.03 34.44 ± 2.25 -4.08 0.0738 
I294A 3 30.36 ± 3.03 30.69 ± 1.75 -0.33 0.8276 
 
Table 3.4. Summary of the internalisation mean and SEM values of the ECL2 alanine 
substitution and WT receptor following stimulation ± 10-7M CGRP and normalisation to 
the non-activated receptor.  
Cos7 cells were transfected with WT and alanine substitution receptor and cell surface 
expression was measured by ELISA. Following expression, cells were fixed with 
formaldehyde and blocked with 1% BSA in PBS. The WT and alanine substitution receptor 
cell surface expression was measured using a primary α-HA antibody probing for an N-
terminal HA tag on the extracellular N-terminus of the receptor. An α-mouse secondary 
antibody conjugated to HRP was used and the absorbance of an OPD substrate was 
measured at 450nm. Data were normalised to the blank mean and WT mean to produce 
relative minimum and maximum values respectively. Mean + SEM were taken of the 
normalised data and significance determined using a paired t-test. *p < 0.05, ** p < 0.01, 
***p <0.001. 
 
 
Reduced internalisation value Increased internalisation value 
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Figure 3.14. Graphical summary of the difference between the mean internalisation 
values of the ECL2 alanine substitution compared with the WT receptor.  
A negative difference represents a reduction in ECL2 alanine substitution receptor 
internalisation compared to the WT receptor. Cos7 cells were transfected with WT and 
alanine substitution receptor and cell surface expression was measured by ELISA. Following 
expression, cells were fixed with formaldehyde and blocked with 1% BSA in PBS. The WT 
and alanine substitution receptor cell surface expression was measured using a primary α-
HA antibody probing for an N-terminal HA tag on the extracellular N-terminus of the 
receptor. An α-mouse secondary antibody conjugated to HRP was used and the absorbance 
of an OPD substrate was measured at 450nm. Data were normalised to the blank mean and 
WT mean to produce relative minimum and maximum values respectively. Mean and SEM 
were taken of the normalised data and significance determined using a paired t-test. *p < 
0.05, ** p < 0.01, ***p <0.001. 
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3.4 Discussion 
The results of the alanine substitution mutagenesis study of the ECL2 domain of the 
CGRP receptor described in this chapter provide evidence for the importance of this 
loop in CGRP-mediated receptor activation. 14 out of the 24 amino acids 
investigated had a significant reduction in CGRP-mediated cAMP signalling. These 
residues have been highlighted according to their side chain properties in Figure 
3.15. The importance of so many residues within this loop is similar to that 
observed in the GLP1R ECL2 study which found that over half the residues had a 
significant effect on cAMP signalling (Koole et al., 2012). This compares with only six 
out of 30 residues investigated with the V1AR (Conner et al., 2007b) and two out of 
16 residues with the CRHR1 (Gkountelias et al., 2009). The involvement of ECL2 
residues is therefore variable and not consistent within the receptor families. 
3.4.1 ECL2 alanine substitution data integrity 
3.4.1.1 cAMP signalling 
The Perkin Elmer Lance® cAMP assay was optimised for cos7 cells and the CGRP 
receptor as described in section 2.2.15.1. The cAMP data for the ECL2 alanine 
substitutions are presented in Table 3.1 and Figure 3.10 to Figure 3.12.  
The WT CLR pEC50 data for each ECL2 substitution are described in Table 3.1 and 
Figure 3.10. The pEC50 values varied from 8.81 (S275A and L276A) to 10.71 (C282A 
and W283A). This variation of ~100 fold in WT CLR potency is greater than 
expected. Using a transiently transfected cos7 system a variation in potency of ~10 
fold (pEC50 9.5-10.5) has been previously observed (Barwell et al., 2011). The 
variation in WT CLR pEC50 values is explained through differences in coupling 
efficiencies between cells as the data were collected in excess of a year. This 
variation has been previously observed with CGRP receptors (Howitt et al., 2003; 
Poyner et al., 1998). To control for this, a paired design-test was used so that each 
substitution was compared in the same experiment against a corresponding WT 
control. The standard error at each ECL2 position varied from 0.04 (D280A) to 0.59 
(A271L and I272A). This variation does not reflect the differences observed in the 
WT CLR pEC50 mean data between ECL2 substitutions supporting the explanation 
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that this is due to the time span the data set was accumulated over. 14 ECL2 alanine 
substitutions had a significant reduction in potency. Seven alanine substitutions had 
a greater than 10 fold reduction (R274A, Y278A, D280A, C282A, W283A, I284A and 
T288A). Of the remaining seven that had a less than 10 fold reduction in signalling 
potency, four substitutions (Y277A, S285A, D287A and L290A) had between 5-10 
fold reduction in cAMP potency. The remaining three substitutions (A273L, L291A 
and Y292A) had a less than 5 fold reduction in cAMP signalling potency. Given the 
variation observed using the transient transfection system the greatest emphasis 
for biological effect will be placed on those residues with a greater than 10 fold 
reduction in potency with some interest in those residues with a 5-10 fold 
reduction. Substitutions with a less than 5 fold reduction in signalling potency, 
whilst statistically significant, are unlikely to have much biological effect. 
The cAMP basal values are described in Table 3.1 and Figure 3.11. These values 
ranged from -4.29 % (Y277A) to 22.75 % (I294A) normalised to WT CLR basal 
signalling. The standard error varied from 1.01 % (N281A) to 12.96 % (H289A). 
Figure 3.11 clearly shows this data variation. This more likely reflects the variation 
observed using a transiently transfected cell based system with differing 
transfection efficiencies and therefore differing transfected cell numbers in the 
assay. It is unlikely that the statistically significant alanine substitutions (N281A, 
S285A, T288A and I294A) reflect a biological effect.  
The cAMP Emax values are described in Table 3.1 and Figure 3.12. They ranged from 
91.27 % (S275A) to 116.1 % (T288A) normalised to WT CLR Emax signalling. The 
standard errors of the data set ranged from 0.75 % (Y292A) to 15.86 % (H289A). As 
observed with the cAMP basal values, this spread of data most likely reflects the 
variation of a transiently transfected cell based system. The values with a 
statistically significant difference ranged from 93.4 % (S285A) to 116.1 % (T288A). 
This change is not substantial enough to reflect a strong biological effect.  
3.4.1.2 Cell surface expression 
The cell surface expression of the ECL2 alanine substitutions normalised to WT CLR 
is described in Table 3.2 and Figure 3.13. The cell surface expression of the ECL2 
alanine substitutions was broadly 100 % compared with the WT CLR control. There 
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is a four amino acid cluster between C282A and S285A that had a significantly 
reduced cell surface expression (54.65 % - 39.80 %) and separately, H289A had a 
significantly reduced cell surface expression (74.83 %). This level of cell surface 
expression has been previously shown to not have a detrimental effect on the 
signalling ability of the receptor (Conner et al., 2006a) however considering that 
each residue in this sequence of four had a significant reduction in cell surface 
expression and given the small standard error observed at these data points (1.00 % 
- 8.12 %), it suggests a biological importance of this cluster of residues in allowing 
the receptor to be successful expressed at the cell surface.  
3.4.1.3 Radioligand binding 
The radioligand binding data are described in Table 3.3. pKd values were 
determined using the radioligand at a single concentration. Saturation binding to 
determine Bmax was not done. The first set of ECL2 alanine substitutions chosen to 
test for binding affinity were key residues in the centre of the ECL2 domain. The 
radioligand binding work was continued to include important residues at the 
TM4/ECL2 and ECL2/TM5 interface however these experiments were not successful 
and data were not included. Within this central section of ECL2, five out of seven 
residues selected for binding affinity experiments had a reduced ability to bind 
CGRP (Y278A, D280A, C282A, W283A and T288A). Binding for S285A could not be 
detected. Only Y277A retained WT binding affinity. The greatest reductions were 
observed with R274A and Y278A (~30 fold reduction). This confirms that the 
reduced signalling observed in this section of the loop is due to disrupted ligand 
binding. What these data does not confirm is whether this is because of direct 
ligand-receptor interactions or a structural change in the ligand binding pocket. 
3.4.1.4 Internalisation 
The WT CLR and alanine substitutions were stimulated with 10-7M CGRP to measure 
the effect on internalisation at ~99 % WT CLR occupancy. The substitutions that had 
a significant reduction were R274A, Y278A, D280A, C282A, W283A and T288A. 
These substitutions had a reduction in signalling of 10-300 fold. In the 
internalisation assay, the receptor was stimulated with 10-7M CGRP, a 
concentration 100 fold higher than that of the receptor Kd (~10
-9M). Given the 
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reduction in signalling caused by the alanine substitution, stimulation with CGRP at 
this concentration would fail to activate a large proportion of receptors, 
corresponding with reduced downstream internalisation.  This showed that 
receptor internalisation required the activation of the receptor. However this 
experimental set up does not show if the alanine substitutions have an effect on 
receptor internalisation separate to activation. To investigate this, the ECL2 alanine 
substitution could be stimulated by a CGRP concentration at a consistently 
increased concentration to the pEC50 (e.g. 100 fold). Due to time constraints and the 
continuation of the study, this was not done. 
3.4.2 ECL2 alanine substitution analysis 
ECL2 was originally proposed to extend from R274 through to H289. In this study, 
the alanine scan was extended to A271 through to I294 to investigate the TM/ECL2 
interfaces, which were hypothesised to be extensions of the loop domain. The 14 
amino acids which resulted in a significant reduction in cAMP signalling after alanine 
substitution can be split into three different regions within ECL2 (see Figure 3.15). 
The first is at the TM4/ECL2 interface (A273A and R274A). The majority of the 
alanine substitutions with reduced signalling are located in the middle of the loop 
(Y277, Y278, D280, C282, W283, I284, S285, D287 and T288) and there are three 
residues at the ECL2/TM5 interface where alanine-substitution had an effect on 
signalling (L290, L291 and Y292). 
3.4.2.1 TM4/ECL2 interface 
Mutation of A271L and I272A did not affect any aspect of receptor function that 
was investigated. A273L however did have a small, significant reduction in cAMP 
signalling (~3 fold) with no change in cell surface expression. Adjacent to A273L, 
R274A had a large reduction in pEC50 (~100 fold) together with an almost complete 
abolition of internalisation (~10%). These two residues form an interesting doublet 
at the N-terminus of the loop, which were not expected to be involved directly in 
the ligand binding pocket. The properties of each side chain, a short hydrophobic 
methyl group (alanine) and a positively charged terminus of a hydrocarbon chain 
(arginine) suggest that these residues maybe important in creating a structural  
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Figure 3.15. A schematic of the N-terminal 18 residues of the CGRP peptide and the ECL2 
domain of CLR with key residues of the alanine substitution analysis highlighted.  
CGRP residues 1-11 and each ECL2 residue that had a significant reduction in cAMP pEC50 
after substitution with alanine have been highlighted to describe the property of the side 
chain.  
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scaffold with the hydrophobic membrane and the polar environment of the 
phospholipid bilayer, conferring structural stability to the loop. Polar resides (such 
as lysine, arginine, tryptophan and tyrosine) in TM helices can extend their side 
chains perpendicular to the membrane to orientate them away from the 
hydrophobic membrane core towards the polar interface in an effect known as 
snorkelling (Chamberlain et al., 2004). The conserved basic residue at the TM4-ECL2 
interface could be positioned within the membrane helix and follow this behaviour. 
This positioning at the top of TM4 is observed in the two family B crystal structures 
(Hollenstein et al., 2013; Siu et al., 2013).  The equivalent basic residue in the GCGR 
is a lysine (K286) and substitution of this residue to a leucine residue attenuates 
binding (Siu et al., 2013). In the author’s model, this effect was predicted to be due 
to a salt bridge formed with E290. The GLP-1R alanine scan also identified the 
importance of a basic residue at the TM4-ECL2 interface (Koole et al., 2012). K288 
appears to function similarly to R274 of CLR and K286 of GCGR. Like GCGR, four 
residues into the loop from K288 is a glutamate (E292) which has reduced binding 
and pEC50 when substituted with alanine. It is not unreasonable to predict that a 
similar structural bridging could be occurring in the GLP-1R ECL2 domain as 
observed with the GCGR. The equivalent interaction could occur in CLR between 
R274 and D280 or a similar interaction could occur between R274 and either Y277 
or Y278. The sequence alignment of the family B GPCR ECL2 domains in Figure 3.4 
shows a conserved basic residue in each receptor at the equivalent R274 position. 
This conservation, together with its positioning away from the middle of the TM 
bundle suggests that this residue does not have a direct ligand binding effect but 
that the reduction in receptor signalling observed through the alanine substitution 
is due to indirect, possible structural interactions of this residue. This will be 
discussed further in the modelling section. The large reduction of CGRP-mediated 
internalisation with the R274A substitution mutant reflects the dramatic loss of 
receptor signalling ability. 
3.4.2.2 ECL2 domain 
The ligand-receptor binding sites of ECL2 are expected to occur in the middle of the 
loop, which is itself predicted to extend into the middle of the transmembrane 
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bundle. The results of this study support this prediction with 9 out of the 14 
residues between position S275 and T288 having a significant reduction in cAMP 
signalling. Of these, six had a reduction greater than 10 fold (Y278A, D280A, C282A, 
W283A, I284A and T288A) which illustrates how important these residues are in 
receptor signalling. Only one other substitution in the rest of the loop had a greater 
than 10 fold reduction in pEC50 (R274A).  
The greatest reductions were observed with substitutions D280A (~100 fold) and 
W283A (~300 fold). T288A has a more modest reduction of ~20 fold. Interestingly, 
each side chain of these residues has a different property. Aspartate has a 
negatively charged carboxyl group at the terminus of a hydrocarbon chain, 
tryptophan has a large imidazole-benzene double ring structure and threonine has a 
polar hydroxyl group at the terminus of a hydrocarbon chain. The negative charge 
of the D280 side chain and the hydroxyl group polarity or methyl group of the T288 
side chain provide potential contact sites with the CGRP ligand. W283 could either 
be forming direct hydrophobic or electrostatic interactions with CGRP or by creating 
structural integrity in the centre of the loop. 
The importance of a negatively charged residue in ECL2 in a position similar to that 
of D280 in CLR was observed in the study of the GLP-1R ECL2 domain (Koole et al., 
2012). In this receptor there is a cluster of two adjacent acidic residues (E292 and 
D293) just to the N-terminus of the disulphide bonded cysteine which had reduced 
signalling after mutation to alanine. In the GCGR there is an EN motif just before the 
conserved cysteine, which also reduces ligand binding upon substitution (E290A, 
N291A and N291D). According to the author’s model, the glutamate residue is not 
thought to make direct interactions with the glucagon ligand but indirectly 
facilitates ligand binding through a salt bridge with K286 (Siu et al., 2013). An 
identical interaction could exist between R274 and D280 of CLR. The importance of 
acidic residues in ECL2 has not just been observed in the family B GPCRs but is also a 
feature in family A GPCRs with mutation of these residues having a detrimental 
effect on ligand binding and receptor activation (Kim et al., 1996; Moro et al., 1999; 
Walker et al., 1994).   
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The other residues in the middle of ECL2 with reduced signalling (Y278A, C282A and 
I284A) have a smaller reduction in CGRP-mediated cAMP stimulation (~10 fold). 
Tyrosine is interesting as the side chain is a phenol, comprising a benzene ring and a 
hydroxyl group. This leads to a variety of potential interactions that could occur, 
from hydrophobic interactions with the carbon ring, pi-cation or stacking 
interactions with the delocalised electrons in a planar orientation above and below 
the ring or polar interactions with the hydroxyl group. From these data it is not 
possible to establish what these functional interactions are. Isoleucine at position 
284 has a branched hydrocarbon chain forming hydrophobic interactions. Again, 
similar to the tryptophan adjacent to this residue (W283), the nature of the 
hydrophobic properties could be due to direct interactions with CGRP or structural 
effects within the loop.  
Apart from C282, W283 is the only other conserved residue in the family B GPCR 
ECL2 domains. Both the cysteine and tryptophan were important in the GLP-1R 
(Koole et al., 2012). Mutation of these residues to alanine resulted in a loss of ligand 
binding, cell surface expression and receptor signalling.  This importance is also in 
the family A V1AR (Conner et al., 2007b). The function of this tryptophan is not just 
of significance for CLR, but for family B GPCRs as a whole and potentially family A 
GPCRs as well. 
The cysteine at position 282 is conserved across GPCR families and forms a 
disulphide bond with a cysteine at the top of TM3 (Wheatley et al., 2012). In the 
case of CLR, this is C212. The disulphide bond confers structural integrity to the loop 
in other GPCRS (Conner et al., 2007b) therefore its effect was investigated further 
for the CGRP receptor. The single alanine substitution (C212A) had a similar 
reduction in cAMP signalling to that of C282A however the double alanine 
substitution (C212A/C282A) had a WT response (Woolley et al., 2013). This 
experiment shows that the disulphide bond for the CGRP receptor is not essential 
for receptor integrity and that reduction in signalling caused by the single alanine 
substitution is more likely due to the disruption from the free sulfhydryl group from 
the remaining cysteine. This result has also been observed in the GLP-1R (Mann et 
al., 2010). Mutation of the TM3 cysteine to alanine (C226A) reduced GLP7-36 
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potency. This was recovered with the double TM3-ECL2 cysteine to alanine 
substation (C226A/C296A). Interestingly the single ECL2 cysteine to alanine 
substitution (C296A) had WT potency indicating that the disruption in signalling is 
due to the free sulfhydryl in ECL2. This recovery with the double alanine 
substitution is not always observed. With the C5aR, the double alanine substitution 
did not produce a signalling response upon ligand stimulation however 
constitutively active substitutions remained active (Klco et al., 2005). In this case the 
disulphide bond was required for ligand based activation of the receptor but is not 
required for the receptor to achieve an active conformation. 
The remaining three substitutions in the middle of the loop (between S275 and 
T288) with a significant reduction in cAMP signalling are Y277A, S285A and D287A. 
Mutation to alanine at each of these positions resulted in a 5-10 fold reduction in 
signalling. As with Y278, the effect at position 277 could be due to potential 
hydrophobic, pi-cation, stacking or polar interactions of the phenol side chain. 
Similar to threonine, serine has a polar hydroxyl group at the terminus of a 
hydrocarbon chain allowing potential hydrogen bond interactions. The negatively 
charged carboxylic acid group of D287 allows for potential salt bridge interactions 
(electrostatic or hydrogen bonding). The Y277A mutation did not cause a significant 
change in basal or Emax signalling, however S285A had a significant increase in basal 
(~15%) and decrease in Emax (93.2%). D287A had WT basal signalling but a 
significantly increased Emax (119%). After the CW motif on GLP-1R, there is a 
sequence of polar and basic residues important for binding affinity and signalling 
(Koole et al., 2012). This is similar to the S/T sequence in CLR, except CLR has an 
acidic D287 residue instead of R299. 
The cluster of residues between C282 and S285 all have a reduction in cell surface 
expression (60-70% of WT). This level of cell surface expression has been previously 
shown to not have a detrimental effect on the signalling ability of the receptor 
(Conner et al., 2006a) however considering that each residue in this sequence of 
four has a significant reduction in cell surface expression, it suggests an importance 
of these residues in allowing the expression of the receptor to the cell surface. 
There is a similar motif in the GLP-1R of (C296, W297 and R299) of which alanine 
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substitution results in a decrease in cell surface expression (Koole et al., 2012). 
However the threonine adjacent to W297 results in an increased expression upon 
mutation to alanine. Cell surface expression requires successful completion of 
multiple stages. The receptor needs to be correctly folded across the membrane, 
post translational modifications including oligomerisation need to occur and 
successful translocation from the ER through the Golgi network to the cell surface is 
required (Achour et al., 2008; Drake et al., 2006; Tan et al., 2004). The reduced cell 
surface expression observed with the C282 to S285 alanine substitutions does not 
reveal the mechanism for the loss of cell surface expression. However it does 
suggest this motif may have structural or conformational integrity.  
Within this central section of ECL2, five out of seven residues selected for binding 
affinity experiments had a reduced ability to bind CGRP (Y278A, D280A, C282A, 
W283A and T288A). This confirms that the reduced signalling observed in this 
section of the loop is due to disrupted ligand binding. What these data does not 
confirm is whether this is because of direct ligand-receptor interactions or a 
structural change in the ligand binding pocket. 
Considering the reduction in binding affinity and receptor signalling of these key 
substitutions, it is not surprising that these also resulted in a reduced 
internalisation. The substitutions that had a significant reduction were R274A, 
Y278A, D280A, C282A, W283A and T288A. These substitutions had a reduction in 
signalling of 10-300 fold. In the internalisation assay, the receptor was stimulated 
with 10-7M CGRP, a concentration 100 fold higher than that of the receptor Kd (~10
-
9M). Given the reduction in signalling caused by the alanine substitution, 
stimulation with CGRP at this concentration would fail to activate a large proportion 
of receptors, corresponding with reduced downstream internalisation.   
3.4.2.3 ECL2/TM5 
The C-terminal extension of the alanine screen also produced some interesting 
data. The extreme C-terminus of ECL2 (I293 and I294) did not result in any change in 
cAMP signalling. This contradicts published data, which found I294A to show 
constitutive activity (Woolley et al., 2013). Further experimental repeats changed 
the significance of these results, however with a p value close to 0.05 in all 
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experiments, there is no certainty in either finding. This substitution had a 
significantly increased basal (~23% increase of WT) and Emax (110% of WT). 
Isoleucine has a branched hydrophobic side chain. It is possible that this stabilises 
the inactive conformation of the receptor through interaction with the hydrophobic 
chains of the phospholipid bilayer. Removal of the side chain could allow for greater 
flexibility of the receptor for the active conformation.  
Individual alanine substitution of three adjacent residues (L290A, L291 and Y292A) 
all had small reductions in receptor pEC50 values (3-10 fold). This hydrophobic 
cluster forms an interesting motif. It is possible that they form intermolecular 
interactions with the phospholipid bilayer, or form intramolecular interactions with 
either each other or adjacent residues from other domains. Either set of 
interactions is likely to confer structural integrity to the loop, facilitating ligand 
binding, which is diminished with the alanine substitution. The alanine substitution 
had no significant effect on basal or Emax signalling, with the exception of a slight 
increase in Emax for Y292A (110% of WT). Cell surface expression and internalisation 
were unaffected. The end of ECL2 for GLP-1R contains important hydrophobic 
residues in Y305 and W306, similar to the LLY motif of CLR (Koole et al., 2012). The 
tyrosine residue at the ECL2-TM5 interface has been previously shown to be 
important in family A GPCR ligand binding and receptor signalling (Conner et al., 
2007b). There appears to be a conserved functional effect of hydrophobic residues 
at the top of TM5 across GPCR families. 
3.4.3 CGRP receptor modelling 
At this moment, the only structural information on the CGRP receptor is a crystal 
structure of the RAMP1 ECD and the heterodimeric CLR-RAMP1 ECD in complex 
with synthetic antagonists (Kusano et al., 2008; ter Haar et al., 2010). This has 
provided excellent information into both the structure of the ECD of the CGRP 
receptor and also in identifying key residues involved in the interaction of the CLR-
RAMP1 interface and contact sites with particular ligands. However at this moment, 
no structure has been obtained for the complete receptor. Instead, a high degree of 
computer modelling has been done, using molecular dynamics to predict 
thermodynamically stable receptor conformations. This data has been used 
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iteratively with experimental data to refine and adjust the model as more data is 
produced. The publication of family A GPCR structures, first with bovine rhodopsin 
(Palczewski et al., 2000) followed by 2-AR (Rasmussen et al., 2007) and a number 
of more recent structures, can be used as a framework for the modelling of other 
GCPRs. However a particular difficulty with family B GCPRs until very recently was 
the lack of a crystal structure of any receptor in this family and a lack of sequence 
homology with family A GCPRs to facilitate computer modelling based on those 
structures. A novel approach was used with the CGRP receptor (Vohra et al., 2013), 
which used a plant GPCR (GCR1) that has sequence similarity to both family A and 
family B mammalian GPCRs. 2-AR-GCR1 and GCR1-CLR homology was used to 
produce a computer model of CLR based on the 2-AR-Gs crystal structure (pdb 
code 3SN6). 
The results from the alanine scan described in this results chapter were used by 
collaborators to refine the CLR model (Vohra et al., 2013) and to predict a potential 
CGRP docking site (Woolley et al., 2013). Molecular dynamics generated a number 
of different ECL2 structures and potential CGRP docking orientations. Results from 
the alanine scan were used to predict the most likely conformations. A number of 
loops adopted similar conformations which satisfied many of the requirements 
from the mutagenesis studies. These included CGRP T6 interacting with CLR ECL2 
D280, D287 and T288, CGRP not directly interacting with CLR ECL2 R274 and W283 
(of CLR ECL2) positioned vertically allowing interaction with T191 (TM2) and H219 
(TM3), which have been identified as important residues during previous alanine 
substitution investigations (Barwell et al., 2011; Vohra et al., 2013). 
3.4.3.1 Predicted ECL2 structure 
Six high scoring conformations of the published model have been edited using the 
Swiss-PdbViewer 4.1.0 software to isolate the ECL2 domain. Figure 3.16 shows 
these six conformations of ECL2 with selected residues of ECL2 identified as 
important through the alanine substitution work highlighted to show the 
orientation compared with the loop. The highest scoring model is shown in Figure 
3.17 with residues that result in a greater than 10 fold reduction and a less than 10 
fold reduction in pEC50 signalling values highlighted both separately and together. 
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Figure 3.16. Six high scoring models of the ECL2 domain of CLR as proposed in Woolley et 
al., 2013 and edited using Swiss-PdbViewer 4.1.0.  
Selected key residues have been highlighted to show their position and orientation with 
respect to the loop. R274 is violet, Y277 and Y278 are cyan, D280 and D287 are red, C282 is 
yellow, W283 in blue, T288 is magenta. 
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Figure 3.17. A high scoring model of the ECL2 domain of CLR as proposed in Woolley et 
al., 2013 and edited using Swiss-PdbViewer 4.1.0.  
The first row presents the loop in three orientations with the seven amino acids side chains 
of residues with a greater than 10 fold reduction in cAMP signalling during the alanine 
highlighted. The second row presents the loop in three orientations with the seven amino 
acids side chains of residues with a less than 10 fold reduction in cAMP signalling during the 
alanine highlighted. The third row   presents the loop in three orientations with all the 
residues highlighted. Charged side chains are red, polar are purple, hydrophobic are cyan, 
hydrophobic and polar are blue and the cysteine is yellow. 
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These ECL2 conformations show both similarities and differences in loop structure. 
All the models have the domain as a loop that covers the TM bundle but without 
any defined secondary structure. With the exception of model 5, the N-terminal half 
of ECL2 extends to the middle of the TM bundle with the C-terminal half forming a 
groove as it loops back to TM5.  
The predicted length of the loop in each of the models is fairly consistent. In models 
one to four, ECL2 begins at I272 and extends to L290. In model 5 ECL2 begins at 
R274 and extends to L291. In model 6 it begins at A273 and extends to L290. This is 
slightly different to the TM4-ECL2 and ECL2-TM5 interfaces of the crystal structures. 
In the GCGR structure, ECL2 begins at the F289, three residues to the C-terminus of 
the conserved basic residue at the start of ECL2 (Siu et al., 2013). The loop is shorter 
than expected (12 residues) and ends at N300. In CRHR1 ECL2 begins at Y253, three 
residues to the C-terminus of the conserved basic residue. ECL2 is longer than GCGR 
(17 residues) and ends at D269 (Hollenstein et al., 2013). 
The overall position of the loop between conformations in Figure 3.16 is broadly 
similar with most of the variation occurring between side chain orientations. A good 
example of this is R274 which is either projecting away from the TM bundle (model 
1 and 4) towards the plasma membrane (model 2) or pointing towards the TM 
bundle (model 3, 5 and 6). The CLR models propose that possible bridging can occur 
between R274 and either Y277 or D280. This is an effect seen with the modelling of 
the GCGR between K286 and E290 (Siu et al., 2013). The side chains of Y278, D280, 
I284 and T288 are all positioned within the loop forming potential structural 
interactions or direct ligand-receptor interactions. W283 adopted a number of 
different combinations during the modelling process but the version that satisfied 
the results for the experimental data was the vertical positioning of the side chain. 
This positions the side chain away from likely CGRP contact sites. This broadly 
agrees with the orientation of the tryptophan residue in the CRHR1 ECL2 CW motif, 
in which the tryptophan side chain points back towards TM3 and TM4, away from 
the centre of the bundle (Hollenstein et al., 2013). The orientation of the CW 
tryptophan residue in the GCGR crystal structure is orientated in the opposite 
direction, towards the middle of the TM bundle (Siu et al., 2013).  What is evident    
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from this model, is how concentrated to the centre of the loop these side chains 
are. It shows that this area of the receptor is of fundamental importance for ligand 
based activation. The separation of residues that have a greater than 10 fold and a 
less than 10 fold reduction in signalling in Figure 3.17 reveals that the residues with 
the biggest reduction in signalling are often located in the middle of the loop. The 
majority of the residues with a small reduction in cAMP signalling are on the 
terminals of the loop (A271, L291 and Y292) or are positioned away from the middle 
of the domain (Y277 and S285). Only D287 and potentially L290 are positioned 
towards the middle. 
Comparing the highest scoring structure of CLR ECL2 proposed in the model in 
Figure 3.17 with that of the published family B structures (Figure 3.3), it can been 
seen that all three share a similar loop structure, extending into the middle of the 
bundle forming a slight lid over the TM pocket (Hollenstein et al., 2013; Siu et al., 
2013). However, compared with both the CRHR1 and GCGR structures, the loop of 
ECL2 proposed in the model of CLR has a more prominent groove occurring 
between D280 and T288 (Figure 3.17). This may be due to the differences in ligand 
binding discussed in the next section. The equivalent groove in the CRHR1 starts 
with an acidic side chain (E256) however at the end of the groove are the basic 
residues K262 and R263. GCGR has a valine (V292) in place of the CLR aspartate 
(D280), however the end of the groove has a similar sequence of amino acids to CLR 
(D287 and T288), with an aspartate (D299) followed by an asparagine (N300). 
What is also evident is that in computer modelling which has restrained TM4 and 
TM5 to that of the 2-AR-Gs and restricted the position of the centre of the loop 
through the disulphide bond between TM3 and ECL2 (C212-C282), there is still a 
reasonable amount of variation in the number of energetically favourable 
conformations of the loop. This may reflect limitations in the computer modelling 
process, reinforcing the importance of the experimental data. It also may suggest 
that ECL2 is able to adopt these variable and energetically favourable 
conformations. This might be an explanation into the multiple signalling and 
physiological effects being observed with GCPRs. 
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3.4.3.2 Potential CGRP-ECL2 docking sites 
Figure 3.18 illustrates potential docking sites between CGRP and six CLR models 
(Woolley et al., 2013). CGRP is shown together with the ECL1, ECL2 and ECL3 
domains of CLR. As discussed, these CGRP-CLR interaction sites all occur in the 
central part of ECL2. D280 interacts much further towards the C-terminus of CGRP 
than previously thought, forming contacts with H10 and R11 of CGRP. I284, S285 
and D287 of CLR form a shelf at the bottom of the bind pocket, holding A5 CGRP at 
the bottom of the CGRP N-terminal loop in position. The T6 CGRP residue interacts 
with T288 of CLR. The hydrophobic side chain of CLR L290 positioned towards the 
centre of the domain makes interactions with L12 on CGRP. 
ECL2-CLR intramolecular bonds are also very interesting. W283, orientated down 
into the TM region is able to form interactions with residues in other TM helices 
(TM2 and TM3). R274 in its orientation away from the binding pocket, forms 
contacts with Y277, suggesting a structural role. It was also predicted that R274 
could bridge with D280 facilitating the interaction between D280 of CLR and R11 of 
CGRP. L291, which again angles away from the ligand binding pocket, might be 
exerting its effect through interactions with TM7 or interestingly, RAMP1.  
As discussed in section 3.4.3.1, the predicted ligand binding groove formed between 
D280 and T288 of CLR is much more pronounced than in the CRHR1 and GCGR 
crystal structures. These structures did not incorporate the peptide ligand, 
therefore binding had to be assumed. In each case however, the binding pocket was 
proposed to extend into the TM bundle (Hollenstein et al., 2013; Siu et al., 2013). 
This is different to the ligand binding proposed in the CGRP model in which CGRP 
docked to the extracellular side of the ECLs. The N-terminus of the CRHR1 and GCG 
ligands are alpha helices that form a stick-like structure able to penetrate into the 
TM core. It is possible that the N-terminal loop of CGRP formed by the disulphide 
bond between residues C2 and C7 forms a ball-like structure that sterically holds 
the ligand at the membrane surface. The greater resulting interaction with the ECL 
domains may result in the more pronounced ligand binding groove of CLR.   
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Figure 3.18. Proposed CGRP and ECL docking taken from the six highest scoring models 
described in Woolley et al., 2013.  
Each model has been presented in two orientations. ECL1 is coloured blue, ECL2 is 
magenta, ECL3 is green, and CGRP is coloured violet. 
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3.4.4 Conclusions 
This study has established for the first time that the ECL2 domain of the CGRP 
receptor has a substantial involvement in CGRP-based receptor activation. Each 
region of the loop has apparent functional roles. The TM4-ECL2 interface is likely to 
be of structural importance, particularly the R274 residue possibly forming 
interactions with the lipid bilayer and the centre of the loop. In the middle of ECL2, 
D280, W283, D287 and T288 are the most important residues, probably forming 
direct CGRP contacts and stabilising intramolecular interactions. The ECL2-TM5 
interface is again of structural importance with a hydrophobic cluster of L290, L291 
and Y292 essential for CGRP-mediated cAMP signalling. 
Computer modelling has created a number of high scoring loop conformations. 
There is variation between structures but they broadly agree on the fundamental 
loop conformation. This exists as a loop structure acting as a lid over the TM bundle, 
similar to that of the family B crystal structures of CRHR1 and glucagon (Hollenstein 
et al., 2013; Siu et al., 2013). The modelling proposes contact sites between D280, 
D287 and T288 with the CGRP ligand. The effects of residues at the TM interfaces 
are likely to be structural.  
Having identified ECL2 residues of functional importance, establishing the precise 
effect of these residues and the exact contact sites with CGRP would be the focus 
for the next aspect of the ECL2 research. 
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 Non-alanine substitution analysis of the 4
extracellular loop two domain of the CGRP 
receptor 
4.1 Introduction 
The ECL2 domain of GPCRs has a diverse structural and functional role. The recent 
influx of crystal structures together with the original rhodopsin and β2-AR 
structures have shown how varied ECL2 can be, especially with relation to ECLs 1 
and 3 (Cherezov et al., 2007; Chien et al., 2010; Palczewski et al., 2000; Park et al., 
2012; Shimamura et al., 2011). Mutagenesis and chimeric receptor studies have 
implicated this domain in direct ligand binding (Conner et al., 2007b; Koole et al., 
2012; Olah et al., 1994), presentation of the ligand to the TM ligand binding domain 
(Colson et al., 1998; Perlman et al., 1997), facilitating the conformational change of 
the receptor to an active conformation (Ahuja et al., 2009) or retaining the receptor 
in its inactive conformation (Klco et al., 2005).   
Analysis of the individual alanine substitution mutagenesis of the CLR ECL2 domain 
described in chapter 3 provided evidence for the first time that this loop has a direct 
involvement in CGRP-mediated receptor activation. 14 residues of the CGRP 
receptor ECL2 domain had a significant reduction in CGRP-mediated cAMP 
signalling. Seven of these alanine substitutions had a greater than 10 fold reduction 
in pEC50 signalling, highlighting the importance of this loop in ligand mediated 
activation. The remaining seven mutants had a less than 10 fold reduction in cAMP 
pEC50 signalling. In comparison, only nine residues of ECL1 had a significant change 
in cAMP signalling (five alanine substitutions resulted in a decreased potency and 
four had an increase). In ECL3 only two substitutions had a significant change in 
signalling (both reduced potency) (Barwell et al., 2011). All of the ECLs of CLR have 
now been investigated with alanine substitution mutagenesis and the residues of 
ECL2 have been identified as being particularly important with respect to CGRP-
mediated receptor activation. 
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Alanine substitution analysis identifies residues that have an effect on receptor 
activation through the interactions of their side chains. Common alternatives to 
alanine for substitution mutagenesis include cysteine or histidine substitutions. 
These were discussed in the introduction to chapter 3. These types of mutations 
utilise the properties of the side chains to provide information on their proximity to 
other residues within the receptor or to other interacting molecules (Elling & 
Schwartz, 1996; Javitch et al., 2002). Another type of mutagenesis analysis uses 
random mutagenesis and screening. This was done for the M3 muscarinic receptor, 
which was screened in genetically modified yeast organisms to recover activity of 
previously studied point mutations (Li et al., 2005; Schmidt et al., 2003). This 
method identified functional motifs within this receptor.   
The effects of specific residues have been analysed further by using point mutations 
to investigate particular properties such as charge or polarity. This methodology 
discovered that R314 in the CLR ICL3 domain could be mutated to either glutamate 
(R314E) or glutamine (R314Q) and still retains wild type signalling. This showed that 
polarity is the important functional property at this position for signalling, not 
specifically the positive charge of the WT arginine residue (Conner et al., 2006a). 
Properties of amino acids have also been mimicked. For example, using aspartate or 
glutamate substitutions to confer a similar effect to that of phosphorylation to the 
protein being studied (Prado et al., 1998). Single site saturation mutagenesis is a 
technique that mutates a single amino acid to each of the remaining 20. This was 
used with GCGR to create an allosteric inhibitory antibody (Mukund et al., 2013). 
In the publication of the GCGR crystal structure, a number of substitution mutations 
were created throughout the receptor and the ligand binding affinity was measured 
(Siu et al., 2013). A variety of substitutions were chosen, including alanine, which 
introduced particular properties to the receptor that could be investigated. This 
type of mutagenesis started to open up new possibilities with respect to the 
information that can be obtained. Not only can substitution analysis identify 
important residues but also the particular effect of those residues can be analysed.  
The aim of the study in this chapter is to provide a detailed understanding of the 
precise molecular interactions that are occurring between CGRP and the ECL2 
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domain of its receptor, which result in CGRP-mediated cAMP stimulation. The 
majority of this investigation will be conducted through a comprehensive set of 
amino acid substitutions of the residues identified in chapter 3 as important for 
ligand-mediated receptor activation. These substitutions will attempt to mimic 
potential interactions through which the WT side chain may exert its effect. This 
information will provide a more comprehensive understanding into the mechanism 
through which CGRP binds and activates its receptor. 
14 residues of ECL2 were identified as being important for CGRP-mediated cAMP 
signalling in chapter 3. This included C282 which probably forms a disulphide bond 
with C212 at the top of TM3. The effects of the C212A mutation were recovered 
with the double cysteine-alanine substitution (C212A/C282A). Therefore it appears 
that the function role of this disulphide bond is to prevent the disruptive properties 
of the remaining non-bonded cysteine side chain. This leaves 13 residues of CLR 
ECL2 that have an important function in ligand-mediated receptor activation, 
through unknown mechanisms. Two additional alanine-substitutions were 
previously identified as possible CAMs (Woolley et al., 2013) however further 
experimental repeats during the investigation in chapter 3 resulted in a loss of 
significance. To ensure the extended investigation into this domain was a 
comprehensive study, these residues were also included in the design of further 
mutants.  
The final aspect of this continued investigation into the ECL2 domain is to examine 
the effect of CGRP8-37 antagonist competition binding on the cAMP signalling for the 
WT receptor and selected alanine substitution mutants. The classic use of 
antagonist competition studies is to determine antagonist activity (Arunlakshana & 
Schild, 1959). This experiment has been simplified to use the competition effect of a 
single concentration of the CGRP8-37 peptide with selected ECL2 alanine substitution 
mutants, to establish whether these substituted ECL2 residues have a change in 
affinity to the CGRP8-37 ligand. This would show if the ECL2 position binds to the 
CGRP ligand at positions 1-7 or 8-37. The experimental design is illustrated in Figure 
4.1. Using the TR-FRET cAMP signalling assay, the CGRP receptor transfected  
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Figure 4.1. Schematic illustration of the interactions that occur between the CGRP agonist 
or the CGRP8-37 antagonist with both the WT and the alanine substitution receptor.  
The predicted effect of the various binding variations on the cAMP signalling response is 
presented with example dose response curves. 
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Cos7 cells were incubated with CGRP8-37 antagonist before dose dependent 
stimulation with CGRP led to a competition between the agonist and the antagonist, 
resulting in an increased pEC50 at equilibrium. If the WT side chain of the residue 
that had been substituted with alanine would normally bind to the first 7 residues 
of CGRP (CGRP1-7), then affinity to the CGRP8-37 antagonist is not likely to be affected 
and the same shift in pEC50 observed with WT receptor was expected to be seen 
with the alanine substitution. If however the WT side chain of the position that had 
been substituted normally binds to CGRP8-37, then the affinity for the CGRP8-37 
antagonist was expected to be reduced and therefore be displaced more easily with 
the full length CGRP ligand. This should result in a reduced shift in pEC50.   
This experiment is a simplified alternative to a full Schild plot analysis. The 
simplified version was chosen as an initial screen to determine the success of this 
method using the alanine substitutions. It was decided that a full Schild plot analysis 
would not be cost and time effective as an initial screen. This approach was chosen 
instead of binding analysis as the Perkin Elmer Lance® cAMP signalling assay 
protocol is established in the laboratory. Radioligand binding has been done by 
collaborators and has not always been successful. 
The substitution mutagenesis and the antagonist competition experiments have 
been designed to study this loop to a level that has not been done before in any 
GPCR. This should greatly enhance the understanding of binding and activation of 
CGRP-CLR specifically and for all GPCRs. 
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4.2 Methods 
The methods used are as described in chapters 2 and 3. Methods that are specific to 
this chapter are described in this section.  
4.2.1 Mutagenesis to create ECL2 substitutions 
The individual substitutions of ECL2 and the double substitutions L290A/L291A, 
L290A/Y292A and L291A/I293A were created using the primers described in Table 
2.2 and an N-terminal HA tagged hCLR construct in the mammalian expression 
vector pcDNA3.1- as a template, following the QuikChange site directed 
mutagenesis protocol (2.2.3). The triple substitution L290A/L291A/Y292A was 
created using the L291A/Y292A primers described in Table 2.2 with the L290A 
alanine- substitution as a template. The S285Y/Y292S double substitution was 
created using the Y292S primers described in Table 2.2 and the S285Y further 
substitution as a template. 
Following DpnI degradation of the template DNA, the PCR product was transformed 
into chemically competent Top10 E.coli cells (2.2.10) and plasmid DNA was 
amplified and purified (2.2.11). The purified DNA was electrophoresed alongside a 
pre-DpnI treated sample (2.2.7) to confirm successful degradation of the template 
DNA. Purified DNA was sent for sequencing (2.2.12) to confirm successful 
mutagenesis. 
4.2.2 cAMP TR-FRET signalling assay with CGRP8-37 competition 
48 hours following transfection, cells were removed from the plate with 0.25% 
(w/v) Trypsin - 0.53 mM EDTA solution, washed with PBS and resuspended in assay 
stimulation buffer (SB, PBS + 0.1% BSA + 0.5mM IBMX). The cells were counted with 
a haemocytometer and the appropriate cell number pelleted at 500g for 4 min, to 
be resuspended in SB + 1/100 AlexaFluor® 647-anti cAMP antibody at an assay 
concentration of 2000 cells/10µl. 2000 cells/well (10µl) were loaded onto a 96 well 
white Optiplate. The cells were incubated in triplicate with 5µl SB ± 4x10-6M CGRP8-
37 (x4 final concentration) and were dose dependently stimulated in triplicate with a 
logarithmic increase of CGRP diluted in SB from 10-6M to 10-12M with SB as a basal 
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in a 5µl volume at a x4 final concentration. The plate was incubated in the absence 
of light for 30 min before 20µl/well of detection mix was added. The plate was 
incubated in the absence of light for a further 60 minutes. TR-FRET was recorded by 
excitation at 320mm and emission at 665nm. 
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4.3 Results 
4.3.1 Amino acid substitution mutagenesis of ECL2 
4.3.1.1 Criteria for deciding on the ECL2 substitutions 
All residues shown to have a significant reduction in CGRP-mediated cAMP pEC50 
signalling in the alanine substitution mutagenesis described in chapter 3 were 
targeted for further investigation, with the exception of C282. Signalling of this 
mutant was recovered with the double alanine substitution C212A/C282A. Two 
additional residues of this loop were included for further investigation. These were 
N281 and I294, previously identified as CAMs (Woolley et al., 2013). The aim of this 
study was to mutate these residues to amino acids different to that of wild type, 
whilst retaining particular properties to that of the wild type, in order to deduce the 
particular molecular interactions that are involved in CGRP-mediated receptor 
interaction. The positions of ECL2 being studied, the amino acids chosen as a 
substitution and the rational for that choice is summarised in Table 4.1. This rational 
will be described in more detail in this section. 
A273: The A273L substitution resulted in an ~3 fold decrease in cAMP signalling 
potency. To investigate whether the extended hydrophobic side chain caused a loss 
of structural integrity of the loop or impeded CGRP binding, glycine (A273G) was 
chosen as a substitution mutation to determine if the reduction of side chain length 
improved signalling compared to WT CLR. 
R274: The R274A substitution resulted in ~100 fold reduction in cAMP signalling 
potency. To establish if it is just a positive charge that is required in this area of the 
loop, or if the particular position of the charge is vital, a conservative substitution of 
a lysine residue (R274K) was selected.  
Y277 and Y278: Both alanine substitutions resulted in ~10 fold reduction in cAMP 
signalling potency. To establish if the effect of the tyrosine side chain is due to the 
OH group, the benzene ring or just the presence of hydrophobicity in this area of 
the loop, mutation to phenylalanine (Y277F and Y278F) and to leucine (Y277L and 
Y278L) was chosen. 
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Alanine ECL2 substitutions Reason 
A273L A273G L reduced pEC50, will G increase pEC50 
R274A R274K Amine group in different position 
Y277A Y277F Benzene ring 
  Y277L Hydrophobic side chain 
Y278A Y278F Benzene ring 
  Y278L Hydrophobic side chain 
D280A D280E Carboxyl group in different position 
  D280L Hydrophobic side chain, similar shape 
  D280N Steric effect with similar polar side chain 
  D280S Polar side chain 
  D280T Extended polar side chain 
N281A N281K Inactivation lock with positive charge 
W283A W283F Benzene ring 
  W283H Imidazole ring 
I284A I284F Hydrophobic side chain different shape 
  I284L Hydrophobic side chain different shape 
  I284Q Polar side chain with similar shape 
S285A S285D Negative charge similar position 
  S285N Polar effect 
  S285T OH group in different position 
  S285Y Control for the S285YY292S reciprocal 
  S285Y/Y292S Reciprocal substitution testing for recovery 
D287A D287E Carboxyl group in different position 
  D287L Hydrophobic side chain, similar shape 
T288A T288D Negative charge similar position 
 T288N Polar effect similar position 
  T288S OH group in different position 
  T288V Hydrophobic side chain, similar shape 
L290A-Y292A L290A/L291A/Y292A Combined effect of triple mutant 
  L290A/L291A Combined effect of double mutant 
  L290A/Y292A Combined effect of double mutant 
  L291A/I293A Combined effect of double mutant 
  L290N Polar side chain with similar shape 
  L291N Polar side chain with similar shape 
  Y292S Control for the S285YY292S reciprocal 
I294A I294G Increased CAM effect 
 
Table 4.1. Summary of the new substitutions selected for further investigation of key 
residues identified through alanine substitution analysis. 
The amino acids chosen for substitution at each position and the hypothesis for the effect 
being tested with the new substitution is described. 
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D280: The D280A substitution resulted in a ~100 fold reduction in cAMP signalling 
potency. The computer modelling of ECL2 (Woolley et al., 2013) positioned D280 in 
the middle of the loop projecting towards the centre of the TM bundle. This 
suggests that D280 may be important in CGRP binding and subsequent receptor 
activation. A number of substitutions were therefore chosen at this position to 
establish the role of the aspartate residue at position 280. These were a 
conservative glutamate substitution (D280E) to see if just the presence of a 
negative charge is required. Leucine (D280L) was chosen as its side chain closely 
resembles the steric properties of the aspartate side chain however with all the 
charged properties removed. To determine if polarity at a position close to the 
negative charge of the aspartate side chain is sufficient to recover signalling, 
asparagine, serine and threonine were also selected (D280N, D280S and D280T 
respectively). 
N281: The N281A substitution previously resulted in a CAM (Woolley et al., 2013). It 
was speculated that the polarity of the asparagine side chain could act as a lock, 
retaining the receptor in the inactive conformation. Lysine (N281K) was selected for 
substitution in an attempt to increase the effects of this potential locking effect 
through the positive charge of the side chain.  
W283: The W283A substitution resulted in ~300 fold reduction in cAMP signalling 
potency. The tryptophan side chain consists of an imidazole ring and a benzene ring. 
To establish which component of the side chain is important, mutation to histidine 
and phenylalanine was chosen (W283H and W283F respectively). 
I284: The I284A substitution had ~10 fold reduction in CGRP-mediated cAMP 
signalling potency. To determine if this position requires hydrophobicity, 
substitutions to both phenylalanine (I284F) and leucine (I284L) were selected. 
Phenylalanine has a large hydrophobic side chain. The side chain of leucine has a 
similar steric effect to isoleucine and is therefore a conservative substitution to 
attempt to recover signalling. The polar side chain of glutamine was used to see if 
the function of this position is due to the shape of the side chain as opposed to the 
hydrophobicity.  
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S285: The S285A substitution had ~5 fold reduction in cAMP signalling potency. To 
establish whether there was flexibility in the size and position of the hydroxyl group 
in the side chain, a conservative threonine substitution (S285T) was used. 
Asparagine (S285N) was chosen to determine if the role of S285 is due to a 
requirement for general polarity of the side chain, and aspartate (S285D) was 
chosen to see if the effects of the wild type side chain are due to the negative 
polarity within serine hydroxyl group. Earlier models of the ECL2 domain (Pers. 
Comms.) also suggested that the side chain of S285 could form interactions with 
Y292. To test this prediction, a reciprocal double substitution was made 
(S285Y/Y292S) in an attempt to recover signalling, together with the single mutants 
(S285Y and Y292S) as controls. 
D287: The D287A substitution had ~5 fold reduction in cAMP signalling potency. A 
conservative glutamate substitution (D287E) was used to establish if just a negative 
charge is required in this position. A leucine mutation (D287L) was also chosen to 
determine if the effects at this position are due to the shape of the side chain rather 
than the charge. 
T288: The T288A substitution had ~20 fold reduction in cAMP signalling potency. A 
conservative serine substitution (T288S) was used to establish if there is flexibility in 
the positioning of the hydroxyl group to recover signalling. To establish if the 
negative polarity of the wild type hydroxyl group is utilised, an aspartate 
substitution (T288D) was chosen. To determine if the functional effect of the wild 
type is through general polarity in this position, an asparagine substitution was used 
(T288N). 
L290, L291 and Y292: The effects of the alanine substitutions for L290A, L291A and 
Y292A were ~6 fold, ~4 fold and ~2 fold reduction in cAMP signalling potency 
respectively. These reductions are small, however the fact that each residue of this 
triplet of amino acids at the extreme C-terminus of ECL2 has an effect indicates the 
possibility of an important functional motif. To investigate this further, the effect of 
the combined double alanine substitution L290A/L291A L290A/Y292A and 
L291A/I293A and the triple substitution L290A, L291A and Y292A 
(L290A/L291A/Y292A) was tested. Finally, to gain a more detailed understanding 
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into the effect of the two leucine residues at positions 290 and 291, each were 
mutated to asparagine (L290N and L291N), which has a similar shaped side chain, 
however with a polar property instead of a hydrophobic property.    
4.3.1.2 Selecting receptor activation assays 
The criteria for selecting receptor activation assays have been previously described 
in section 3.3.2. The rationale for undertaking the substitution mutagenesis analysis 
is to identify the key molecular interactions of ECL2 that are responsible for the 
ligand mediated activation of the receptor, by observing the effect on cAMP 
signalling. To quantify this effect, the Perkin-Elmer Lance® cAMP detection kit will 
be used. As previously described it is important to ascertain whether any effect on 
signalling is shown by a receptor that is successfully expressed at the cell surface. To 
account for this the cell surface expression ELISA will be used.  
It was decided that cAMP signalling and cell surface expression analysis would be 
sufficient for the investigation of the substitution mutations. The Lance® TR-FRET 
cAMP signalling assay used in chapter 3 provided a sensitive and accurate means to 
measure ligand-induced receptor activation. Any effect on ligand binding was 
detected through this assay. It was therefore decided that the signalling assay 
would be a sufficient means to test for receptor activation. Receptor internalisation 
occurs in response to receptor activation. Like the binding assays, receptor 
internalisation levels in the alanine scan were in direct relation to signalling. It was 
decided that results from the internalisation assay would not provide any further 
useful information. 
4.3.1.3 cAMP signalling of ECL2 substitutions 
The effect of the substitutions of the ECL2 domain of CLR on receptor activation was 
tested by measuring the effect on CGRP-mediated cAMP signalling using a TR-FRET 
based cAMP assay. 
Cos7 cells were transfected with WT or mutated CLR (together with a RAMP1 
construct) and the TR-FRET cAMP assay and analysis were carried out as previously 
described (2.2.15 and 2.2.18).  
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A comprehensive summary of the pEC50, basal and Emax results is presented in Table 
4.2. Significantly reduced cAMP pEC50 values have been separately highlighted to 
show a <10 fold decrease (orange), a 10-100 fold decrease (purple) and a >100 fold 
decrease (red) compared with WT receptor. Significantly increased pEC50, basal and 
Emax values have also been highlighted (blue). A representative cAMP signalling 
curve for each substitution is shown in Figure 4.2 to Figure 4.7.  
36 new CLR ECL2 substitutions were constructed and analysed as described. These 
are shown in Table 4.2. These results will be separated into pEC50, basal and Emax 
sections to allow each component of the receptor signalling data to be clearly 
described. 
4.3.1.3.1 pEC50 values 
The pEC50 values are shown in full in Table 4.2. In this table the pEC50 mean and SEM 
values are detailed for both the substituted receptor and the WT experimental 
control. The substitutions have been highlighted to describe the level of reduction 
observed compared with WT. 
Seven ECL2 substitutions (A273G, Y277F, Y277L, Y278F, W283H, D287E and I294G) 
have pEC50 values statistically similar to that of the WT receptor showing a complete 
recovery in cAMP signalling compared with the alanine substitution. 10 
substitutions had a modest reduction (<10 fold) in cAMP pEC50 signalling (N281K, 
I284L, S285D, S285N, S285T, D287L, T288S, L290N, L291N and Y292S). 16 
substitutions had a 10-100 fold reduction in cAMP pEC50 signalling (R274K, Y278L, 
D280E, D280L, D280N, D280S, D280T, W283F, I284F, I284Q, S285Y, S285Y/Y292S, 
T288N, T288V, L290A/Y292A and L291A/I293A). Three substitutions had a >100 fold 
reduction in cAMP pEC50 signalling (T288D, L290A/L291A/Y292A and L290A/L291A). 
It is useful to compare how the cAMP pEC50 signalling with the substitution 
mutations compares with that of the original alanine substitution analysis from 
chapter 3. This was determined by comparing the difference in pEC50 values 
between the substituted receptor with its WT experimental control and the alanine 
substitution with its experimental WT control.   
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Decrease < 10 fold Decrease 10-100 fold Decrease > 100 fold Increase  
 
ECL2 
substitution 
pEC50 (ECL2 substitution) pEC50 (WT CLR) pEC50 Basal (ECL2 substitution) Emax (ECL2 substitution) 
Mean SEM N Mean SEM N difference t-test Mean SEM N t-test Mean SEM N t-test 
A273G -10.74 0.09 3 -10.85 0.12 3 -0.11 0.4798 13.37 4.94 3 0.1136 104.30 2.11 3 0.1804 
R274K -8.62 0.52 3 -10.03 0.52 3 -1.41 0.0007*** -0.33 3.03 3 0.9236 99.30 6.86 3 0.928 
Y277F -9.87 0.53 4 -10.02 0.45 4 -0.15 0.2103 13.56 6.13 4 0.1137 100.40 6.30 4 0.9481 
Y277L -9.57 0.44 4 -9.88 0.42 4 -0.31 0.1308 16.64 6.40 4 0.0805 109.30 4.88 4 0.1513 
Y278F -9.81 0.41 4 -9.92 0.49 4 -0.10 0.4251 16.71 8.22 4 0.1349 110.50 4.42 4 0.0983 
Y278L -8.98 0.46 3 -10.11 0.54 3 -1.13 0.0085** 9.58 5.09 3 0.2003 99.79 5.68 3 0.9743 
D280E -8.78 0.46 4 -10.03 0.42 4 -1.25 0.0231* 2.58 7.54 4 0.7545 112.90 9.48 4 0.2673 
D280L -8.44 0.23 4 -10.41 0.29 4 -1.97 0.0157* 11.14 10.11 4 0.3508 99.15 3.44 4 0.8206 
D280N -8.71 0.23 4 -10.44 0.30 4 -1.73 0.0335* 20.95 6.21 4 0.0432* 107.40 5.52 4 0.2728 
D280S -8.66 0.39 4 -10.06 0.44 4 -1.40 0.0005*** 4.18 8.97 4 0.6733 97.86 9.32 4 0.8334 
D280T -8.89 0.35 4 -10.20 0.43 4 -1.31 0.0038** 14.54 6.92 4 0.1265 94.66 2.78 4 0.1503 
N281K -9.19 0.31 6 -10.04 0.30 6 -0.85 0.0141* 15.42 7.27 6 0.0874 102.20 8.63 6 0.8114 
W283F -9.07 0.33 5 -10.13 0.20 5 -1.06 0.0111* 7.57 8.10 5 0.4031 103.30 5.14 5 0.5609 
W283H -10.81 0.09 4 -10.86 0.09 4 -0.05 0.7674 16.37 5.72 4 0.0645 104.60 6.02 4 0.4964 
I284F -9.76 0.20 3 -10.89 0.22 3 -1.13 0.0048** 13.66 3.16 3 0.0494* 113.10 3.45 3 0.0629 
I284L -10.24 0.10 3 -10.73 0.13 3 -0.49 0.0059** 6.24 4.05 3 0.2633 108.60 5.56 3 0.2619 
I284Q -9.45 0.05 3 -11.15 0.11 3 -1.70 0.0024** 14.45 3.76 3 0.0617 104.00 0.19 3 0.0021** 
S285D -9.26 0.39 4 -10.00 0.40 4 -0.74 0.0057** 5.43 2.90 4 0.1579 99.25 5.37 4 0.8974 
S285N -9.83 0.30 6 -10.35 0.28 6 -0.52 0.011* 5.78 4.70 6 0.273 98.55 4.13 6 0.7401 
S285T -9.96 0.36 5 -10.30 0.35 5 -0.34 0.0004*** 13.51 5.89 5 0.0833 95.48 4.74 5 0.3943 
S285Y -9.12 0.29 3 -10.48 0.22 3 -1.36 0.0051** 8.19 2.08 3 0.0591 91.01 9.77 3 0.4544 
S285YY292S -8.32 0.51 3 -9.89 0.45 3 -1.57 0.0058** 11.45 3.43 3 0.0792 116.30 14.54 3 0.3782 
D287E -10.70 0.18 3 -10.90 0.25 3 -0.20 0.2112 15.03 4.23 3 0.0709 106.50 2.43 3 0.115 
D287L -10.53 0.13 4 -10.94 0.14 4 -0.41 0.0196* 17.17 6.16 4 0.0686 103.80 4.46 4 0.4554 
T288D -7.35 0.30 3 -9.66 0.35 3 -2.31 0.0047** 5.03 6.71 3 0.5317 97.91 16.69 3 0.9119 
T288N -8.54 0.48 3 -10.15 0.55 3 -1.61 0.0025** 7.64 4.62 3 0.2399 93.93 8.48 3 0.5487 
T288S -9.56 0.41 4 -9.90 0.49 4 -0.35 0.0079** 12.76 2.38 4 0.0127* 104.20 4.74 4 0.4376 
T288V -8.52 0.45 3 -10.36 0.26 3 -1.84 0.0247* 8.12 6.19 3 0.3195 102.30 4.91 3 0.6865 
LLYAAA -6.46 0.74 3 -10.38 0.43 3 -3.92 0.0065** 10.27 1.99 3 0.0355* 104.60 2.90 2 0.3581 
L290AL291A -7.93 0.13 3 -10.58 0.12 3 -2.65 0.0084** 16.39 7.15 3 0.1489 110.40 3.95 3 0.1199 
L290AY292A -7.84 0.31 4 -9.47 0.42 4 -1.63 0.0007*** 0.16 5.41 4 0.9789 114.40 10.75 4 0.2727 
L291AI293A -8.01 0.07 4 -9.09 0.10 4 -1.08 0.0006*** 10.80 3.08 4 0.0393* 118.90 12.49 4 0.2274 
L290N -10.18 0.03 4 -10.87 0.05 4 -0.69 0.0009*** 10.58 6.99 4 0.2274 97.65 2.16 4 0.3571 
L291N -10.60 0.10 5 -10.88 0.04 5 -0.28 0.0386* 17.50 2.91 5 0.0038** 110.10 5.25 5 0.1267 
Y292S -9.27 0.44 3 -9.97 0.50 3 -0.71 0.0059** 15.63 7.93 3 0.1876 112.60 14.05 3 0.4647 
I294G -10.48 0.38 4 -10.31 0.40 4 0.17 0.4323 10.16 9.51 4 0.3634 109.30 7.72 4 0.3138 
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Table 4.2. Summary of the pEC50, basal and Emax mean and SEM values for the ECL2 substitution and the WT receptor. 
Cos7 cells transfected with WT and substituted receptor were dose dependently stimulated with CGRP and levels of the cAMP second messenger were 
detected using a TR-FRET based cAMP assay. A sigmoidal dose response curve was fitted to the data using GraphPad Prism software. The substituted 
receptor data were normalised to WT, taking the maximum and minimum values obtained from the WT dose response curve.  The number of experimental 
repeats is denoted in the N column and the significance was obtained through paired t-test. *p < 0.05, ** p < 0.01, ***p <0.001. 
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Figure 4.2. Representative cAMP signalling curves for A273G, R274K, Y277F, Y277L, Y278F 
and Y278L substitutions.  
Cos7 cells transfected with WT and mutated receptor were stimulated with CGRP in a dose-
dependent manner. Levels of the cAMP second messenger were detected using a TR-FRET 
based cAMP assay. A sigmoidal dose response curve was fitted to the data using GraphPad 
Prism software. The substituted receptor data were normalised to WT, taking the maximum 
and minimum values obtained from the WT dose response curve.   
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Figure 4.3. Representative cAMP signalling curves for D280E, D280L, D280N, D280S, 
D280T and N281K substitutions. 
Cos7 cells transfected with WT and substituted receptor were stimulated with CGRP in a 
dose-dependent manner. Levels of the cAMP second messenger were detected using a TR-
FRET based cAMP assay. A sigmoidal dose response curve was fitted to the data using 
GraphPad Prism software. The substituted receptor data were normalised to WT, taking the 
maximum and minimum values obtained from the WT dose response curve.   
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Figure 4.4. Representative cAMP signalling curves for W283F, W283H, I284F, I284L, I284Q 
and S285D substitutions.  
Cos7 cells transfected with WT and substituted receptor were stimulated with CGRP in a 
dose-dependent manner. Levels of the cAMP second messenger were detected using a TR-
FRET based cAMP assay. A sigmoidal dose response curve was fitted to the data using 
GraphPad Prism software. The substituted receptor data were normalised to WT, taking the 
maximum and minimum values obtained from the WT dose response curve.   
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Figure 4.5 Representative cAMP signalling curves for S285N, S285T, S285Y, S285Y/Y292S, 
D287E and D287L substitutions.  
Cos7 cells transfected with WT and substituted receptor were stimulated with CGRP in a 
dose-dependent manner. Levels of the cAMP second messenger were detected using a TR-
FRET based cAMP assay. A sigmoidal dose response curve was fitted to the data using 
GraphPad Prism software. The substituted receptor data were normalised to WT, taking the 
maximum and minimum values obtained from the WT dose response curve.   
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Figure 4.6. Representative cAMP signalling curves for T288D, T288N, T288S, T288V, 
L290A/L291A/Y292A and L290A/L291A substitutions. 
Cos7 cells transfected with WT and substituted receptor were stimulated with CGRP in a 
dose-dependent manner. Levels of the cAMP second messenger were detected using a TR-
FRET based cAMP assay. A sigmoidal dose response curve was fitted to the data using 
GraphPad Prism software. The substituted receptor data were normalised to WT, taking the 
maximum and minimum values obtained from the WT dose response curve.  
 
183 
 
-1 3 -1 2 -1 1 -1 0 -9 -8 -7 -6
-5 0
-2 5
0
2 5
5 0
7 5
1 0 0
1 2 5
1 5 0
L 2 9 0 A /Y 2 9 2 A
lo g  [C G R P ]
%
 W
T
 c
A
M
P
W T
L 2 9 0 A /Y 2 9 2 A
-1 3 -1 2 -1 1 -1 0 -9 -8 -7 -6
-5 0
-2 5
0
2 5
5 0
7 5
1 0 0
1 2 5
1 5 0
L 2 9 1 A /I2 9 3 A
lo g  [C G R P ]
%
 W
T
 c
A
M
P
W T
L 2 9 1 A /I2 9 3 A
-1 3 -1 2 -1 1 -1 0 -9 -8 -7 -6
-5 0
-2 5
0
2 5
5 0
7 5
1 0 0
1 2 5
1 5 0
L 2 9 0 N
lo g  [C G R P ]
%
 W
T
 c
A
M
P
W T
L 29 0N
-1 3 -1 2 -1 1 -1 0 -9 -8 -7 -6
-5 0
-2 5
0
2 5
5 0
7 5
1 0 0
1 2 5
1 5 0
L 2 9 1 N
lo g  [C G R P ]
%
 W
T
 c
A
M
P
W T
L 29 1N
-1 3 -1 2 -1 1 -1 0 -9 -8 -7 -6
-5 0
-2 5
0
2 5
5 0
7 5
1 0 0
1 2 5
1 5 0
Y 2 9 2 S
lo g  [C G R P ]
%
 W
T
 c
A
M
P
W T
Y 2 9 2 S
-1 3 -1 2 -1 1 -1 0 -9 -8 -7 -6
-5 0
-2 5
0
2 5
5 0
7 5
1 0 0
1 2 5
1 5 0
I2 9 4 G
lo g  [C G R P ]
%
 W
T
 c
A
M
P
W T
I2 9 4 G
 
Figure 4.7 Representative cAMP signalling curves for L290A/Y292A, L291A/I293A, L290N, 
L291N, Y292S and I294G.  
Cos7 cells transfected with WT and substituted receptor were stimulated with CGRP in a 
dose-dependent manner. Levels of the cAMP second messenger were detected using a TR-
FRET based cAMP assay. A sigmoidal dose response curve was fitted to the data using 
GraphPad Prism software. The substituted receptor data were normalised to WT, taking the 
maximum and minimum values obtained from the WT dose response curve.   
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The results from this analysis are presented in Table 4.3 and illustrated graphically 
in Figure 4.8. In Table 4.3 the first set of columns detail the pEC50 difference of the 
alanine substitutions with the WT control for the residues, which were chosen for 
further investigation. The second set of columns detail the pEC50 difference of the 
substituted receptor with the WT control. The final column shows the results of the 
unpaired t-test comparing the differences of the substituted receptor with that of 
their respective alanine substitutions. In this column, values are highlighted to 
distinguish between substitutions that: 
1. Recover signalling (no significant different between substituted receptor and WT 
pEC50). 
2. Partially recover signalling (significant difference between substituted receptor 
with WT pEC50 and substituted receptor with alanine substitution pEC50 difference). 
3. Substitutions with no recovery (significant difference between substituted 
receptor with WT pEC50 but no difference between substituted receptor with 
alanine substitution pEC50 log difference). 
4. Those that further reduced the pEC50 values compared with the alanine 
substitution (significant difference between substituted receptor with WT pEC50 and 
substituted receptor with alanine substitution pEC50 difference).  
Figure 4.8 is a graphical representation of the difference between the substituted 
receptor and WT pEC50 values for both the alanine substitution and the substituted 
receptor analysis. The results of the statistical comparison between these two set of 
values is also shown. 
The results of this analysis show the effect of the substitutions compared with the 
original alanine substitution analysis. Six substitutions (A273G, Y277F, Y277L, Y278F, 
W283H and I294G) had a complete recovery of cAMP signalling. Six substitutions 
(R274K, D280S, W283F, I284L, T288S and L291N) had a partial recovery of cAMP 
signalling compared with the respective alanine substitution. 14 substitutions 
(Y278L, D280E, D280L, D280N, D280T, I284F, S285D, S285N, S285T, D287L, T288N, 
T288V, L290N and Y292S) show no recovery of cAMP signalling. Five substitutions 
(N281K, I284Q, S285Y, S285Y/Y292S and T288D) resulted in a significant reduction  
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Decreased EC50 Full recovery Partial recovery No recovery  Reduced signalling 
 
Table 4.3 Summary of the mean and SEM values of the difference between the 
substitution and WT pEC50 values for both the alanine substitution and the substituted 
receptor investigations.  
The difference between the substitution and WT pEC50 values for each experimental repeat 
were obtained and mean and SEM values calculated. A paired t-test was used to determine 
significance between substitution and WT values. To calculate significance between the 
alanine and the substituted receptor an unpaired t-test was used on the values calculated 
from the difference between alanine substitution vs WT and substituted receptor vs WT. 
pEC50 difference alanine vs wt pEC50 difference non-alanine vs wt alanine vs 
Alanine Mean SEM N t test (WT) Non-alanine Mean SEM N t test (WT) non-alanine t test 
A271L 0.01 0.03 3 0.8891   
   
    
I272A 0.00 0.01 3 0.86   
   
    
A273L -0.47 0.09 3 0.034* A273G -0.12 0.14 3 0.4798 0.0964 
R274A -2.18 0.16 3 0.0054** R274K -1.42 0.04 3 0.0007*** 0.0098** 
S275A -0.16 0.13 3 0.36   
   
    
L276A -0.12 0.03 3 0.05   
   
    
Y277A -0.89 0.16 4 0.0121* Y277F -0.16 0.10 4 0.2103 0.0087** 
  
   
  Y277L -0.31 0.15 4 0.1308 0.0402* 
Y278A -1.08 0.20 5 0.006** Y278F -0.10 0.11 4 0.4251 0.0057** 
  
   
  Y278L -1.13 0.11 3 0.0085** 0.8561 
N279A -0.20 0.13 4 0.23   
   
    
D280A -1.90 0.16 3 0.0067** D280E -1.26 0.29 4 0.0231* 0.1431 
  
   
  D280L -1.97 0.40 4 0.0157* 0.8861 
  
   
  D280N -1.73 0.46 4 0.0335* 0.7781 
  
   
  D280S -1.40 0.09 4 0.0005*** 0.0302* 
  
   
  D280T -1.31 0.16 4 0.0038** 0.0509 
N281A 0.10 0.14 5 0.5182 N281K -0.85 0.23 6 0.0141* 0.0085** 
C282A -1.13 0.12 3 0.0119*   
   
    
W283A -2.54 0.17 3 0.0042** W283F -1.06 0.24 5 0.0111* 0.0046** 
  
   
  W283H -0.05 0.15 4 0.7674 < 0.0001**** 
I284A -1.11 0.12 3 0.012* I284F -1.13 0.08 3 0.0048** 0.8695 
  
   
  I284L -0.50 0.04 3 0.0059** 0.0091** 
  
   
  I284Q -1.70 0.08 3 0.0024** 0.0165* 
S285A -0.70 0.18 5 0.018* S285D -0.75 0.11 4 0.0057** 0.831 
  
   
  S285N -0.52 0.13 6 0.011* 0.4477 
  
   
  S285T -0.34 0.03 5 0.0004*** 0.083 
  
   
  S285Y -1.36 0.10 3 0.0051** 0.0375* 
  
   
  S285YY292S -1.57 0.12 3 0.0058** 0.0141* 
S286A 0.07 0.13 3 0.63   
   
    
D287A -0.71 0.22 4 0.0475* D287E -0.19 0.11 3 0.2112 0.1172 
  
   
  D287L -0.41 0.09 4 0.0196* 0.2427 
T288A -1.39 0.14 4 0.0021** T288D -2.31 0.16 3 0.0047** 0.0071** 
  
   
  T288N -1.61 0.08 3 0.0025** 0.2576 
  
   
  T288S -0.35 0.12 4 0.0079** 0.0012** 
  
   
  T288V -1.83 0.29 3 0.0247* 0.1902 
H289A -0.03 0.17 3 0.86   
   
    
L290A -0.86 0.12 3 0.019* LLYAAA -3.92 0.32 3 0.0065**   
L291A -0.65 0.07 3 0.013* L290AL291A -2.65 0.25 3 0.0084**   
  
   
  L290AY292A -1.63 0.11 4 0.0007***   
  
   
  L291AI293A -1.08 0.07 4 0.0006***   
  
   
  L290N -0.69 0.05 4 0.0009*** 0.2078 
  
   
  L291N -0.28 0.09 5 0.0386* 0.0318* 
Y292A -0.46 0.13 4 0.0347* Y292S -0.71 0.05 3 0.0059** 0.1771 
I293A -0.23 0.09 3 0.13   
   
    
I294A 0.39 0.14 4 0.0679 I294G 0.17 0.19 4 0.4323 0.3858 
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Figure 4.8. A graphical summary of the difference between the pEC50 values of both the ECL2 alanine substitution and substituted CGRP receptors 
compared with the pEC50 values of the WT receptor detailed in Table 4.2. 
A negative change indicates a decrease in potency of the CLR substitution. The statistical significance between the substituted receptor pEC50 difference and 
the alanine substitution pEC50 log difference is also shown. Cos7 cells transfected with WT and substituted receptor were dose dependently stimulated with 
CGRP and levels of the cAMP second messenger were detected using a TR-FRET based cAMP assay. The difference in pEC50 values between the WT and 
substituted receptor for each experimental repeat were used to calculate mean and SEM values. To compare the difference observed with the alanine 
substitution and the substituted receptor, an unpaired t-test was used. The results of the t-test are displayed on the graph. *p < 0.05, ** p < 0.01, ***p < 
0.001, ****p < 0.0001. 
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in cAMP signalling compared with their respective alanine substitution. D287E had 
no significant difference with both the WT and the alanine substitution in the 
analysis.  
In this investigation four multiple amino acid substitutions were tested 
(L290A/L291A/Y292A, L290A/L291A, L290A/Y292A and L291A/I293A). For these 
substitutions, there was not an appropriate individual alanine substitution mutant 
to use for a statistical comparison. If the effects of the two alanine substitutions are 
not related, one might expect a multiplier effect. If they are affecting exactly the 
same process, one might expect the same pEC50 shift as the alanine-subs and if they 
are acting at a similar effect but in different ways, one might expect an effect in 
excess of the multiplication of the two alanine subs. This is interesting and hints to 
an effect but requires more analysis for a full explanation. Multiplying the individual 
pEC50 difference of the L290A, L291A and Y292A substitutions results in ~100 fold 
reduction in cAMP signalling. However the triple alanine substitution 
L290A/L291A/Y292A results in an almost 10,000 fold reduction in signalling. 
Multiplying L290A and L291A results in ~30 fold reduction in signalling. The double 
substitution L290A/L291A results in ~450 fold reduction in cAMP signalling. 
Multiplying L290A and Y292A results in ~20 fold reduction. The double substitution 
L290A/Y292A is much less severe with ~40 fold reduction. Finally the multiplied 
L291A and I293A values result in ~5 fold decrease, with the L291A/I293A double 
substitution resulting in an ~12 reduction.  
4.3.1.3.2 Basal signalling 
The basal values for the ECL2 substitutions are shown in Table 4.2 and the 
difference between the wild type and the substituted receptor basal values are 
illustrated graphically in Figure 4.9. 
Six of the 36 substitutions investigated had a significant increase in basal cAMP 
signalling compared with that of WT (D280N, I284F, T288S, L290A/L291A/Y292A, 
L291A/I293A and L291N). The greatest increase was that of D280N with a 20.95 % 
increase on WT. L291N had an increase of 17.5% that of WT. The remaining 
substitutions had an increase of between 10-15% of WT basal signalling. These 
positions are different to the alanine substitutions which resulted in a significantly  
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Figure 4.9. A graphical summary of the basal mean + SEM value of the ECL2 substitution 
following normalisation to the WT receptor. 
Cos7 cells transfected with WT and substituted receptor were dose dependently stimulated 
with CGRP and levels of the cAMP second messenger were detected using a TR-FRET based 
cAMP assay. A sigmoidal dose response curve was fitted to the data using GraphPad Prism 
software. The substituted receptor data were normalised to WT, taking the maximum and 
minimum values obtained from the WT dose response curve.   Significance was obtained 
using a paired t-test. *p < 0.05, ** p < 0.01, ***p <0.001. 
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increased basal signalling (N281A, S285A, and I294A) with the exception of T288 
(T288A). 
None of the substitutions resulted in a significant decrease in basal signalling 
compared with WT. This is comparable with the alanine substitutions. 
4.3.1.3.3 Emax 
The data for the Emax cAMP signalling of the substituted receptor normalised to WT 
(WT normalised to 100%) are described in Table 4.2. The results are presented 
graphically in Figure 4.10. 
Only one substitution has a significantly altered Emax compared with WT. I284Q has 
a significant increase at 104% of WT however this is a very small effect. This is 
different to the results of the alanine substitutions which had a significantly 
increased Emax at five positions (N281A, D287A, T288A, Y292A and I294A) and a 
significantly reduced Emax at one position (S285A). 
4.3.1.4 Cell surface expression of ECL2 substitutions 
To measure the levels of expression of the substituted receptor at the plasma 
membrane, a cell surface expression ELISA was used. Cos7 cells were transfected 
with WT or substituted CLR and RAMP1. The cell surface expression ELISA and 
analysis were carried out as previously described (2.2.16 and 2.2.19).  
The results of the cell surface expression ELISA are shown in Table 4.4 and 
represented graphically in Figure 4.11. Six mutations have a significantly reduced 
cell surface expression compared with WT (Y278L, D280L, D280T, L291A/I293A, 
L290N and I294G). The greatest reduction is observed with D280T, with cell surface 
expression levels at 37.33% that of WT. The remainder (Y278L, D280L, L291A/I293A 
and L290N) have cell surface expression levels ~80% of WT with the exception of 
I294G, which is higher at 86%. 
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Figure 4.10. A graphical summary of the Emax mean and SEM value of the ECL2 substituted 
CGRP receptor normalised to the WT receptor. 
Cos7 cells transfected with WT and substituted receptor were dose dependently stimulated 
with CGRP and levels of the cAMP second messenger were detected using a TR-FRET based 
cAMP assay. A sigmoidal dose response curve was fitted to the data using GraphPad Prism 
software. The substituted receptor data were normalised to WT, taking the maximum and 
minimum values obtained from the WT dose response curve.  Significance was obtained 
using a paired t-test. *p < 0.05, ** p < 0.01, ***p <0.001. 
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Substitution n Cell surface expression P value 
A273G 3 98.05±1.60 0.346 
R274K 4 94.44±3.07 0.1681 
Y277F 3 97.96±10.54 0.8641 
Y277L 3 99.12±1.83 0.6777 
Y278F 3 104.5±4.41 0.4134 
Y278L 4 77.65±5.65 0.0289* 
D280E 3 94.62±5.99 0.4643 
D280L 4 78.11±2.54 0.0033** 
D280N 3 91.74±4.33 0.1972 
D280S 3 88.87±8.05 0.3006 
D280T 3 37.33±2.07 0.0011** 
N281K 3 101.9±3.22 0.6144 
W283F 3 100.4±1.68 0.8166 
W283H 4 94.37±1.92 0.0609 
I284F 3 101.8±3.97 0.698 
I284L 4 109.9±3.92 0.0862 
I284Q 3 103.2±3.44 0.4535 
S285D 3 106±2.22 0.1122 
S285T 3 94.26±5.78 0.4258 
S285V 3 106±1.94 0.0907 
S285Y 3 95.57±4.38 0.4184 
S285Y/Y292S 3 95.92±1.32 0.0905 
D287E 3 104.6±2.55 0.2095 
D287L 3 94.12±2.72 0.1639 
T288D 3 94.14±2.87 0.1793 
T288N 3 97.42±0.93 0.1108 
T288S 3 97.04±1.11 0.1162 
T288V 3 97.37±1.61 0.155 
L290A/L291A/Y292A 3 85.72±4.38 0.0825 
L290A/L291A 3 91.80±3.69 0.1561 
L290A/Y292A 3 80.39±5.59 0.0725 
L291A/I293A 3 82.87±3.38 0.0368* 
L290N 4 83.68±2.82 0.0103* 
L291N 3 99.96±2.64 0.9902 
Y292S 3 96.77±4.78 0.5687 
I294G 3 86.11±2.10 0.0070** 
 
Table 4.4. Summary of the cell surface expression mean and SEM values of the ECL2 
substitution normalised to the WT receptor.  
Cos7 cells were transfected with WT and substituted receptor and the cell surface 
expression was measured by ELISA. Following expression, cells were fixed with 
formaldehyde and blocked with 1% BSA in PBS. The WT and substituted receptor cell 
surface expression was measured using a primary α-HA antibody probing for an N-terminal 
HA tag on the extracellular N-terminus of the receptor. An α-mouse secondary antibody 
conjugated to HRP was used and the absorbance of an OPD substrate was measured at 
450nm. Data were normalised to the blank mean and WT mean to produce relative 
minimum and maximum values respectively. Mean and SEM were taken of the normalised 
data and significance determined using a paired t-test. *p < 0.05, ** p < 0.01, ***p <0.001. 
Decreased cell surface expression value 
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Figure 4.11. Graphical summary of the cell surface expression mean and SEM values of 
the ECL2 substitution normalised to the WT receptor.  
Cos7 cells were transfected with WT and substituted receptor and the cell surface 
expression was measured by ELISA. Following expression, cells were fixed with 
formaldehyde and blocked with 1% BSA in PBS. The WT and substituted receptor cell 
surface expression was measured using a primary α-HA antibody probing for an N-terminal 
HA tag on the extracellular N-terminus of the receptor. An α-mouse secondary antibody 
conjugated to HRP was used and the absorbance of an OPD substrate was measured at 
450nm. Data were normalised to the blank mean and WT mean to produce relative 
minimum and maximum values respectively. Mean and SEM were taken of the normalised 
data and significance determined using a paired t-test. *p < 0.05, ** p < 0.01, ***p <0.001. 
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4.3.2 Antagonist competition study 
A modification to the TR-FRET cAMP assay was devised to investigate the 
interaction points between the CGRP ligand and the ECL2 domain. This was 
described in the introduction and Figure 4.1. 
Four ECL2 residues were selected as part of this study (R274, D280, D287 and T288). 
This was due to their distribution throughout the loop, the significant reduction in 
cAMP signalling observed with their respective alanine substitutions and having 
being identified as potentially interacting with CGRP in the collaborative computer 
modelling in chapter 3. Following this prediction this work was done to see if the 
interaction was with the 1-7 or 8-37 region of CGRP. Ligand competition was 
optimised to use an antagonist concentration of 10-6M which resulted in ~50-100 
fold reduction of pEC50 value for the WT receptor.  
The results are summarised in Table 4.5  with representative curves of the results in 
Figure 4.12. None of the alanine substitutions investigated resulted in a significant 
variation in the change in pEC50 values with and without antagonist competition 
compared to the WT receptor. As only two or three experimental repeats were 
done for each substitution, more N numbers are required. 
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Table 4.5. Summary of the mean and SEM of the difference in pEC50 values for WT CLR ± 
CGRP8-37 and alanine substituted CLR ± CGRP8-37.  
Cos7 cells transfected with WT and alanine substituted receptor were incubated ± 10-6M 
CGRP8-37 and dose dependently stimulated with CGRP. Levels of the cAMP second 
messenger were detected using a TR-FRET based cAMP assay. A sigmoidal dose response 
curve was fitted to the data using GraphPad Prism software. The data were normalised to 
WT, taking the maximum and minimum values obtained from the WT dose response curve. 
The mean and SEM difference in pEC50 values for the WT and mutant receptor ± CGRP8-37 
competition were calculated. The number of experimental repeats is denoted in the N 
column and the significance was obtained through paired t-test. *p < 0.05, ** p < 0.01, 
***p <0.001. 
 
ECL2 WT pEC50 difference Alanine pEC50 difference N t-test 
substitution Mean SEM Mean SEM   (paired) 
R274A 1.67 0.20 1.76 0.26 2 0.3743 
D280A 1.83 0.19 1.68 0.10 2 0.3536 
D287A 1.77 0.04 1.45 0.13 3 0.1425 
T288A 1.84 0.08 2.28 0.02 2 0.0843 
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Figure 4.12. Representative cAMP signalling curves for alanine substitution and WT 
receptor incubated ± CGRP8-37 and stimulated in a dose dependent manner with CGRP.  
Cos7 cells transfected with WT and alanine substituted receptor were incubated ± 10-6M 
CGRP8-37 and dose dependently stimulated with CGRP. Levels of the cAMP second 
messenger were detected using a TR-FRET based cAMP assay. A sigmoidal dose response 
curve was fitted to the data using GraphPad Prism software. The data were normalised to 
WT, taking the maximum and minimum values obtained from the WT dose response curve.  
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4.4 Discussion 
36 substitutions were created to investigate 15 ECL2 residues. Seven ECL2 
substitutions (A273G, Y277F, Y277L, Y278F, W283H, D287E and I294G) had pEC50 
values that were not statistically different to WT CLR showing a complete recovery 
in cAMP signalling compared with the alanine substitution. 10 substitutions had a 
modest reduction (<10 fold) in cAMP pEC50 signalling (N281K, I284L, S285D, S285N, 
S285T, D287L, T288S, L290N, L291N and Y292S). 16 substitutions had a 10-100 fold 
reduction in cAMP pEC50 signalling (R274K, Y278L, D280E, D280L, D280N, D280S, 
D280T, W283F, I284F, I284Q, S285Y, S285Y/Y292S, T288N, T288V, L290A/Y292A and 
L291A/I293A). Three substitutions had a >100 fold reduction in cAMP pEC50 
signalling (T288D, L290A/L291A/Y292A and L290A/L291A). 
The current data set for the antagonist study investigating potential contact sites 
between residues R274, D280, D287 and T288 show that these residues bind to the 
1-7 region of the ligand. However the number of experimental repeats is low (two 
or three) therefore more are required to be confident in these results.  
4.4.1 ECL2 extended substitution investigation data integrity  
4.4.1.1 cAMP signalling 
The cAMP data for the signalling extended substitution investigation of ECL2 are 
presented in Table 4.2 and Figure 4.2 to Figure 4.7.  
4.4.1.1.1 pEC50 values 
The pEC50 values described in Table 4.2 are graphically illustrated in Figure 4.8. The 
WT CLR pEC50 values varied from 9.09 (L291A/I293A) and 11.15 (I284Q). This 
variation of ~100 fold in pEC50 values was also observed during the alanine 
substitution investigation in chapter 3 and was explained as reflecting differences in 
coupling efficiencies between cells due to the time period that the data was 
collected over. This data set was collected over a similar time period (over a year) 
and this observed difference is not unexpected. To control for this, a paired design-
test was used so that each mutant was compared in the same experiment against a 
corresponding WT control. The standard error for the WT CLR controls varied from 
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0.09 (W283H) to 0.55 (T288N). This range is similar to the SEM variation observed 
during the alanine substitution analysis. 
4.4.1.1.2 Basal signalling 
The basal signalling of the ECL2 substitutions is described in Table 4.2 and Figure 
4.9. Basal signalling was normalised to WT CLR (0 %) and ranged from -0.33 % WT 
CLR (R274K) to 20.95 % (D280N). The standard error ranged from 1.99 % 
(L290A/L291A/Y292A) to 10.11 % (D280L). Six substitutions had a statistical 
significant difference from WT CLR basal signalling. These are D280N, I284F, T288S, 
L290A/L291A/Y292A, L291A/I293A and L291N. However as Figure 4.9 illustrates 
quite clearly, the differences observed in these basal values are very similar to the 
differences in basal values for the majority of the substitutions. It is unlikely that 
this statistical significant has any biological impact.  
4.4.1.1.3 Emax signalling 
The Emax signalling of the ECL2 substitutions is described in Table 4.2 and Figure 
4.10. The Emax signalling was normalised to WT CLR (100 %) and ranged from 91.01 
% (S285Y) to 118.9 % (L291A/I293A). The standard error ranged from 0.19 % 
(I284Q) to 16.69 % (T288D). Figure 4.10 clearly illustrates how all the data points 
are broadly 100 % of WT CLR Emax signalling. One ECL2 substitution Emax (I284Q) had 
a statistically significant increase to WT CLR. However the Emax was 104 % WT CLR. 
This difference is unlikely to have any biological effect.     
4.4.1.2 Cell surface expression 
The cell surface expression data are described in Table 4.4 and Figure 4.11. Levels of 
cell surface expression for the ECL2 substitutions varied from 37.33 % WT CLR 
(D280T) to 109.9 % (I284L).  The standard error ranged from 0.93 % (T288N) to 
10.54 % (Y277F). Six ECL2 substitutions had a statistically significant reduction in cell 
surface expression compared with WT CLR. The greatest difference observed was 
with D280T (37.33 %). This was unexpected as this level of cell surface expression is 
substantially lower that all the other substitutions, including other substitutions of 
D280. If a substitution of this residue prevents successful cell surface expression of 
the receptor, it would be expected that other substitutions would have a similar 
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effect, especially the conservative D280S substitution. This substitution was not 
significantly different to WT CLR. The D280T plasmid DNA was sequenced to see if 
the effect was due to an issue with the DNA however the sequencing was returned 
successfully. The reduction in D280T signalling might be a result of the low 
expression however this level has been previously observed to retain WT signalling 
(Conner et al., 2006a). Y278L and D280L both had a similar significant reduction in 
WT CLR cell surface expression (~78 %). This should not be enough to effect cAMP 
signalling however it might be biologically relevant. The remaining three ECL2 
substitutions to result in a significant reduction in cell surface expression were 
L291A/I293A, L290N and I294G (~85 % WT CLR). As illustrated in Figure 4.11 these 
values are lower than the majority of the ECL2 substitutions but not substantially. 
Again the effect of these substitutions is unlikely to be biologically important.  
4.4.1.3 Antagonist competition study     
The data for the antagonist competition study are shown in Table 4.5 and Figure 
4.12. The representative curves that most accurately illustrated the differences 
observed in pEC50 values for both the WT CLR control and the alanine substitution 
+/- CGRP8-37 were selected. However this may not always accurately reflect the 
specific differences in signalling.  The difference in pEC50 values +/- CGRP8-37 
antagonist for the WT CLR control ranged from 1.67 to 1.84. The standard errors 
ranged from 0.04 to 0.2. The difference observed for each WT CLR control value is 
broadly comparable. The difference in pEC50 values +/- CGRP8-37 antagonist for the 
alanine substitutions was greater, ranging from 1.45 (D287A) to 2.28 (T288A). No 
substitution had a statistically significant difference from WT CLR. 
4.4.2 Analysis of ECL2 substitutions 
The purpose of this study was to investigate the residues of the ECL2 domain that 
had been identified as important for CGRP-mediated receptor activation during the 
alanine substitution study in chapter 3. This involved a targeted selection of 
substitutions of these key residues to amino acids with a particular side chain 
property comparable to WT. This was to test through which particular interactions 
the WT residue had its effect. This approach has been previously used to study 
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particular functional motifs within a receptor (Conner et al., 2006a) and expanded 
to study a greater range of residues in ligand binding of the GCGR (Siu et al., 2013). 
This is the first time this method has been used to comprehensively investigate the 
molecular interactions of a functional domain. 
In total, 36 new substitution mutations were created to investigate 15 functionally 
important residues of ECL2 identified through the alanine substitution study. These 
mutations had a range of cAMP signalling responses compared with the original 
alanine substitutions, from complete recovery to more disrupted signalling. This 
information has provided a deeper understanding into the mechanism by which 
CGRP binds and activates its receptor.  
The results of this chapter will be initially discussed with respect to each individual 
residue of ECL2 that was studied in order to understand the information gained 
through each set of amino acid substitutions. The results of this will be brought 
together in an overall conclusion.   
4.4.2.1 Key findings 
The ECL2 substitution analysis has revealed some very interesting properties of this 
loop. The N-terminus of ECL2 in all family B GPCRs contains a conserved basic 
residue (R274 in CLR). This positive charge may be required to “anchor” the loop to 
the membrane, however two family B GPCR models have predicted this side chain 
to form a bridge with a central ECL2 acidic residue orientating this for ligand binding 
(Siu et al., 2013; Woolley et al., 2013). This acidic residue is located four amino acids 
away from the basic residue in the GCGR (Siu et al., 2013) similar to a functionally 
important acidic residue in the GLP-1R (Koole et al., 2012). In CLR the equivalent 
residue is Y278 however R274 is predicted to form interactions with Y277 in a 
greater number of CLR models. Given that Y277L retains WT signalling it makes it 
unlikely that an R274-Y277 interaction is occurring. Therefore R274 is more likely to 
interact with either Y278 or D280. Given that the R274A and D280A alanine 
substitutions cause a similar reduction in cAMP signalling (~100 fold) an R274-D280 
interaction remains a strong possibility. The fact that a conservative lysine 
substitution (R274K) has ~25 fold reduction in signalling highlights the importance 
of the size of this side chain. This might account for the lack of recovery observed 
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with the D280 substitutions, particularly the conservative D280E mutation. W283 is 
an important residue in a complex part of the receptor that appears to be exerting 
its effects through a number of different interactions. Recovery with both histidine 
and phenylalanine (W283H and W283F) was unexpected and strengthens the 
hypothesis that the W283 side chain forms interactions with TM2 and 3, however 
there are still a variety of interactions through which this could happen. There is an 
electrostatic shelf created by residues S285 and D287 that requires the hydroxyl 
group and negative charge respectively that is likely to form the base of the ligand 
binding pocket. T288 requires hydroxyl group however there is flexibility in the 
positioning. The CLR models predict that the C-terminal half of ECL2 forms multiple 
interactions with the CGRP ligand. The recovery in signalling observed with a 
greater number of substitutions in this half of the domain may reflect a level of 
flexibility of this part of the loop that may have functional effects with respect to 
the activation mechanism. 
4.4.2.2 Detailed discussion of the substitutions at each ECL2 position 
A273: The leucine substitution (A273L) at this position resulted in ~3 fold reduction 
in cAMP signalling potency. Given that the extension to the WT alanine methyl 
group reduced signalling ability, the glycine substitution was used to see the effect 
of reducing the side chain length. The A273G substitution recovered signalling to 
that of WT. A space or interaction is required in this position which is produced by 
both the alanine and the glycine. The slight reduction in cAMP signalling observed 
with the initial leucine substitution in chapter 3 is more likely to be due to a 
disruption caused by the extension of the leucine side chain, rather than a function 
of the WT residue. In the six high scoring models of CLR described in chapter 3, the 
start of ECL2 was I272 (four models), A273 (one model) and R274 (one model). A273 
is therefore likely to be at the TM4/ECL2 junction. Both the alanine and glycine 
residues could provide a structural flexibility at this interface that the leucine 
restricts.   
R274: The alanine substitution (R274A) resulted in ~100 fold reduction in cAMP 
signalling potency. Mutation to lysine (R274K) partially recovered signalling to ~25 
fold reduction compared to WT. This shows that just having a positive charge in this 
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region of the loop is not sufficient for wild type signalling; the precise position is 
important. A positively charged residue at the start of ECL2 is a conserved feature of 
the family B GPCRs and its importance has been shown with the disruption in 
binding affinity and signalling in mutagenesis experiments for the GCGR and GLP1-R 
(Koole et al., 2012; Siu et al., 2013). However both signalling and binding affinity 
was recovered in the GLP1-R with an K288R substitution (Al-Sabah & Donnelly, 
2003a). In the published CLR model (Woolley et al., 2013), R274 may be forming a 
bridge with Y277 or D280, which is an effect similar to those proposed in other 
family B GPCRs between the equivalent residues (Siu et al., 2013). If this is the 
function of R274 then the precise positioning of its positive charge could be vital in 
forming the bridge with either Y277 or D280.  
Y277: The alanine substitution (Y277A) reduced cAMP signalling potency by ~10 
fold. Substitution to both phenylalanine and leucine (Y277F and Y277L) recovered 
pEC50 signalling to WT. The phenylalanine recovery shows that the hydroxyl group is 
not a necessary part of ligand binding. However this similarity between side chains 
does not guarantee recovery. A study of the Thyrotropin-Releasing Hormone 
Receptor (TRHR) found that a Y181F (ECL2) substitution resulted in no ligand 
binding at the concentrations investigated (Perlman et al., 1997). However given 
the similarity between tyrosine and phenylalanine side chains, there is likely to be 
shared interactions between these amino acids. The recovery with leucine is more 
surprising. This side chain has hydrophobic properties like phenylalanine but lacks 
the ring structure and delocalised electrons. This suggests that the key effect in this 
position is through hydrophobicity. The shared functional effects of phenylalanine 
and leucine have been observed in the A2BR (Peeters et al., 2011). An F71L 
substitution in ECL1 resulted in an increase in agonist potency. There was a slight 
reduction in potency with a F71Y mutation. A number of the CLR models in Woolley 
et al., 2013 had Y277 interacting with R274. The WT signalling of Y277L makes the 
models that proposed electrostatic interactions between these residues much less 
likely. If interactions between R274 and Y277 occur then they are hydrophobic, or 
Y277L induces a conformational change that maintains WT signalling. This is 
unlikely.   
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Y278: As with Y277A, the Y278A alanine substitution resulted in an ~10 fold 
reduction in cAMP signalling potency. Again, signalling was recovered to WT with 
the phenylalanine substitution (Y278A) however unlike Y277 the leucine 
substitution (Y278L) showed no significant recovery. This confirms the importance 
of the aromatic ring of both the phenylanine and the WT tyrosine residue and the 
redundancy of the hydroxyl group. However there are properties of the aromatic 
ring that are vital for signalling. This could be either through hydrophobicity or the 
delocalized pi electrons. This maintains the possibility that electrostatic interactions 
could be occurring through R274 and Y278 however this is not favoured by the high 
scoring CLR conformations.  
D280: The alanine substitution (D280A) resulted in ~80 fold reduction in cAMP 
signalling potency. This large disruption in signalling together with the positioning of 
the residue in the middle of the loop suggested that D280 is a key residue in the 
binding to CGRP and activation of the receptor. A number of substitutions were 
used to investigate this residue (D280E, D280L, D280N, D280S and D280T). None of 
these substitutions significantly recovered signalling to that of WT. This shows that 
both the positioning and the charge in this position is specifically required for 
signalling. The leucine and asparagine substitutions (D280L and D280N) both had 
large reductions similar to that of alanine (~100 fold and 50 fold respectively). 
Substitution for glutamate, serine and threonine (D280E, D280S and D280T) all 
resulted in between 15-25 fold reduction in signalling however only D280S was 
significant different to the alanine substitution. This is due to the high standard 
error with the other substitutions. The reduction in D280T signalling might be a 
result of the low expression (~37% WT) however this level of expression has been 
previously observed to retain WT signalling (Conner et al., 2006a). These data show 
the importance of the WT aspartate at this position to maintain receptor integrity. 
Even the conservative glutamate substitution was unable to have the same 
functional effect as the WT aspartate. A similar effect was also observed in the ECL2 
domain of the human A2AR. Reduction in ligand binding caused by an E151A 
mutation was not recovered with a conserved E151D mutation (Kim et al., 1996). 
The effect of the carboxylic acid side chain can vary even within the same receptor 
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domain. Investigation of ECL2 of the P2Y1 receptor showed disruption in signalling 
using an alanine substitution at position D204, which was exacerbated with further 
asparagine and glutamate substitutions. However abolished signalling caused by an 
alanine substitution at position E209 was recovered by aspartate, glutamine and 
arginine mutations (Hoffmann et al., 1999). In another case, an aspartate in the 
ECL1 domain of the adenosine A2BR was substituted for a diverse range of amino 
acids without any detrimental effect on ligand binding. These included glutamine, 
serine and tyrosine as well as the more conserved glutamate (Peeters et al., 2011). 
D280 was predicted to interact with R274 in some of the CLR models. Alanine 
substitutions at both of these residues (R274A and D280A) resulted in a similar 
reduction in cAMP potency (~100 fold) and signalling could not be recovered to WT 
even with conservative mutations (R274K and D280E). This could be explained 
through interactions between these residues side chains however the current data 
are not sufficient to confirm this.  
N281: The alanine substitution (N281A) resulted in a CAM in Woolley et al., 2013. 
Further experimental repeats in chapter 3 resulted in a loss of statistical 
significance. As part of the comprehensive study of this chapter this residue was still 
chosen for further substitution analysis. The hypothesis in creating a lysine 
substitution (N281K) was that the CAM effect of the alanine substitution could be 
due to a locking effect through hydrogen bonding in the asparagine side chain. The 
lysine mutation was an attempt to increase the effect of this lock if this was due to 
hydrogen bonding through the δ+ H atoms. Substitution with an acidic residue to 
investigate the same speculated hydrogen bonding effect with the δ- N or O atoms 
of the side chain was not investigated. CGRP mediated cAMP signalling was indeed 
dramatically impeded, with a reduction of ~10 fold from WT. This effect could be 
due to locking effects, holding the receptor in the inactive state. It is also possible 
that the introduction of a positive charge disrupts signalling or receptor integrity 
and signalling is reduced through this effect. The evidence as it stands is not 
sufficient to clarify this discrepancy. 
W283: The alanine substitution (W283A) resulted in ~300 fold reduction in cAMP 
signalling potency. This was substantially improved with a phenylalanine 
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substitution (W283F) which resulted in ~10 fold reduction in signalling compared to 
WT. However mutation to histidine (W283H) resulted in a complete recovery of 
signalling.  The imidazole ring of histidine is in a similar position to the imidazole 
ring of tryptophan. Therefore the recovery is likely to be due to shared interactions. 
In the CLR models with the vertically orientated W283 residue, the imidazole group 
was predicted to form a hydrogen bond with H219 in TM3. This can also be formed 
with the W283H residue. The effect of W283F is more surprising, as the benzene 
ring is much closer to the backbone than with tryptophan where the benzene ring is 
extended further out. This cross over could be explained if the hydrogen bonding 
with H219 (TM3) is with the delocalised electron ring of the imidazole group, an 
effect that would be similar for the phenylalanine benzene ring. It is also possible 
that a novel set of interactions is occurring compensating for the change in amino 
acid in this position. In the GCGR, alanine substitution of the equivalent CW 
tryptophan residue in ECL2 resulted in abolition of ligand binding. This binding was 
recovered with leucine and phenylalanine, however substitution with histidine 
resulted in no binding similar to the alanine substitution (Siu et al., 2013). This 
difference in recovery could be due to the variations in orientation of the 
tryptophan residues proposed to point toward the middle of the transmembrane 
bundle in the glucagon receptor crystal structure (Siu et al., 2013) and in a more 
vertical position in the  CGRP receptor model (Woolley et al., 2013) more similar to 
that of the CRHR1 (Hollenstein et al., 2013). 
I284: Alanine substitution caused an ~10 fold reduction in cAMP signalling potency. 
The conserved leucine mutation (I284L) partially recovered signalling (~3 fold 
reduction). A phenylalanine substitution (I284F) did not recover signalling and 
glutamine (I284Q) had a more detrimental effect than the alanine substitution. 
These effects are not surprising. Leucine is a conservative mutation exerting similar 
effects to the WT isoleucine but showing that the steric effect of the side chain 
branching is important at this position. Phenylalanine has a different side chain 
arrangement, which causes more disruption in signalling. Glutamine was used to 
introduce polarity instead of hydrophobicity. This has the most pronounced 
reduction in signalling showing that a linear hydrophobic chain is important in this 
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position. The CLR model in Woolley et al., 2013 proposed that I284 together with 
W283 could interact with residues at the top of TM2 and 3. I284 was also predicted 
to interact with CGRP A5. This interaction would explain why the substitutions of 
phenylalanine and glutamine were more detrimental to signalling.  
S285: The alanine substitution (S285A) resulted in ~5 fold reduction in cAMP 
signalling potency. This signalling was not recovered with any of the substitutions. 
This included the conserved threonine mutation (S285T; ~2 fold reduction) which 
almost reached significance (P 0.083), the negative charge of aspartate (S285D; ~5 
fold) and the similarly polar asparagine (S285N; ~3 fold). This shows the importance 
of the hydroxyl group and its positioning. The S285Y/Y292S reciprocal mutation 
resulted in an increased reduction in signalling making it unlikely that these two 
residues form a sole interaction with each other. 
D287: The alanine substitution (D287A) had ~5 fold reduction in cAMP signalling 
potency. The D287E substitution had ~1.6 fold reduction in cAMP signalling 
potency. This value was not significantly different to either the WT or the alanine 
substitution. More experimental repeats are required to determine the effect of 
this substitution. The sterically similar but hydrophobic leucine substitution (D287L) 
did not recover signalling compared with the alanine substitution. This shows that a 
negative charge is required in the side chain of this residue however more 
experimental repeats are required to establish if there is flexibility as to the precise 
position of this charge.  
T288: The alanine substitution (T288A) resulted in ~25 fold reduction in cAMP 
signalling potency. The conservative serine mutation (T288S) almost completely 
recovered signalling (~2 fold reduction) but was significantly reduced compared 
with WT. Signalling was not recovered with the polar asparagine residue (T288N) or 
the leucine substitution (T288L). The aspartate substitution (T288D) had 
significantly reduced signalling compared with the alanine substitution (T288A). In 
the CLR models (Woolley et al., 2013), T288 was the most likely residue to interact 
with the functionally important T6 residue of CGRP. In the GCGR model (Siu et al., 
2013), N298 at the C-terminus of ECL2 was predicted to interact with the glucagon 
ligand. Substitution to alanine or aspartate resulted in a 4-10 fold reduction in 
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ligand binding and the conserved glutamine substitution caused a >10 fold 
reduction. These two models of family B GPCRs predict ligand-receptor interactions 
between an ECL2 C-terminal polar residue and the peptide ligand. 
L290, L291 and Y292: This motif resulted in small significant signalling reductions 
during the alanine substitution analysis (~7, 4 and 3 fold respectively). The double 
and triple mutants in these positions had dramatic reductions in cAMP signalling 
(L290A/L291A/Y292A ~10,000 fold reduction, L290A/L291A ~450 fold, L290A/Y292A 
~45 fold, L291A/I293A ~10 fold).) The prediction from the model in chapter 3 was 
that L290 could form interactions with CGRP (residues L12 and L291) with TM7 of 
CLR and also potentially with RAMP1. This could help explain the significant effects 
seen through these double and triple mutations. It may also explain the unexpected 
and different results observed with the substitution of both L290 and L291 to 
asparagine (L290N and L291N). L290N did not recover signalling compared with the 
alanine substitution however L291N partially recovered signalling to ~2 fold 
reduction. This suggests that the ligand receptor interactions between CGRP and 
L290 are hydrophobic, however the effects of L291 are either different or there is 
some compensatory effect occurring. According to the high scoring CLR models, 
ECL2 is predicted to extend to either L290 or L291. If L291 is at the membrane 
interface then it could potential be forming hydrophobic interactions with the 
membrane core or the L291N substitution could form polar interactions with the 
hydrophilic head group.    
I294: The alanine substitution (I294A) created a CAM in Woolley et al., 2013 
however further experimental repeats in chapter 3 made this result not significant. 
As part of the comprehensive study of this chapter this residue was chosen for 
further substitution. It was speculated that the CAM effect was due to a “locking” 
action of the hydrophobic WT isoleucine residue, potentially with the plasma 
membrane. If the alanine substitution “freed” this position from the locked 
conformation then further substitution to glycine may increase the CAM effect. 
I294G had WT signalling. It is unlikely that this residue is having an important 
functional effect.ECL2 substitution further work 
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4.4.2.3 ECL2 substitution further work 
The current hypothesis to be emerging from these results with respect to CGRP-
mediated receptor activation is that the N-terminal half of ECL2 has a structural role 
providing structural integrity to the remainder of the loop which directly binds to 
the CGRP ligand.  
R274 appears to be a key residue forming potential interactions with either Y277, 
Y278 or D280. An important next step would be to investigate this further. If R274 is 
interacting with either of the tyrosine resides, it is likely to be through pi-cation 
interactions with the delocalised electrons of the aromatic ring. To test this 
substitutions of each tyrosine reside to glutamate could test for recovery through 
electrostatic interactions between the basic and acid side chains.  Reciprocal 
mutagenesis of each pairing (R274-Y277 and R274-Y278) can also be used to test for 
these interactions. Two combinations are either direct reciprocals (R274Y/Y277R 
and R274Y/Y278R) or reciprocals of the previously mentioned substitution 
(R274E/Y277R and R274E/Y278R). An alternative interaction possibility is between 
R274 and D280 which was proposed to form a bond with CGRP R11 (Woolley et al., 
2013). Reciprocal mutagenesis would be useful in testing this possibility including 
using a CGRP R11E analogue. Combinations of mutagenesis would include 
R274E/D280N(H)/CGRPR11, R274/D280N(H)/CGRPR11E and 
R274E/D280H(R/K)/R11E.  
The next residue of particular interest is W283. The W283H substitution resulted in 
WT signalling suggesting that the functional effect of the tryptophan residue is 
through the imidazole ring. A W283Y substitution could test for the possibility of 
hydrogen bonding at this positon and a W283E substitution would test for 
interactions through the aromatic imidazole ring. Potential interaction partners of 
W283 include Y278 in ECL2 and H219 in TM3. To test the Y278-W283 interaction, 
the reciprocal Y278W/W283Y mutant could be used. To test for hydrogen bonding 
to histidine residues, Zn2+ binding experiments are a suitable option. 
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4.4.3 CGRP8-37 antagonist competition  
This study was designed to determine the residues of ECL2 that interact with the 
CGRP1-7 loop domain and the remaining CGRP8-37 part of the ligand. An antagonist 
competition assay was used to measure the change in pEC50 values observed using 
the CGRP8-37 antagonist between the WT receptor and four selected alanine 
substitutions. R274A, D280A, D287A and T288A were chosen because of their 
significantly reduced cAMP signalling, their distribution throughout ECL2 and the 
prediction in the CGRP receptor modelling described in chapter 3 that they interact 
with CGRP. 
No alanine substitution resulted in a significant difference in the change in pEC50 
value compared with WT CLR +/- CGRP8-37. These data show that if these ECL2 
residues are interacting with CGRP, it is with the 1-7 loop. However given the small 
differences observed when comparing pEC50 values and the low number of 
experimental repeats, more N numbers are required to be confident in this 
conclusion. 
4.4.3.1 CGRP8-37 antagonist competition further work 
In the current state, these results show that any interaction between CGRP and 
ECL2 residues R274, D280, D287 and T288 are through the 1-7 region of the ligand. 
However this may change following further experimental repeats. Following this 
then other ECL substitutions can be tested in this way. 
4.4.4 Overall conclusion 
The ECL2 substitution analysis has revealed several key features of this domain and 
provided evidence to an emerging hypothesis on a function mechanism for the 
loop. The N-terminal half of ECL2 is proposed to function as a scaffold providing 
structural integrity to the remainder of the loop facilitating CGRP binding to the C-
terminal half. R274 is expected to be a key residue potentially forming interactions 
with either Y277, Y278 or D280. W283 is another important residue forming 
interactions through the imidazole ring of the side chain potentially with Y278 
(ECL2) or H219 (TM3). The remainder of the loop is expected to form interactions 
with CGRP, most notably the T288 residue.   
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 CGRP receptor signalling 5
5.1 Introduction 
Agonist-induced GPCR activation causes a structural rearrangement of the 
intracellular domains consisting of the intracellular loops (ICLs), helix 8 (H8) and the 
C-terminus. This is induced by the rearrangement of the TM helices, specifically a 
movement of TM5 coupled with a rotation of TM6 that results in an intracellular 
outward movement of the helix (Sansuk et al., 2011; Standfuss et al., 2011). This 
conformational change creates a G protein-binding pocket that facilitates the 
exchange of GDP for GTP in the G protein and leads to subsequent activation of 
downstream signalling pathways. In the active structure of the β2-AR, the G protein 
can bind through interactions with residues in TM3, 5 and 6 and ICL2 (Rasmussen et 
al., 2011b). 
The effect of individual GPCR domains on GPCR signalling was first investigated 
through the co-expression of the ICL3 domain of the α1B-adrenergic receptor (α1B-
AR) with α1B-AR. This resulted in a reduced Emax of ligand induced IP3 signalling 
(Luttrell et al., 1993). Following this, ICL2, ICL3 and the C-terminal domains of the 
α1B-AR were co-transfected with α1B-AR. Both the α1B-AR ICL3 and C-terminal 
domains significantly reduced IP3 maximal accumulation with the α1B-AR and the 
M1AChR. Only the α1B-AR ICL3 and C-terminus reduced cAMP maximal signalling 
for the D1A dopamine receptor (D1ADR) (Hawes et al., 1994). The -OR ICL3 domain 
was transfected into cells stably expressing -OR, -OR, 2-AR and the 2AR. The 
expressed peptide was able to inhibit G protein GTP binding and downstream 
signalling not only for the -OR but in other receptors signalling through the same G 
protein (Morou & Georgoussi, 2005). 
In the CGRP receptor, residues in each of the ICLs have been shown to be involved 
in cAMP signalling and residues in ICL2 and 3 are involved in both cAMP signalling 
and cell surface expression (Conner et al., 2006a; Conner et al., 2006b). The H8 
domain is important for cell surface expression of the receptor and the remainder 
of the C-terminus is involved in receptor internalisation (Conner et al., 2008). 
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The role of the ICL and C-terminal domains in cell surface expression, cAMP 
signalling and internalisation makes them possible candidates for pharmaceutical 
targeting. To determine the effect of these individual domains in the functioning of 
the CGRP receptor, the DNA encoding each domain was separately amplified using 
PCR and cloned into the mammalian expression vector pcDNA3.1-. Each domain 
was co-transfected with the CGRP receptor and the functional effect was measured 
through the effect on cAMP production. 
In GPCR signalling research, there are multiple variables that need to be taken into 
account. These include the coupling of the GPCR with different G proteins, 
differences in membrane localisation of signalling components and signalling 
through G protein independent pathways. In an attempt to minimise this variability 
a GPCR-Gαs fusion protein was created through the cloning of the Gαs DNA to the 3’ 
terminus of the β2-AR (Bertin et al., 1994). The β2-AR-Gαs fusion construct was 
expressed in S49 cyc- cells that lack endogenous Gαs and was able to recover cAMP 
signalling. 
Gαs fusion to the GPCR allows for consistency in the 1:1 stoichiometry between 
receptor and G protein, the close proximity of these signalling components and the 
membrane localisation of the G protein required for analysis of this signalling 
process. This approach has been successfully applied to a number of different 
GPCRs and G proteins and used to calculate expression levels, rates of GTP turnover 
and hydrolysis and efficacies of partial agonists and inverse agonists (Seifert et al., 
1999). 
This approach to GPCR signalling analysis was applied to the CGRP receptor. The 
DNA encoding the rGαs gene was kindly provided by David Poyner at Aston 
University and was cloned into the CLR C-terminus following mutation of the CLR 
stop codon. A single amino acid substitution of rGαs created the hGαs sequence. Two 
CLR fusion constructs will therefore be created for functional analysis, CLR-hGαs and 
CLR-rGαs.  
The purpose of this chapter is to provide a proof of concept for the intracellular 
loop competition study and the CLR-Gαs fusion construct technique described in this 
section. If successful these techniques could be useful new tools in studying the 
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structure and function of the CGRP receptor and could also provide a target for new 
pharmaceuticals.  
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5.2 Methods 
5.2.1 Selecting ICL1/ICL2/ICL3/H8/C-terminal domain DNA 
sequences 
The ICL1, ICL2, ICL3, H8 and C-terminal DNA sequences were selected based on the 
sequences identified in Conner et al., 2006a and Conner et al., 2008. 
5.2.2 ICL1/ICL2/ICL3/H8/C-terminal domains into pcDNA3.1- 
mammalian expression vector 
ICL1 and H8 double stranded DNA ligation inserts with overhanging restriction site 
ends were created directly by annealing the primers described in Table 2.3 
following protocol 2.2.5.  
ICL2, ICL3 and C-terminal DNA sequences were amplified using the polymerase 
chain reaction (PCR, section 2.2.4) with the primers described in Table 2.3 and the 
N-terminal HA tagged hCLR construct as a template, described in Figure 2.2. 
Following PCR amplification, the PCR products were digested using restriction 
enzymes XbaI and EcoR1 as described in section 2.2.6.  
The pcDNA3.1- vector was digested using restriction enzymes XbaI and EcoR1 and 
the 5’ phosphate groups were removed using calf intestinal phosphatase following 
protocol 2.2.6 to prevent self-ligation. The restriction digest products were 
separated using agarose gel electrophoresis following protocol 2.2.7. The required 
DNA band was excised and purified using a Qiagen gel extraction kit.  
The intracellular domain fragments were ligated into the pcDNA3.1- vector 
following protocol 2.2.8. The ligation reaction was transformed into chemically 
competent Top10 E.coli cells (2.2.10) and plasmid DNA was amplified and purified 
(2.2.11). The purified DNA was sequenced (2.2.12) to confirm successful 
mutagenesis. 
5.2.3 Generating the CLR-Gαs fusion constructs 
The molecular biology approach used to create the CLR-Gαs fusion proteins is 
described in Figure 5.1. The CLR stop codon of the N-terminal HA tagged hCLR  
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Figure 5.1. Creation of the CLR-Gαs fusion proteins. 
A summary of the molecular biology approach used to synthesise the CLR-hGαs fusion 
protein from the HA-CLR template in the pcDNA3.1- vector and the rGαs gene. The protocol 
is described in detail in 5.2.3. Briefly, the CLR stop codon was mutated to alanine. The rGαs 
gene was amplied with a 5’EcoRI site and 3’ KpnI site using PCR. The CLR (STOP/A) and rGαs 
PCR DNA were digested with EcoRI and KpnI and rGαs was ligated into CLR (STOP/A). CLR-
rGαs was changed to CLR-hGαs (N139D) using sited directed mutagenesis. 
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construct (in the mammalian expression vector pcDNA3.1-) was mutated to alanine 
using the primers described in Table 2.4, following the QuikChange site directed 
mutagenesis protocol (2.2.3) to create a CLR (stopA) construct. Following DpnI 
degradation of the template DNA, the product was transformed into chemically 
competent Top10 E.coli cells (2.2.10) and plasmid DNA was amplified and purified 
(2.2.11). The purified DNA was electrophoresed alongside a pre-DpnI treated 
sample (2.2.7) to confirm successful degradation of the template DNA and the 
purified DNA was sequenced (2.2.12) to confirm successful mutagenesis.  
The rGs gene was PCR amplified with a 5’ EcoRI and 3’ KpnI site using primers 
described in Table 2.4 following protocol 2.2.4. Following amplification the PCR 
product was digested using restriction enzymes EcoRI and KpnI following protocol 
2.2.6.  
The CLR (stopA) construct was digested using restriction enzymes EcoRI and KpnI 
and the 5’ phosphate groups were removed using calf intestinal phosphatase 
following protocol 2.2.6 to prevent self-ligation. The restriction digest products 
were separated through agarose gel electrophoresis following protocol 2.2.7. The 
required DNA band was excised and purified using a Qiagen gel extraction kit.  
The rGs fragment was ligated into the CLR (Stop to A) vector following protocol 
2.2.8. The ligation reaction was transformed into chemically competent Top10 E.coli  
cells (2.2.10) and plasmid DNA was amplified and purified (2.2.11).  
The CLR-rGs fusion construct was mutated to CLR-hGs using primers described in 
Table 2.4 and an N-terminal HA tagged hCLR construct in the mammalian 
expression vector pcDNA3.1- as a template, following the QuikChange site directed 
mutagenesis (2.2.3). Following DpnI degradation of the template DNA, the PCR 
product was transformed into chemically competent Top10 E.coli cells (2.2.10) and 
plasmid DNA was amplified and purified (2.2.11). The purified DNA was 
electrophoresed alongside a pre-DpnI treated sample (2.2.7) to confirm successful 
degradation of the template DNA. The purified DNA was sequenced (2.2.12) to 
confirm successful mutagenesis.  
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5.3 Results 
5.3.1 Effect of ICL1/ICL2/ICL3/H8/C-terminal co-expression on CGRP 
receptor signalling 
The effect of the competition of the individual intracellular domains of CLR and WT 
CLR with the downstream signalling components was tested by measuring the 
effect of the co-expression of the CGRP receptor with each specific intracellular 
domain on cAMP signalling. 
The results are summarised in Table 5.1. Rows highlighted in blue show a significant 
increase in pEC50, basal or Emax levels. The cAMP signalling curve for each biological 
repeat of the tested WT CGRP receptor co-transfected with each intracellular 
domain is shown in Figure 5.2 to Figure 5.6. 
There was no significant difference in cAMP pEC50 values for any of the intracellular 
domains co-transfected with the WT receptor. Co-expression of ICL2 and the C-
terminus with the CGRP receptor had a significant increase in basal signalling (15.89 
% and 22.31 % respectively). ICL1 did not have a significant difference in basal 
values. ICL3 and H8 had a significantly increased basal which was lost following 
Bonferroni correction. Co-expression of the C-terminus resulted in a significantly 
increased Emax (~117.7 %). There was no significant difference in the Emax values for 
the other intracellular domains. 
5.3.2 CGRP receptor and G protein-coupling 
The signalling capability of the CLR-Gαs fusion proteins was measured using a cAMP 
signalling assay. This was to confirm that the CLR unit of the fusion protein is able to 
initiate a cAMP signalling response following stimulation with CGRP.  
The pEC50, basal and Emax results for the CLR-hGαs fusion protein are summarised in 
Table 5.2. The CLR-rGαs construct did not produce a signalling response after 
multiple experimental repeats. Rows highlighted in blue show a significant increase 
in values and rows highlighted in red show a significant decrease. The CLR-hGαs dose 
response curves are shown in Figure 5.7. 
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Intracellular  pEC50 (WT CLR + ICD) pEC50 (WT CLR) Statistical analysis Basal (WT CLR + ICD) Statistical analysis Emax (WT CLR + ICD) Statistical analysis 
domain (ICD) Mean SEM N Mean SEM N t-test Bonferroni  Mean SEM N t-test Bonferroni  Mean SEM N t-test Bonferroni 
ICL1 -8.48 0.2 3 -8.48 0.1 3 0.9811 1 6.12 7.16 3 0.4827 1 105.3 8.99 3 0.6179 1 
ICL2 -8.2 0.22 3 -8.48 0.1 3 0.4433 1 15.89 0.94 3 0.0035** 0.0105* 102.4 10.83 3 0.8476 1 
ICL3 -8.33 0.13 3 -8.48 0.1 3 0.2344 0.7032 23.85 3.84 3 0.0249* 0.0747 112.5 8.97 3 0.2985 0.8955 
H8 -8.45 0.09 3 -8.9 0.07 3 0.077 0.154 14.34 3.131 3 0.0445* 0.089 114.5 7.853 3 0.2061 0.4122 
CT -8.4 0.24 3 -8.9 0.07 3 0.1959 0.3918 22.31 2.031 3 0.0082** 0.0164* 117.7 2.727 3 0.023* 0.046* 
 
 
Table 5.1. Summary of the pEC50, basal and Emax mean and SEM values for the CGRP receptor co-transfected with the CLR intracellular domains and the 
WT receptor paired in each experiment.  
Cos7 cells transfected with WT and alanine substitution receptor were dose dependently stimulated with CGRP and levels of the cAMP second messenger 
were detected using a TR-FRET based cAMP assay. A sigmoidal dose response curve was fitted to the data using GraphPad Prism software. The intracellular 
domain co-expression was normalised to WT, taking the maximum and minimum values obtained from the WT dose response curve.  The number of 
experimental repeats is denoted in the N column and the significance was obtained through paired t-test. *p < 0.05, ** p < 0.01, ***p <0.001. 
Increased pEC50/basal/Emax  value 
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Figure 5.2. Dose response curves of cAMP signalling data produced for the CGRP 
mediated cAMP stimulation of the WT receptor co-expressed with the ICL1 domain.  
Transfected Cos7 cells were dose dependently stimulated with CGRP and levels of the 
cAMP second messenger were detected using a TR-FRET based cAMP assay. A sigmoidal 
dose response curve was fitted to the data using GraphPad Prism software. The co-
transfected ICL1 data were normalised to WT, taking the maximum and minimum values 
obtained from the WT dose response curve.  
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Figure 5.3. Dose response curves of cAMP signalling data produced for the CGRP 
mediated cAMP stimulation of the WT receptor co-expressed with the ICL2 domain.  
Transfected Cos7 cells were dose dependently stimulated with CGRP and levels of the 
cAMP second messenger were detected using a TR-FRET based cAMP assay. A sigmoidal 
dose response curve was fitted to the data using GraphPad Prism software. The co-
transfected ICL2 data were normalised to WT, taking the maximum and minimum values 
obtained from the WT dose response curve. 
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Figure 5.4. Dose response curves of cAMP signalling data produced for the CGRP 
mediated cAMP stimulation of the WT receptor co-expressed with the ICL3 domain.  
Transfected Cos7 cells were dose dependently stimulated with CGRP and levels of the 
cAMP second messenger were detected using a TR-FRET based cAMP assay. A sigmoidal 
dose response curve was fitted to the data using GraphPad Prism software The co-
transfected ICL3 data were normalised to WT, taking the maximum and minimum values 
obtained from the WT dose response curve. 
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Figure 5.5. Dose response curves of cAMP signalling data produced for the CGRP 
mediated cAMP stimulation of the WT receptor co-expressed with the H8 domain.  
Transfected Cos7 cells were dose dependently stimulated with CGRP and levels of the 
cAMP second messenger were detected using a TR-FRET based cAMP assay. A sigmoidal 
dose response curve was fitted to the data using GraphPad Prism software. The co-
transfected helix 8 data were normalised to WT, taking the maximum and minimum values 
obtained from the WT dose response curve. 
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Figure 5.6. Dose response curves of cAMP signalling data produced for the CGRP 
mediated cAMP stimulation of the WT receptor co-expressed with the C-terminus 
domain.  
Transfected Cos7 cells were dose dependently stimulated with CGRP and levels of the 
cAMP second messenger were detected using a TR-FRET based cAMP assay. A sigmoidal 
dose response curve was fitted to the data using GraphPad Prism software. The co-
transfected C-terminus data were normalised to WT, taking the maximum and minimum 
values obtained from the WT dose response curve. 
 
 
223 
 
 
 
 
Receptor pEC50 CLR-hGαs pEC50 WT CLR pEC50 Basal CLR-hGαs Basal Emax CLR-hGαs Emax 
construct Mean SEM N Mean SEM N t-test Mean SEM N t-test Mean SEM N t-test 
CLR-hGαs -9.17 0.16 3 -10.42 0.23 3 0.0108* 18.30 1.14 3 0.0039** 62.12 3.07 3 0.0065** 
 
 
Table 5.2. Summary of the EC50, basal and Emax mean and SEM values for the CLR-hGαs fusion and WT CLR receptor co-transfected with RAMP1.  
Transfected Cos7 cells were dose dependently stimulated with CGRP and levels of the cAMP second messenger were detected using a TR-FRET based cAMP 
assay. A sigmoidal dose response curve was fitted to the data using GraphPad Prism software. The intracellular domain co-expression was normalised to 
WT, taking the maximum and minimum values obtained from the WT dose response curve.  The number of experimental repeats is denoted in the N column 
and the significance was obtained through unpaired t-test. *p < 0.05, ** p < 0.01, ***p <0.001. 
Reduced pEC50/basal/Emax value Increased pEC50/basal/Emax  value 
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Figure 5.7. Dose response curves of cAMP signalling data of the CLR-hGαs fusion and WT 
CLR co-transfected with RAMP1.  
Transfected Cos7 cells were dose dependently stimulated with CGRP and levels of the 
cAMP second messenger were detected using a TR-FRET based cAMP assay. A sigmoidal 
dose response curve was fitted to the data using GraphPad Prism software. The CLR-hGαs 
fusion receptor co-transfected with RAMP1 data were normalised to WT, taking the 
maximum and minimum values obtained from the WT dose response curve. 
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The CLR-hGαs construct produced a cAMP signalling response, however with a 
significantly reduced pEC50 value (~20 fold reduction) and Emax (~62% of WT) and a 
significantly increased basal (~18% above WT). 
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5.4 Discussion 
5.4.1 Data integrity 
5.4.1.1 Co-expression of individual intracellular domains with WT CLR 
The cAMP signalling data is shown in Table 5.1 and Figure 5.2 to Figure 5.6. The 
pEC50 values for the WT CLR control were lower than expected (8.48 to 8.9) 
compared with previously published values (9.5 to 10.5) (Barwell et al., 2011). 
However these values were similar to pEC50 values observed in the alanine 
substitution study of chapter 3 and were consistent across experimental repeats. 
They were therefore considered acceptable to use. The basal and Emax signalling 
illustrated in Figure 5.2 to Figure 5.6 often showed higher levels when co-expressed 
with the intracellular domains. This was reflected in a higher mean for all the basal 
(6.12 % to 23.85 %) and Emax (102 % to 117 %) values however the only statistically 
significant differences were observed with ICL2 and C-terminus co-expression for 
basal and C-terminus for the Emax. It has been previously observed that higher basal 
and Emax signalling reflects variations in the assay set up (e.g. cell numbers) 
however it was unlikely that this occurred in each experimental repeat for each co-
expression treatment. Further investigation would be required to ensure this is a 
biological effect.  
5.4.1.2 Synthesis and functional analysis of the CLR-hGs fusion protein 
The functional analysis of the CLR-hGs fusion protein was done through cAMP 
signalling. These results are shown in Table 5.2 and Figure 5.7. The pEC50 value for 
the WT CLR control was 10.42 which is consistent with published data (Barwell et 
al., 2011). The signalling observed with the CLR-Gs fusion protein had a consistently 
reduced pEC50 value, increased basal and reduced Emax. All these variations were 
statistically significant. However signalling was successful at a reduced pEC50 of ~ 
20 fold and an Emax of 62.12 % WT CLR.  
5.4.2 Co-expression of individual intracellular domains with WT CLR 
The expression of individual GPCR ICL domains has been previously shown to inhibit 
receptor signalling. This was done through the expression the -OR ICL3 domain in 
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cells expressing a variety of GPCRs. The inhibition was common between receptors 
that shared similar G protein signalling pathways indicating inhibition through G 
protein interaction (Morou & Georgoussi, 2005). Co-expression of both the α1B-AR 
ICL3 and C-terminal domain was found to reduce the maximal IP3 signalling of the 
α1B-AR, however when tested, basal and pEC50 values were not significantly 
different to WT (Hawes et al., 1994; Luttrell et al., 1993). 
Work in this chapter investigated the effect on receptor signalling through co-
expression of the intracellular domains of the CGRP receptor. These included ICL1, 
ICL2, ICL3, H8 and the C-terminus. Co-expression of these domains with the WT 
CGRP receptor did not result in a significant change in cAMP pEC50 values. Basal 
levels of CGRP receptor co-transfected with ICL2 and the C-terminus were 
significantly increased (15.89 % and 22.31 % respectively). ICL2 of the WT receptor 
is expected to interact with the G protein during the activation process. It is possible 
that the isolated loop is interacting with the G protein resulting in an increased 
signalling response. The CGRP receptor co-expressed with the C-terminal domain 
had a significantly increase Emax. The increased basal and Emax signalling observed 
with the co-expression of the C-terminus could be explained with this domain 
competing with the internalisation machinery that is known to bind to the C-
terminus (Conner et al., 2008) preventing internalisation of the WT receptor and 
increasing the maximum signalling capacity. These results show that the co-
expressed CLR intracellular domains do have an effect on receptor function 
however to be certain that this is as a result of successful expression and 
competition of the intracellular domains, further experiments are required.  
The -OR ICL3 domain was cloned into a mammalian expression vector using a 
similar approach, except a ribosome consensus sequence was included at the 5’ 
terminus. An N-terminal GST-tagged construct was also created. Expression of the 
-OR ICL3 domain was determined using RT-PCR and western blot analysis. 
Successful expression of the intracellular domains of the CGRP receptor was not 
tested; therefore the absence of significant signalling effect may be due to a lack of 
expression or degradation of expressed protein. The nature of the experimental 
design, by cloning only the intracellular domain DNA sequences without tags or 
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markers and the test for functional effect through the cAMP signalling assay was 
used as an initial screen due to limits in time. To continue this investigation further, 
the introduction of tags and fluorescent markers to the isolated intracellular 
fragments could be used to ensure successful expression. If successful expression of 
these isolated domains is occurring then it is also possible that they may interfere 
with the cell surface expression of the receptor or internalisation following CGRP-
mediated activation. To measure this, the cell surface expression ELISA could be 
used. 
5.4.3 Synthesis and functional analysis of a CLR-Gs fusion protein 
GPCR-Gs fusion proteins have been shown to signal at levels similar or greater than 
co-expression of the individual subunits (Bertin et al., 1994; Seifert et al., 1998a; 
Seifert et al., 1998b). This has provided a more consistent platform for the study of 
GPCR-G protein interactions in cell systems consisting of sub-units in 1:1 
stoichiometry. Two CLR-Gs fusion constructs were created as a proof of concept to 
use this technique to study interactions between these two components specifically 
for the CGRP receptor. The CLR-hGs produced a CGRP-mediated signalling 
response, however with a significantly reduced pEC50 value (~20 fold reduction), 
increased basal value (~18%) and reduced Emax (~62%). The increased basal activity 
could be explained due to the close proximity of the hGs subunit to the receptor. 
Given the fluid nature of the receptor to exist in multiple conformations and exhibit 
constitutive activity, a more closely associated G protein could be activated more 
frequently than an independently expressed subunit, resulting in an increase in 
signalling. However this close association could also explain the reduced Emax. A 
fused G protein is less able to dissociate and be recycled and also to allow other G 
proteins to be activated by the same receptor. Another factor to be considered is 
the endogenous G proteins of the Cos7 cell line. The CLR-rGs fusion protein did not 
produce a cAMP signalling response. This is unexpected as the primary sequence of 
these two proteins only differs by a single amino acid. More experiments are 
required to see if this is a real result or instead reflects an issue with the DNA 
construct or transfection process. 
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This is preliminary evidence to support a proof of concept that the fusion Gαs sub-
unit is being used for signalling (at least in part) and that this construct might be 
useful for future work. As the observed cAMP response could be through the 
endogenous Cos7 Gs proteins, signalling would need to be shown in cells that do 
not express the endogenous Gs proteins. Mutagenesis of the Gs subunit has been 
done that impaired GDP binding or increased GTPase activity, which reduced 
receptor-mediated activation (Warner & Weinstein, 1999; Warner et al., 1998). 
Repeating this with the CLR-hGs construct would show if signalling is through the 
fused Gs protein or the endogenous one. This was not done due to time 
limitations. 
5.4.4 Conclusions 
This chapter set out to provide evidence for proof of concept of two novel signalling 
investigation techniques for the CGRP receptor. These experiments were designed 
to see whether CGRP receptor signalling could be manipulated with the co-
expression of its intracellular domains or studied through a functional CLR-hGs 
fusion protein. The first set of experiments created receptor fragments that had a 
functional effect on cAMP signalling when co-expressed with the WT receptor. The 
second set of experiments created a CLR-hGs fusion protein that produced a 
successful set of preliminary signalling results. A more comprehensive set of 
experiments are now required to confirm this however this could be a useful new 
construct for the study of receptor-G protein interactions. 
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 Final Discussion 6
6.1 Introduction 
This thesis has described studies that investigated various signalling aspects of the 
CGRP receptor. The main focus has been the ECL2 domain of CLR, the GPCR 
component of the receptor. This project has shown that ECL2 is the most important 
single, functional domain for ligand-based activation of the CGRP receptor, with 
evidence for the first time that a large number of residues are involved. These were 
initially identified through alanine substitution mutagenesis of each individual 
residue of ECL2, described in chapter 3. These results were used by collaborators to 
iteratively develop and refine a computer model of CLR bound to CGRP in the active 
state.  An extensive program of mutagenesis targeting important residues of ECL2 
has started to reveal the complex set of intra- and inter-molecular interactions that 
occur for both structural integrity and ligand-mediated receptor activation. These 
results are described in chapter 4. The final part of the study into CGRP receptor 
function looked at the intracellular interactions that occur during receptor 
signalling. The involvement of each intracellular domain of the CGRP receptor in 
signalling was studied and preliminary results for a new CLR-hGαs fusion construct 
that could be used for receptor-G protein interaction research were described. 
These results are described in chapter 5. 
6.2 Key aspects of the mutagenesis program 
The work described in chapters 3 and 4 used substitution mutagenesis on each 
individual residue of ECL2, including the interface with TM4 and 5, to investigate the 
function of each amino acid of this loop in cell surface expression, ligand binding, 
receptor signalling and internalisation. 24 residues were substituted with alanine 
and of these, 14 were found to have a significantly reduced pEC50 compared with 
WT. The most dramatic reductions were R274A (~100 fold reduction), D280A (~80 
fold reduction) and W283A (~300 fold reduction). These three residues have been 
highlighted on the highest scoring models for both the CGRP and AM receptor. The 
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equivalent three residues have also been highlighted on the CRHR1 and GCGR 
crystal structures (Hollenstein et al., 2013; Siu et al., 2013). These are shown in 
Figure 6.1. The amino acids selected were the conserved TM4/ECL2 basic residue 
and the conserved ECL2 tryptophan residue. The ECL2 acidic residue that is 
predicted to form a salt bridge with the TM4/ECL2 basic residue in the crystal 
structures was chosen however is located in a different position in the ECL2 primary 
sequence to D280. 
Also notable were Y277A and Y278A (both ~10 fold reduction), I284A (~10 fold 
reduction) and T288A (~20 fold reduction). C282A had significantly reduced 
signalling (~10 fold) however the double alanine substitution C212AC282A 
recovered signalling indicating its function in disulphide bond formation.  
Using this data, receptor modelling was undertaken by collaborators that indicated 
that R274 had a structural role, potentially bridging with the plasma membrane and 
D280 or the nearby tyrosine residues (Y277 or Y278). The precise length of the R274 
side chain was important as substitution with the conservative R274K only partially 
recovered signalling compared with the alanine substitution. Signalling at positions 
Y277 and Y278 was recovered with an individual phenylalanine substitution (Y277F 
and Y278F), showing the importance of the aromatic part of the tyrosine side chain. 
However at position Y277, a leucine substitution (Y277L) also recovered signalling 
indicating that the functional effect at this position is due to hydrophobicity. This 
result also makes the predicted R274-Y277 interaction unlikely. The dramatic 
reduction in signalling of the alanine substitution at position D280 (D280A) was not 
recovered by a number of amino acid replacements, including the conservative 
glutamate substitution (D280E) indicating the required specificity of the charge and 
position of the aspartate side chain. Given the similar reduction in signalling 
potency of the R27A and D280A substitutions and the requirement of the WT 
residue for full functional effect at each position, the predicted R274-D280 
interaction remains possible. The highest scoring CGRP model (Figure 6.1) does not 
position these two residues close enough to form a salt bridge however the highest 
scoring AM receptor model does.   
232 
 
 
Figure 6.1. Key ECL2 residues highlighted in CGRP and AM receptors models and 
equivalent residues in CRHR1 and GCGR1 crystal structures.  
CLR structures for the highest scoring CGRP and AM receptor models are shown. The 
CRHR1 crystal structure (PDB 4K5Y) and the GCGR crystal structure (PDB4L6R) are also 
shown. TM2 (light blue), TM3 (lilac), TM4 (salmon), TM5 (turquoise) and ECL2 (purple) are 
shown. R274 (pink), D280 (purple) and W283 (blue) are highlighted. The equivalent resides 
selected in the CRHR1 and GCGR1 are the TM4/ECL2 conserved basic residue, the ECL2 
acidic residues predicted to form a salt bridge with the TM4/ECL2 basic residue and the 
conserved ECL2 tryptophan residue.  
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The mutagenesis of W283 produced some of the most interesting data. The ~300 
fold reduction observed with the alanine substitution mutant was partially 
recovered with a phenylalanine substitution (W283F, ~100 fold) however was 
completely recovered with a histidine substitution (W283H). This brings our 
attention to the imidazole portion of the tryptophan side chain, through which 
computer modelling proposes can form hydrogen bonds with histidine residues in 
TM2 and 3. The orientation of W283 back towards the TM helices instead of into 
the centre of the TM bundle more closely resembles the CRHR1 structure compared 
with GCGR (Figure 6.1). 
The middle and the C-terminus of the loop are predicted to be involved in both 
structural and ligand interactions. Important contact points with CGRP are thought 
to be through D280, D287 and T288, however this has not yet been empirically 
deduced. Residues D287 and T288 at the C-terminus of ECL2 are speculated to be 
CGRP binding sites. Conservative substitutions at each of these positions (D287E 
and T288S) recovered signalling. This suggests that although the electrostatic 
properties of the side chain are important for receptor function, the precise 
location at these positions is more flexible.  Cell surface expression remained 
unaffected except for a cluster of four residues from C282 to S285 which all had 
significantly reduced expression levels (50-70% WT). This cluster may be a 
coincidental finding or could reflect a trafficking motif.  
There is a hydrophobic cluster of residues at the ECL2/TM5 interface at which 
individual alanine substitutions result in a small reduction in cAMP signalling (3-10 
fold reduction) however multiple alanine substitutions produce substantial effects 
(L290AL291AY292A, ~10,000 fold reduction; L290AL291A, ~300 fold reduction; 
L290Y292, ~30 fold reduction). This suggests that this cluster functions as a 
functional hydrophobic motif that is maintained during the removal of individual 
side chains of this cluster however is dramatically lost if two or more of these side 
chains are removed. 
234 
 
6.3 Signalling elements within the intracellular regions of 
CLR 
Chapter 5 presents preliminary findings of new experimental techniques that can be 
used to study CGRP receptor signalling in further detail.  
The first was the use of a co-expression system using individually expressed CLR 
domains together with the WT receptor to investigate the functional effect. More 
precisely, the intracellular domains were cloned into a mammalian expression 
vector, co-expressed with the WT CGRP receptor and the effect of ligand-mediated 
cAMP signalling was measured. This approach has successfully identified ICL3 and 
the C-terminus as G protein-binding partners in other GPCRs (Hawes et al., 1994; 
Luttrell et al., 1993). Co-expression of the intracellular domains resulted in some 
significant changes to cAMP signalling, most notable a significantly increased Emax 
(~115% of WT) with the co-expression of the C-terminal domain with the CGRP 
receptor. 
The second was the creation of a functional receptor-Gαs protein fusion construct. 
Two fusion constructs were created. These were CLR-hGαs and CLR-rGαs. CLR-hGαs 
produced a CGRP-induced signalling response, however with a reduced pEC50, an 
increased basal and a reduced Emax. CLR-rGαs did not produce a cAMP signalling 
response. This is the first time a GPCR-G protein fusion approach has been used for 
family B GPCRs. Before this system can be used to study CLR-hGαs interactions 
further work is required to verify that the observed signalling is through the fused 
Gαs protein, however this is a promising new strategy for the future of CGRP 
receptor signalling research. 
6.4 Physiological relevance of structure and function 
understanding of the CGRP receptor 
CGRP is a potent vasodilator, released from the central and peripheral nervous 
system, with a physiological role in migraine, neurogenic inflammation, 
hypertension and has been found to be cardioprotective (Doggrell, 2001). CGRP 
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receptor antagonists have been investigated as possible therapeutics in the 
treatment of migraine (Durham & Vause, 2010) and during myocardial ischemia, 
CGRP release stops the development of myocardial infarction (Franco-Cereceda & 
Liska, 2000). There is evidence that CGRP has a protective effect in hypertension 
(Smillie & Brain, 2011). Given the involvement of CGRP in a number of 
pathophysiological conditions, understanding the mechanism through which the 
ligand binds to and activates its receptor is of considerable interest and importance 
in the design and development of therapeutics to tackle these conditions. The data 
described in this work provide the platform for potential therapeutic design as it 
can be used to investigate the docking site of CGRP with its receptor.  
6.5 Future work 
The results described in chapters 3 and 4 show that the CLR ECL2 domain is very 
important for CGRP binding and activation. The key residues of this domain that are 
involved have been identified and some of the interactions through which these 
residues function have been determined. This information is now ready to be built 
on to understand the structure of the loop, the location of the ligand binding pocket 
and the mechanism through which receptor activation occurs. The combined work 
of the alanine substitution mutagenesis in chapter 3 and the computer modelling of 
CLR (Woolley et al., 2013) indicates that the N-terminal portion of the loop 
(between R274 and D280) is important for the structural integrity of this domain 
with the C-terminal portion of the loop likely to bind CGRP.  
The computer modelling suggests that the structural scaffold of the N-terminal part 
of the loop could be conferred through interactions with either R274 and D280 or 
between R274 and either of the two tyrosines (Y277 or Y278). The further 
substitution mutagenesis of chapter 4 shows how important the exact positioning 
of the charge of the side chain is for both R274 and D280 and the requirement of 
the aromatic ring of either tyrosine of phenylalanine (Y or F) at position Y278, 
however do not confirm what each residue is interacting with. A further set of 
mutagenesis experiments, either creating reciprocal pairings of R274-D280 
(R274D/D280R), R274-Y277 (R274Y/Y277R) and R274-Y278 (R274Y/Y278R) could 
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start to pinpoint the exact site of interactions. One of the higher scoring models 
predicted R274 to interact with D280 enabling binding to R11 of CGRP. To test this, 
a number of reciprocal mutants of both CLR and CGRP could be used together with 
a CGRP analogue at position 11, CGRP R11E. These include R274E/D280N(H)/R11, 
R274/D280N(H)/R11E and R274E/D280H(R/K)/R11E. 
The speculated ligand binding section of ECL2 (N-terminus) allowed a greater 
flexibility in amino acid substitutions in chapter 4. Given that this is the expected 
location for CGRP binding it is experimentally more difficult to determine 
interactions site. It therefore appears to be more strategic to refine the loop 
structure through the N-terminus allowing for a more directed approach in studying 
the C-terminus.   
There are a number of other experimental techniques that can be used to 
determine the positioning of individual amino acids and therefore deduce the 
topography of the domain. These include the scanning cysteine accessibility method 
(SCAM) which provides information of the exposure of the selected residue to the 
aqueous environment (Javitch et al., 2002) and Zn2+ cross linking of substituted 
histidine residues to measure the proximity of selected residues (Elling & Schwartz, 
1996). 
All of the signalling analysis on the CGRP receptor in this thesis has focused on the 
cAMP signalling pathway. This is the best characterised signalling pathway of this 
receptor (Walker et al., 2010) and therefore was the most appropriate tool to 
measure receptor function. However current understanding of GPCR signalling 
acknowledges that receptors signal through multiple pathways with ligands acting 
as agonists, antagonist or inverse agonists depending on the pathway (Kenakin, 
2007). The CGRP receptor has been shown to signal through Gαq with intracellular 
increases in Ca2+ and through β-arrestin measured through ERK1/2 (Walker et al., 
2010). To gain comprehensive understanding into the mechanism through which 
CGRP activates its receptor, the effect of the ECL2 substitution mutagenesis on 
these alternative pathways could be investigated. 
The preliminary results introduced in chapter 5 could produce novel methods for 
CGRP receptor research to study the functional effect of individual domains and the 
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specific points of interaction between the receptor and coupled proteins. Currently 
more work is required to validate both methods as being robust and reliable 
screens for receptor function. With respect to the intracellular domain co-
expression experiments, the successful expression of these domains needs to be 
shown more conclusively. Before the CLR-hGαs fusion protein can be used to study 
coupling interactions, it needs to be verified that the observed signalling is through 
the fused hGαs and not endogenous G proteins.  
6.6 Final summary 
The work described in this thesis has produced novel and unique information that 
contributed to both the specific knowledge and understanding of the CGRP receptor 
and to the field of GPCR research in general. The CLR ECL2 domain was shown to be 
fundamental with respect to CGRP binding and receptor activation. The individual 
residues that are involved in this process were identified and through a 
comprehensive set of substitution mutagenesis, the molecular interactions that 
produce this functional effect have started to be deduced. Further to this, two new 
approaches to CGRP receptor functional analysis have been tested and shown to be 
promising techniques for the future research of this receptor. 
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The calcitonin gene-related peptide (CGRP) receptor is a complex of a cal-
citonin receptor-like receptor (CLR), which is a family B G-protein-coupled
receptor (GPCR) and receptor activity modifying protein 1. The role of the
second extracellular loop (ECL2) of CLR in binding CGRP and coupling to
Gs was investigated using a combination of mutagenesis and modelling. An
alanine scan of residues 271–294 of CLR showed that the ability of CGRP to
produce cAMP was impaired by point mutations at 13 residues; most of
these also impaired the response to adrenomedullin (AM). These data were
used to select probable ECL2-modelled conformations that are involved in
agonist binding, allowing the identification of the likely contacts between
the peptide and receptor. The implications of the most likely structures for
receptor activation are discussed.1. Introduction
The extracellular loops of G protein-coupled receptors (GPCRs) are important for
receptor function. They contribute to protein folding, provide structure to the extra-
cellular region and mediate movement of the transmembrane (TM) helices on
activation. The secondextracellular loop (ECL2) is of significance for ligandbinding
and receptoractivation [1–3]. In familyB (or secretin-like)GPCRs, it is themost con-
served and often the longest of all the ECLs, and so is in a good position to interact
with the endogenous peptide agonists for these receptors and is in a prominent cen-
tral position to mediate conformational changes [1]. The peptide ligands typically
contain 30–50 amino acids. The family B receptors are characterized by a large
N-terminal domain (approx. 100 amino acids), which interacts with the C-termini
of their cognate peptide ligands [4]. The N-termini of these peptides interact with
the ECLs and the TM region of the receptors resulting in activation [4,5]. ECL2
has been implicated in agonist binding at the GLP-1, secretin and CRF1 receptors
[6–10]. For the GLP-1 receptor, ECL2 plays an important role in directing coupling
towards stimulation of ERK1/2 activation versus Gs and activation of adenylate
cyclase [7]. However, the molecular basis for this observation remains obscure.
Several distinct conformations have been recognized for ECL2 in family A
GPCRs, ranging from the ‘lid’ seen in rhodopsin, which encloses the bound reti-
nal ligand, to the extended sheet seen for most of the peptide GPCRs [11–13].
Movement of ECL2 seems to be important in the activation of family A GPCRs;
this is linked to agonist-induced changes in TM5 and helps propagate these
changes to other parts of the GPCR [11,14].
There is currentlyno crystal structure showinghowapeptideagonist bindsto the
ECLs or TM domain of a family B GPCR. A number of models have been proposed
based on cross-linking and mutagenesis data [8,15,16] but it has proved extremely
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2difficult to accurately predict the ECL conformations by this
approachor bysimulation [17].Given thevariety in familyBpep-
tide sequences [5,17], it seems likely that there is no single mode
of peptide binding to the ECLs of family B GPCRs [18].
We have previously used a combination ofmutagenesis and
computation to produce a model indicating how the TM
domain of the calcitonin receptor-like receptor (CLR) can inter-
act with Gs [19]. CLR is the GPCR component of the calcitonin
gene-relatedpeptide (CGRP) receptor.CGRP ispart of apeptide
family that also includes adrenomedullin (AM), calcitonin and
amylin and is involved in heart disease and migraine [20].
CLR interacts with a single TM protein, receptor activity-
modifying protein 1 (RAMP1), in order to bind CGRP and
also AM [21], though AM interacts with CLR more strongly in
the presence of RAMP2. Using an independent modelling
approach, Wootten et al. [22] have produced a broadly similar
model for the GLP-1 receptor, which indicates how agonists
can activate the receptor by interacting with different TM resi-
dues. Using both mutagenesis and computation is a powerful
strategy for studying the activation of GPCRs [12], especially
given that structural techniques for instance crystallography
give static pictures ofwhat is fundamentally a dynamic process.
In previous work, we have examined the role of the first and
third ECLs (ECL1/3) of the CGRP receptor. However, only a
small number of residues within ECLs 1 and 3 were implicated
in CGRP binding [18]. Consequently, we have now addressed
the role of ECL2 in this receptor. In an extension of the strategy
used toexamine theTMresiduesofCLR,wehaveexperimentally
identified CLR residues that reside within the last turn of TM4,
ECL2 and the first turn of the turn of TM5 and that are key for
CGRP and AM interactions with the CGRP receptor. We have
then used all of our data for each ECL and the TM domain, in
combinationwith heuristic loopmodelling,molecular dynamics,
docking and sequence analysis to model the interaction between
theN-terminus of theCGRPpeptide andCLR, based on amodel
of the Gs-coupled state of the CGRP receptor.2. Material and methods
2.1. Preparation of mutants, transfection, receptor
expression and radioligand binding
The preparation of mutants and molecular biology was as descri-
bed earlier [23]. An HA-tagged CLR construct was used to allow
measurement of cell surface receptor expression by ELISA [20,23].
Mutants were transfected into Cos 7 cells using PEI [20,23]. Radio-
ligand binding was carried out on cell membranes using [125I]
iodohistidyl-human alpha CGRP (Perkin Elmer) [20,23].
2.2. Measurement of cAMP
For the investigation of CGRP-mediated activation of the recep-
tor, cAMP was measured using a FRET-based PerkinElmer
LANCE cAMP 384 kit according to manufacturer’s instructions.
Briefly, transfected cells were removed from the plate with trypsin
EDTA, washed with phosphate-buffered saline and resuspended
in assay stimulation buffer (SB; phosphate-buffered saline þ 0.1%
(w/v) bovine serum albumin þ 0.5 mM isobutylmethylxanthine).
Cells were counted with a haemocytometer and the appropriate
cell number resuspended in SB þ 1/100 AlexaFluor 647-anti
cAMP antibody at an assay concentration of 2000 cells/10 ml. A
total of 2000 cells/well were loaded onto a 96-well white Optiplate
(PerkinElmer) and were concentration-dependently stimulated in
triplicate with a logarithmic increase of CGRP diluted in SB from1026 to 10212 M with SB as a basal point. The plate was incubated
in the absence of light for 30 min at room temperature before
20 ml/well of detection mix was added. The plate was incubated
in the absence of light for a further 60 min. FRET was recorded
by excitation at 320 nm and emission at 665 nm. The experimental
pEC50 values for wild-type (WT) receptor in the electronic sup-
plementary materials, table S1 show some variation, reflecting
differences in coupling efficiencies between cells as the data were
collected in excess of ayear. Suchdrift has beenobservedpreviously
withCGRPreceptors [24,25]. To control for this, a paireddesign-test
was used so that each mutant was compared in the same exper-
iment against a corresponding WT control. For the investigation
of AM-mediated stimulation of the CGRP receptor, cAMP was
measured with alphascreen, as described previously [26]. Data
were normalized against the maximum fitted response for CGRP
or AM; basal cAMP was taken as the fitted minimum.
2.3. Data analysis
Curve fitting was done with GRAPHPAD PRISM 5 or 6 (GraphPad
Software Inc., San Diego, CA, USA). Both this and statistical
analysis were as described previously [20].
2.4. CLR models
The starting point for the models indicating the interaction
between CGRP and ECL2 was a recent model of the active state
[19]. The most appropriate X-ray crystal structure model for a
fully active GPCR is that of the b2-adrenergic receptor (b2-AR)
coupled to Gs [27], which is similar to the b2-AR nanobody stabil-
ized [28] and the rhodopsin active structures stabilized by a
C-terminal peptide from transducin [29,30]; these active structures
are characterized by the outward tilt of the intracellular end of TM6
that is necessary for G protein binding. In the absence of G protein
or G protein-derived peptides, X-ray crystal structures of agonists
bound to GPCRs stabilize substates that are not too different to the
inactive form [31], i.e. they lack the outward tilt of TM6; in such
agonist-bound structures, the conformation of Y5.58 is taken to be
indicative of the state because in the inactive form, it usually inter-
acts with L1.63 and L8.50, whereas in the active substate, it stabilizes
the active conformation of R3.50. Our active structures are stabilized
by the Gs C-terminal peptide (R373-L394), and hence included the
outward tilt of TM6 [27]. Nevertheless, the conformation of Y5.58
(and the tilt of TM6) was monitored to check that active state char-
acter was maintained as fully as possible and that the simulations
could be terminated should the active structure begin to acquire
inactive character. The underlying alignment was based on a
novel approach to the class A–class B alignment, aided by a
GCR1/class E alignment that was used as a bridge between the
class A and class B sequences. This has been repeated using
improved methodology but the alignment remains unaltered
[32]. The status of GCR1, GCR2 and other putative plant GPCRs
has been questioned [33–35], but GCR1 has all the features
expected for a GPCR fold [32], while GCR2 was predicted [36]
and later shown to be a lanbiotic cyclase [37]. The simulations
that underlie the CLR modelling [19] were extended to 100 ns
(see the electronic supplementary material).
To model the peptide binding, disulfide-bonded cyclic
CGRP1–7 was constructed in Maestro and docked to the active
CLR model (after 80 ns, i.e. just before the first signs of the onset
of inactive character; [19]) using Glide SP [38,39], as described in
the electronic supplementary material. The best-scoring pose was
verified by sequence analysis, as described below. The CGRP
extension (up to residue 32) was modelled onto CGRP1–7 using
the NMR solution structure of salmon calcitonin (PDB code 2glh)
[40], using the alignment of Watkins et al. [5].
In the molecular dynamics simulations, the active structure
begins to acquire some inactive character after 80 ns (i.e. F7.53
switched towards the inactive conformation; see the electronic
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3supplementary material, figure S1). This is well before it would
be possible to fully sample the loop conformations, despite high
principle components for ECL2 residues; see the electronic sup-
plementary material, figure S1D. Thus, given that the MODELLER
scoring functions are approximate, we have taken a heuristic
approach to determining theECL2 conformation.Wehave therefore
generated and refined100 independent loop conformations; suitable
conformations were selected if key loop residues identified by the
mutagenesis interacted with CGRP or AM to within a cut-off of
5.5 A˚. There are many assumptions inherent in this approach, as
discussed below in §3.2.5; this is apparent because it was impossible
to generate conformations where each significant ECL2 residue
interacted with CGRP. Thus, multiple conformations of ECL1 (resi-
dues 202–212), ECL2 (residues 274–293) and ECL3 (residues
353–363) were simultaneously generated in the presence of
CGRP1–32 usingMODELLER [41–43]. Each conformation is character-
ized by its DOPE score; a lower score corresponds to a more likely
conformation. AM binding to CLR was similarly modelled by sim-
ultaneously mutating CGRP to AM and generating the loop
conformations within MODELLER.
2.5. Sequence analysis
The sequences of CGRP and amylin (which binds to the calcito-
nin receptor (CTR)) from several species were aligned [5,44]. The
sequences of amylin and CGRP and the sequences of CTR and
CLR were analysed in parallel to identify mutations that are cor-
related between the CTR–amylin and CLR–CGRP systems, with
a view to identifying contact points.
2.6. Residue numbering
For amino acids within the proposed ECLs of CLR, only the resi-
due numbers are shown. For residues that are within the TM
helices of CLR, a superscript denotes their position using an adap-
tion of the Ballasteros–Weinstein numbering proposed elsewhere
[19]. The peptide residue numbers are given as superscripts.3. Results and discussion
3.1. Experimental analysis of the CGRP receptor
In this section, the results of an alanine scan of the CGRP
receptor will be presented. The implications of these data
will be discussed alongside the modelling in §3.2.3.1.1. Effects of alanine substitution on CGRP-mediated cAMP
production
Twenty-four individual residues of CLR ECL2 from A271
to I294 were mutated to alanine (alanine residues were
mutated to leucine) and their ability to respond to CGRP
and stimulate cAMP production was investigated when co-
expressed with human RAMP1. These residues were selected
as they are most likely to incorporate the whole of ECL2 and
approximately one turn of helices 4 and 5 immediately adja-
cent to the loop, based on our previous analysis [19].
Figures 1 and 2 and the electronic supplementary materials,
table S1 and figure S2 show that the pEC50 values of 14 of
the 24 mutants were significantly different to WT, indica-
ting that ECL2 is particularly important for CGRP receptor
function. Seven mutants resulted in significant cAMP reduct-
ion of more than 10-fold. These are R274A, Y278A, D280A,
C282A, W283A, I284A and T288A. Of the remaining seven
mutations, N281A showed a small increase in potency and
six mutants had small but significant reductions in pEC50.
Y292A and I294A showed significant but small increases
in maximal cAMP response (Emax) (see the electronic
supplementary material, table S2).3.1.2. Cell surface expression of receptors and CGRP binding
Owing to the likelihood of attenuated binding of CGRP, radio-
ligand binding could not be reliably used to provide an
estimate of receptor expression for these constructs. Accord-
ingly, an ELISA to measure receptors at the cell surface was
used (see the electronic supplementary materials, table S3).
All of the mutants were expressed at the cell surface to
within approximately 60% of WT levels. Reductions to this
level of expression has been previously shown to have little
effect on the potency of CGRP-mediated cAMP signalling for
this or CTR expressed in Cos 7 cells [45,46] and in this study,
there was only a very low correlation between expression
and pEC50 (r
2 ¼ 0.23). Mutated receptors that had large
impairments of cAMP production were examined for their
ability to bind CGRP using a radioligand-binding assay (see
the electronic supplementary materials, table S4). All of the
mutants examined, except Y277A had reduced affinity for
the radioligand.
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43.1.3. Effects of alanine substitution on AM-mediated
cAMP production
The CGRP receptor also acts as a functional AM receptor with
an affinity of approximately 10-folds less than that for CGRP
[47]. To explore the effects of the above mutants further, their
ability to respond to AM through cAMP production was sub-
sequently investigated. The majority of the effects were in line
with those seen with CGRP (figure 1 and the electronic sup-
plementary material, table S2), the most notable differences
being the lack of effects of AM at Y277 and Y278 and for
some mutants, it was impossible to measure any activation
of the receptor (figure 3). In the case of R274A, W283A and
D280A, the response was so low that an Emax could not be
reliably determined. There was especially good agreement
between the two agonists for the central area of functional
importance ranging from D280 to T288. As with CGRP,
many of these alanine substitutions reduced AM potency.The effect of mutations at the N- and C-termini of ECL2 was
more variable between the two peptides. At the N-terminus,
the CGRP-affecting mutants Y277A or Y278A did not show
AM-mediated effects on pEC50. However, there were approxi-
mately 25% reductions in the maximal cAMP response. At the
C-terminus of ECL2, the two leucine mutants (L290A and
L291A), which showed a reduction in potency with CGRP,
were not significantly affected when stimulated with AM.
3.1.4. Basal activity
In the investigation of CGRP (with Cos 7 cells from a UK
source and measuring cAMP with a LANCE assay), N281A
and I294A showed a significant increase in basal cAMP
signalling (i.e. constitutive ligand-independent signalling acti-
vity; see the electronic supplementary material, table S2).
These values increased by 9.9+ 0.9% and 21.8+2.9%
above WT, respectively. When the cells were investigated
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5for AM responsiveness (using Cos 7 cells from a New Zea-
land source and Alphascreen), small but statistically
significant elevations were noted for A273L, Y277A and
I284A but not N281A and I294A. Thus, the increase in
basal cAMP depended on experimental conditions and was
always small. In the course of analysing over 200 mutants
of CLR [19,20,48], we have observed very few that showed
elevated activity, possibly indicating that there are multiple
locks in place to keep the receptor in an inactive form; it is
possible that the RAMPs might contribute to this.3.1.5. The importance of the ECL2–TM3 disulfide linkage
As C282 is predicted to form a disulfide bond with C2123.25
[19], further mutagenesis was used to explore this, using
CGRP as the agonist. The mutant C212A impaired cAMP pro-
duction in much the same way as C282A (pEC50 values: WT9.62+0.76, C212A 8.10+0.43, n ¼ 3, p, 0.05, Student’s
t-test); however, the double mutant C212AC282A showed
a WT response (pEC50 values: WT 9.49+0.11 n ¼ 3,
C212AC282A 9.41+0.09, n ¼ 3), thus implying that the disul-
fide bond itself is not crucial for CGRP binding or signalling.3.1.6. The importance of the ECL2/TM5 junction
As noted above, L290A and L291A both showed small but
significant reductions in CGRP potency. As movements
at the top of TM5 have been implicated in the early stages
of activation of the b2-AR and rhodopsin [11], the role of
residues in this region was probed by further mutagenesis.
The individual reduction in EC50 values for L290A (approx.
eightfold) and L291A (approx. fourfold) was highly exacer-
bated by an L290AL291A double mutant that reduced the
EC50 by approximately 500-fold compared with WT (WT
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Figure 4. (a) A sample (20/100) of ECL1, ECL2 and ECL3 conformations generated by MODELLER for the CLR : CGRP complex; each of the 20 loops is shown in a
different colour. CLR is shown in blue, helices are shown as cylinders, CGCR1– 12 is shown in red and CGRP12– 18, which has relatively few interactions to ECL2, is
shown in mauve. The C2–C7 disulfide bond is shown in yellow. (b) A plot of the number of residue– residue interactions between ECL2 and CGRP against the
MODELLER DOPE score for the CLR conformation; the lower the score, the more probable the loop conformation. Conformations that interact with T6 via T288, D287,
D280 or both D287 and T288 are shown as red, blue green and purple crosses (þ), respectively. Conformation were these residues do not interact with T6 are shown
as grey crosses (). (c) The interactions between ECL2 residues and CGRP residues as observed over the full set of 100 ECL2 conformations; the thickness of the line
is broadly in line with the frequency of the interactions. For clarity interactions observed in fewer than 10 structures are omitted (but see the electronic supplemen-
tary materials, figure S3 for the full set of interactions). The coloured lines indicate interactions of specific CGRP residues: D3 (brown), A5 ( purple), T6 (black), T9
(orange), H10 (grey), R11, R18 (red) and L12, L15 (green).
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6pEC50 10.6+0.11, L290AL291A pEC50 7.93+0.13, n ¼ 3,
p, 0.01, Student’s t-test).3.2. Modelling of ECL2 and interactions with CGRP
and AM
3.2.1. Analysis of the MODELLER-generated ECL2 conformations
The loop conformations spanned a large proportion of the
space available to ECL2 (figure 4a). The analysis of the full
set of interactions for all loop conformations is given in
figure 4b,c. Although this analysis includes high-energy con-
formations, it is interesting as it highlights general interaction
preferences of several amino acids in CGRP and ECL2. ECL2
forms an extended loop; this conformation is often seen as
two antiparallel beta-strands in all peptide GPCRs for which
structures are available, creating a large interface forpeptide–receptor contacts [12]. Here, we re-interpret several
previously reported experimental observations that were
made in the absence of a modelled structure [44] and that
are consistent with our models. D3 of CGRP in our model is
not in a constrained pocket, hence it makes few interactions
with ECL2; indeed this position can accommodate a photo-
affinity probe [44]. The fact that it can be readily replaced by
arginine in the AM model provides further justification for
our model. By contrast, A5 of CGRP is sterically constrained
and indeed makes a relatively large number of interactions
(figure 4c), showing that it has many close neighbours. T6 is
discussed in more detail below; here, the preferred interactions
are to T288. In several loop conformations, T9 of CGRP inter-
acts with polar residues such as D280, D287 and T288. There
is some indirect evidence that H10 may also be part of this net-
work that responds to negative charges [44]. L15 of CGRP can
be replaced by a large benzoyl-phenylalanine moiety with
Table 1. Data used to select loop conformations.
CLR residues CGRP effect AM effect
A273
p p
R274
p p
Y277
p
Y278
p
D280
p p
C282
p
W283
p p
I284
p p
S285
p p
D287
p
T288
p p
L290
p
L291
p
Figure 5. The highest scoring docked pose of CGRP1– 7 (mauve). Resides A
1
and T6 reside close to Ala203 and Thr288, respectively (blue). The CGRP dis-
ulfide bond is shown in yellow. The loop conformation shown here for ECL2
was a high scoring (i.e. favoured) conformation. TM7 is shown as transparent.
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7only small changes in affinity (it makes few interactions to
ECL2); however, replacement of L12 of CGRP causes around
a 10-fold decrease (it makes more interactions with ECL2)
[44]. Replacement of R18 of CGRP by alanine has virtually
no effect, and indeed it makes few interactions, but the
double alanine mutant R11AR18A shows 100-fold reduction
in affinity [44]. Replacing either of these arginine residues
with glutamate caused over a 10-fold reduction in affinity;
but replacement with glutamine led to retention of high affi-
nity binding [24,25,49], presumably because glutamine can
still donate hydrogen bonds. Indeed, we see that both D280
and D287 are able to interact with R11, but as D287 is less sig-
nificant for AM (where K substitutes for R11), it is more likely
that D280 is the preferred partner to R11, even though D287
makes more interactions. CGRP residues 1, 4, 8, 13 and
beyond are predicted to make few, if any contacts with
ECL2; this is consistent with the known structure activity
relationships for CGRP where they seem to be of only minor
importance [44]; this observation justifies the orientation of
the helical extension to CGRP1–7.
W283 and I284, which reside in the centre of ECL2, make
the most interactions; these are either to the region around
R11 or to the N-terminal region (see below).
Having analysed the pattern of interactions over all loop
conformations, we see that this pattern is consistent with
known experimental data on the CGRP peptide [44] and so
we can now seek to identify preferred conformations and
interactions from the mutagenesis data given in table 1,
which indicates the most important residues for CGRP or
AM binding.
The residue that is the equivalent to position 6 in CGRP is
conserved as threonine in all members of the CGRP/CT/
AM/amylin family of peptides and is essential for CGRP
agonist activity [44,50]. Sequence analysis shows that the
most likely candidates that are (i) conserved in CLR and
CTR and (ii) able to donate or accept an H-bond are in
ECL2 where D280, D287 and T288 are the best candidates.
As D280 makes few interactions to T6 (see above) and D287
is not significant in AM binding (figure 1) and is of moderate
importance in CGRP activation, it would seem that T288 is
the most promising candidate.Figure 5 shows that the best-scoring docked conformation
of CGRP1–7 satisfies the T
6 criteria (by interacting with D280/
D287/T288) in the presence of a sample ECL2 conformation
(figure 4), and that D3 is not in a sterically crowded region
(see also figure 4c). This indicates that the docked CGRP1–7
has provided a suitable template for modelling the full
CGRP peptide and hence modelling the conformations of
ECL2. In the docked conformation, A1 of CGRP is not only
close to A203 of ECL1 of CGRP, but also able to accommo-
date N-terminal extensions. As discussed in the electronic
supplementary material, this is consistent with mutagenesis
and bioinformatic analysis of CGRP and AM binding.3.2.2. Filtering the ECL2 conformations
The number of interactions made by key ECL2 residues
(table 1) to CGRP for each of the 100 loop conformations
are displayed in figure 4b (y-axis). The ideal loop confor-
mation should make an interaction between T6 of CGRP
and D280, D287 or T288, have a large negative DOPE score,
make a high number of key interactions and ideally have
W283 in a vertical orientation (see below). The majority of
conformations, denoted by a grey cross in figure 4b, do not
make an appropriate interaction with T6 and are discarded.
Several conformations make 6–9 interactions, including
those to T6 via D280, D287 or T288. Because interactions to
D280, D287 or T288 are observed in the top 15% of the most
energetically preferred conformations and because the DOPE
score is an empirical rather than a rigorously accurate score,
it is not advisable to use energy (i.e. the DOPE score) as the
sole criteria to identify the preferred binding mode, hence
the importance of filtering the loop conformations using the
mutagenesis data. Only one conformation (conformation 34,
top left of figure 4b) records a direct interaction with R2744.64,
for either CGRP or AM, but this interaction is to R11 of CGRP
and the distance is long; closer inspection shows that D280
bridges between R2744.64 and R11 of CGRP. Several other
conformations of R2744.64 act in this way, and could help to
orientate a D280-R11 interaction. Thus, a direct interaction
betweenCGRPand R2744.64 is probably an unrealistic selection
criterion. R2744.64 is highly conserved as arginine or lysine
across the class B GPCRs; mutation in the GLP-1 and secretin
receptors also impairs function [6,7,51]. It is possible that
the positively charged head group may also interact with the
phospholipid bilayer [52].
Based on the data in figure 4b (and similarly for AM inter-
actions with the CGRP receptor which altered pEC50), we
selected six conformations for CGRP and seven for AM (see
the electronic supplementary material, figure S4). Apart from
one CLR/CGRP structure (conformation 34), these all have a
similar conformation for ECL2. However, despite a similar
(a)
(b)
(c)
Figure 6. The interactions in the high scoring models for CGRP model. The
interactions include D280 with H10 and R11, T288 with T6 (and A5), S285 with
A5 and D287 with A5 (shown in (b); the ECL2 hydrophobic residue interactions
include W283 with D3 and T4 as well as residues on TM2 and TM3, and I284
with A5. (b) Hydrogen bonds between significant ECL2 residues include R274
interacting with Y277 and D287 (close to A5) interacting with Y278, which
seem to stabilize the ECL2 fold. (c) The remaining significant ECL2 residues,
namely A273, L290 and L291; A273 and L291 do not interact with CGRP,
L290 interacts with L12 in some ECL2 conformations while L291 points
towards TM7, but could also affect the RAMP interaction; it is notable
that most of these non-interacting residues plus Y277 and Y278 are not sig-
nificant in the binding of AM and so it is likely that in CLR they are important
in RAMP1-directed indirect effects on the binding. These structures have not
been refined by molecular dynamics simulations for reasons discussed above
and so the molecular information should not be overinterpreted.
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8ECL2 conformation, there are differences in the orientations of
the W283 side chain, and only one high scoring CGRP and one
high scoring AM conformation have W283 in a vertical orien-
tation (a range of W283 interactions is shown in the electronic
supplementary material, figures S4 and S5). The preferred
CGRP structure (figure 6) satisfies 6/13 of the mutagenesis
results given in table 1,whereas theAMmodel (see the electronic
supplementary material, figure S6) satisfies 4/7.3.2.3. The orientation of W283
The loop generation alone does not help to address the
orientation of W283 as it interacts with CGRP in most confor-
mations of ECL2. However, the docking raises an interesting
question with regard to the site-directed mutagenesis data on
TM2 and TM3, as shown in the electronic supplementary
material, figure S7. A number of residues on TM2 and TM3
(namely T1912.57, L1952.61, V1982.64, A1992.65 and H2193.32)
show reduced cAMP production on mutation [19]. In ourmodel, CGRP can interact with L1952.61, V1982.64, A1992.65
but not T1912.57 and H2193.32 because they lie too deeply
within the helical bundle. If CGRP were positioned to interact
with these residues, it would then most likely not satisfy the
interactions of A1 and T6. The alanine-substitution effect at
T1912.57 and H2193.32 may instead result from interactions
with W283 of ECL2 as suggested by analysis of inactive
CLR simulations and selected high scoring loop conforma-
tions (figure 6; see the electronic supplementary material,
figures S5–S7). The hydrophobic patch of L1952.61, V1982.64
and A1992.65 on TM2 is important in CLR for CGRP-
mediated activation of cAMP production [20] but while this
region is more polar in some GPCRs, alternative hydrophobic
regions reside nearby in other family B GPCRs where W283
could bind. Consequently, we prefer the vertical confor-
mation of W283 as no other conformation satisfies the
mutation data on T1912.57 and H2193.32.3.2.4. AM binding
Our models can also explain the mutagenesis data for AM-
mediated activation of the same receptor. It is proposed
that AM sits in a very similar orientation to CGRP in the pre-
sumed binding pocket (see the supplementary material) but
accesses a slightly different subset of ECL conformations.
There are no direct interactions with R2744.64, Y277 and
Y278, but in the case of CGRP, the model suggests that
there are also few, if any, direct interactions with these
residues and instead they work primarily to stabilize pro-
ductive conformations of ECL2. In the case of CGRP, we
suggest that the consequence of this is to strengthen the inter-
actions between the contact points between the peptide and
ECL2 and so enhance potency. AM probably makes fewer
contacts with ECL2; RAMP2 may be required to generate a
full complement of interactions with this loop.3.2.5. Implications for receptor activation
The binding of an agonist has to stabilize an active confor-
mation of the receptor, increasing the activity of effector
proteins. For the CGRP receptor, the best characterized inter-
action is with Gs, leading to the production of cAMP and,
based on homology with the active crystal structures of rho-
dopsin and the b2-AR and extensive mutagenesis, we
produced a model of how this can take place [19]. Based on
the current data, it is possible to make some broad points
in regard to possible agonist activation mechanisms in CLR.
A change in the C-terminal region of ECL2 could easily be
propagated to TM5 and changes in this helix that are linked
to movement of TM6 have been identified as one of the ear-
liest steps leading to receptor activation in family A GPCRs
[11,53]. It may be significant that T6 of CGRP, important for
agonist activity in both CGRP and AM [44,50], is in close
proximity to the C-terminal region of ECL2 where D287 or
preferably T288 are its most likely interaction partners.
Further support for an important role of TM5 in receptor acti-
vation comes from the disrupting effect of the double mutant
of L220/L221A. A shift in TM5 in CLR could subsequently
allow movement of TM6. In family B GPCRs, there is a con-
served proline residue in TM6, which is likely to produce a
kink [23] analogous to the situation found in family A
GPCRs, so displacement of TM6 will lead to the opening of
a G protein-binding pocket between it and TM3 [11].
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9The conserved N-terminal part of ECL2 [1] links ECL2 not
only with TM4 but is also likely to influence ECL1 and hence
TM2 and 3. While ECL1 is of only minor importance in the
binding of CGRP, residues just below it in TM2 and
H2193.32 of TM3 are of considerable significance for receptor
activation [20]. Similar clusters are not obvious in the upper
regions of the other TMs [19], although systematic mutagen-
esis is needed to test this. These residues at the tops of TM2
and 3 may be in a position to make contacts with residues
at the base of ECL2, such as W283 and I284 as proposed
in this study (see the electronic supplementary material,
figure S7). Thus, CGRP has the potential to influence TM2
and 3 both directly and indirectly via ECL2. In family A
GPCRs, TM3 is of particular importance for receptor acti-
vation partly owing to its angle of tilt across the TM bundle
linking different parts of the bundle together. TM3 also con-
strains the C-terminal end of TM6 in at least some receptors
via an ionic or polar lock [11,54]. In family B GPCRs, the
equivalent of the ionic lock is probably a set of polar inter-
actions involving residues at the C-terminal ends of TMs 2,
3 and 6 [19,22,55]; there are further interactions involving a
polar network in the mid-regions of TMs 2, 3 and 7
[19,22,56]. Any interaction with TMs 2 and 3 is likely to
play a key role in the activation of a family B GPCR.
The model developed for CGRP binding is therefore con-
sistent with what is known about how CGRP activates its
receptor, although it is speculative. It is also important to
note that we have interpreted the effects of the mutations
directly on the conformation of ECL2 itself. We cannot rule
out that some of the effects may be on the TM bundle or extra-
cellular domains of CLR or even of the RAMP. The data can be
used to address these issues more fully once a crystal structure
of the active CLR/RAMP1 complex becomes available.4. Conclusion
We have evaluated the role of ECL2 in the binding of both
CGRP and AM to the CGRP receptor and have interpreted
the results by means of molecular modelling. The study indi-
cates that ECL2 is particularly important for the interaction ofCGRP with its receptor involving 13 ECL2 residues in the
loop out of 24 residues studied. By contrast, only two resi-
dues in ECL1 and one in ECL3 influence the interaction of
CGRP with its receptor [19,20]. Within ECL2, R274, W283,
D280, D287 and T288 are of particular importance. We have
suggested mechanisms where binding to this loop causes
changes to the extracellular ends of TMs 2, 3 and 5, which
in turn can be linked to movements of the cytoplasmic ends
of TMs 3, 6 and 7, to allow G protein binding and activation.
While ECL2 appears to be involved in the binding of many
peptide agonists to family B GPCRs, its precise role is probably
receptor and ligand dependent. Models have been produced
based on either mutagenesis or cross-linking data for the bind-
ing of secretin, GLP-1, VIP and PTH to their receptors
[8,15,16,57,58]. While there are of course limitations to any
modelling study, it is striking that there is no agreement as to
the mode of binding. In the case of some models developed
for GLP-1, secretin and VIP, their N-termini penetrate more
deeply to interact with TM2, providing a more direct method
of altering the conformation of both this helix and probably
the adjacent TM3 during the process of receptor activation.
While GLP-1 may not bind in the same way as CGRP (where
the disulfide bond makes the N-terminus more bulky), a
study of this receptor has provided the clearest evidence yet
that ECL2 is an important determinant of signalling specificity
[6,7]. Even in possession of crystal structures, the flexible nature
of ECLs requires studies such as this to shedmore light on how
GPCRs respond to peptide agonists. Our approach used to
model the interaction between either CGRP or AM and the
receptor may be applicable to other GPCRs. The full set of
structures is available from ftp.essex.ac.uk/pub/oyster/
CLR_ECL2_2013/CLR_ECL2_structures.tar.gz (see also the
electronic supplementary material); these structures compare
favourably to the recent class B X-ray structures of glucagon
and the corticotropin-releasing factor-1 receptors as described
in the electronic supplementary material.
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